Lilium (LILMF) 20-F 28 Mar 23 2022 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2022 shares
Document Information
Document Type	20-F
Document Registration Statement	false
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-40736
Entity Registrant Name	Lilium N.V.
Entity Incorporation, State or Country Code	P7
Entity Address, Address Line One	Claude-Dornier Straße 1
Entity Address, Address Line Two	Bldg. 335
Entity Address, Postal Zip Code	82234
Entity Address, City or Town	Wessling
Entity Address, Country	DE
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Entity Central Index Key	0001855756
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Document Accounting Standard	International Financial Reporting Standards
Entity Shell Company	false
Auditor Name	PricewaterhouseCoopers GmbH
Auditor Firm ID	1275
Auditor Location	Munich, Germany
Business contact member
Document Information
Entity Address, Address Line One	2385 N.W. Executive Center Drive, Suite 300
Entity Address, Postal Zip Code	33431
Entity Address, City or Town	Boca Raton
Entity Address, State or Province	FL
Contact Personnel Name	Roger Franks
City Area Code	561
Local Phone Number	526-8460
Class A ordinary shares
Document Information
Title of 12(b) Security	Class A ordinary shares, nominal value €0.12 per share
Trading Symbol	LILM
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding	369,820,821
Class B ordinary shares
Document Information
Entity Common Stock, Shares Outstanding	23,463,065
Warrants to purchase Class A ordinary shares
Document Information
Title of 12(b) Security	Warrants to purchase Class A ordinary shares
Trading Symbol	LILMW
Security Exchange Name	NASDAQ

Consolidated Statements of Oper

Consolidated Statements of Operations and Other Comprehensive Income (Loss) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Consolidated Statements of Operations and Other Comprehensive Income (Loss)
Revenue		€ 47	€ 97
Cost of sales		(11)	(10)
Gross profit		36	87
Research and development expenses	€ (175,618)	(144,558)	(90,345)
General and administrative expenses	(93,887)	(239,093)	(35,406)
Selling expenses	(12,929)	(17,189)	(15,272)
Other income	6,808	2,274	2,346
Other expenses	(3,268)	(2,036)	(130)
Operating loss	(278,894)	(400,566)	(138,720)
Finance income	30,322	11,288	80
Finance expenses	(1,995)	(20,201)	(49,741)
Financial result	28,327	(8,913)	(49,661)
Share of loss in a joint venture / associate	(2,823)	(848)
Loss before income tax	(253,390)	(410,327)	(188,381)
Income tax benefits / (expense)	326	(709)	(46)
Net loss for the year	(253,064)	(411,036)	(188,427)
Other comprehensive income/ (loss)
Other comprehensive income that may be reclassified to profit or loss	33	44	36
Exchange differences on translation of foreign business units	33	44	36
Items that will not be subsequently reclassified to profit or loss	28	162	(44)
Remeasurement of defined pension benefit obligation	28	162	(44)
Other comprehensive income / (loss)	61	206	(8)
Total consolidated comprehensive loss for the year	€ (253,003)	€ (410,830)	€ (188,435)
Loss per share basic	€ (0.80)	€ (1.91)	€ (0.97)
Loss per share diluted	€ (0.80)	€ (1.91)	€ (0.97)

Consolidated Statement of Finan

Consolidated Statement of Financial Position - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Assets
Intangible assets	€ 870	€ 1,394
Property, plant and equipment	36,699	30,610
Investment in a joint venture / associate	13,410	15,054
Other financial assets	3,386	3,779
Non-financial assets	13,487	8,113
Non-current assets	67,852	58,950
Other financial assets	22,581	219,625
Non-financial assets	18,648	22,994
Income tax receivable	169
Cash and cash equivalents	179,581	129,856
Current assets	220,979	372,475
Total Assets	288,831	431,425
SHAREHOLDERS' EQUITY AND LIABILITIES
Other capital	53,104	40,138
Share premium	843,074	779,141
Other capital reserves	277,654	240,430
Treasury shares	(279)	(151)
Accumulated loss	(970,198)	(717,134)
Accumulated other comprehensive income	148	87
Shareholders' equity	203,503	342,511
Other financial liabilities	21
Lease liabilities	8,353	9,861
Provisions	445	373
Trade and other payables	3,483	2,906
Deferred tax liabilities	10	10
Non-current liabilities	12,312	13,150
Other financial liabilities	4
Lease liabilities	2,616	1,962
Shares-based payment liability	1,046	8,028
Provisions	730	2,422
Income tax payable	128	552
Warrants	26,267	21,405
Trade and other payables	33,658	35,335
Other non-financial liabilities	8,567	6,060
Current liabilities	73,016	75,764
Total Shareholders' Equity and Liabilities	€ 288,831	€ 431,425

Consolidated Statement of Chang

Consolidated Statement of Changes in Equity - EUR (€) € in Thousands	Subscribed capital ELOC	Subscribed capital 2022 PIPE & RDO	Subscribed capital PIPE 2021	Subscribed capital Class B shares	Subscribed capital	Share premium ELOC	Share premium 2022 PIPE & RDO	Share premium PIPE 2021	Share premium Class B shares	Share premium	Other capital reserves 2022 PIPE & RDO	Other capital reserves	Treasury shares Class B shares	Treasury shares	Accumulated loss	Currency translation reserve [Member]	Remeasurement of defined pension benefit obligation	ELOC	2022 PIPE & RDO	PIPE 2021	Class B shares	Total
Beginning balance at Dec. 31, 2019					€ 24,460					€ 65,254		€ 3,981			€ (117,671)	€ 3	€ (114)					€ (24,087)
Loss for the year															(188,427)							(188,427)
Other comprehensive income / (loss)																36	(44)					(8)
Total comprehensive income / (loss)															(188,427)	36	(44)					(188,435)
Share-based payment awards												71,990										71,990
Convertible loans					2,299					65,824		34,084										102,207
Share capital increase					2,791					94,019												96,810
Share buy-back										(738)				€ (25)								(763)
Conversion					2,299					65,824		34,084										102,207
Repurchase										738				25								763
Ending balance at Dec. 31, 2020					29,550					224,359		110,055		(25)	(306,098)	39	(158)					57,722
Loss for the year															(411,036)							(411,036)
Other comprehensive income / (loss)																44	162					206
Total comprehensive income / (loss)															(411,036)	44	162					(410,830)
Share-based payment awards												53,350										53,350
Convertible loans					2,464					127,813		(34,084)										96,193
Reorganization					2,724					51,116		111,109		(81)								164,868
Share capital increase			€ (5,400)					€ (375,808)												€ (381,208)
Share buy-back										45				(45)
Conversion					2,464					127,813		(34,084)										96,193
Repurchase										(45)				45
Ending balance at Dec. 31, 2021					40,138					779,141		240,430		(151)	(717,134)	83	4					342,511
Loss for the year															(253,064)							(253,064)
Other comprehensive income / (loss)																33	28					61
Total comprehensive income / (loss)															(253,064)	33	28					(253,003)
Share-based payment awards												27,380										27,380
Convertible loans					1,303				€ 126	207		(2,072)	€ (126)									(562)
Reorganization					2,724					51,116		111,109										164,868
Share capital increase	€ 674	€ 10,983			5,400	€ 12,520	€ 50,095			375,808	€ 11,916							€ 13,194	€ 72,994			381,208
Share buy-back				€ (6)					(108)				108								€ (6)
Conversion					1,303				126	207		(2,072)	(126)									(562)
Repurchase				€ 6					€ 108				€ (108)								€ 6
Sale of treasury shares held by consolidated entity										877				106								983
Ending balance at Dec. 31, 2022					€ 53,104					€ 843,074		€ 277,654		€ (279)	€ (970,198)	€ 116	€ 32					€ 203,503

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flow from operating activities
Net loss for the year	€ (253,064)	€ (411,036)	€ (188,427)
Adjustments to reconcile consolidated net loss to net cash flows:
Income tax (benefits) / expense	(326)	709	46
Net interest	958	4,289	34,498
Depreciation, amortization and impairment	8,267	6,476	4,159
Share listing expense		111,109
Expenses for other share-based payments	24,261	61,378	50,907
Net gains/losses from the disposal of intangibles and PP&E	17		74
Share of loss in a joint venture / associate	2,823	848
Gain on dilution in investment in joint venture / associate	(1,179)
Fair value changes of financial instruments and expected credit losses	(29,050)	4,625	15,164
Income tax paid	(266)	(196)	(89)
Change in provisions	(1,640)	2,392	116
Working capital adjustments:
Changes in trade and other payables	(1,451)	20,517	8,358
Change in other assets and liabilities	(6,935)	(16,177)	(2,689)
Cash flow used in operating activities	(257,585)	(215,066)	(77,883)
Cash flow from investing activities
Purchases of intangible assets	(200)	(1,597)	(1,212)
Purchases of and advance payments on property, plant and equipment	(8,942)	(17,099)	(7,657)
Disposals of intangible assets, property, plant and equipment		1	4
Proceeds from short-term investments	319,773	50,000
Payments for short-term investments	(120,000)	(220,006)	(50,000)
Payments for acquisition of an associate		(13,680)
Payments for promissory notes		(1,051)	(630)
Interest paid	(466)
Interest received	129	6	23
Cash flow from/ (used in) investing activities	190,294	(203,426)	(59,472)
Cash flow from financing activities
Proceeds from convertible loans		1,850	85,900
Payments for share buy-back			(763)
Proceeds from share capital increase and issue of warrants - RDO & 2022 PIPE	113,971
Proceeds from other share capital increase - ELOC	12,498
Proceeds from other share capital increase and capital contributions	288	7	97,320
Proceeds from the Reorganization		83,393
Proceeds from the 2021 PIPE capital increase		381,208
Payment of transaction cost for capital contribution	(7,402)	(2,227)	(503)
Proceeds from sale of shares held in treasury	983
Payment for foreign exchange contract		(423,372)
Proceeds from foreign exchange contract		407,840
Principal elements of lease payments	(2,720)	(1,781)	(1,439)
Interest paid	(534)	(734)	(560)
Cash flow from financing activities	117,084	446,184	179,955
Cash-based changes in cash and cash equivalents	49,793	27,692	42,600
Effect of foreign exchange rate changes on cash and cash equivalents	(13)	20	(27)
Effect of change in expected credit loss provisions	(55)
Net increase in cash and cash equivalents	49,725	27,712	42,573
Cash and cash equivalents at the beginning of the year	129,856	102,144	59,571
Cash and cash equivalents at the end of the year	€ 179,581	€ 129,856	€ 102,144

Corporate Information

Corporate Information	12 Months Ended
	Dec. 31, 2022
Corporate Information
Corporate Information	1. Corporate Information Lilium N.V. (“the Company”), together with its consolidated entities (“Lilium” or the “Group”), is a start-up in the field of urban air mobility and intends to make regional air mobility a reality. Since its founding, Lilium has primarily engaged in research and development of a self-developed electric Vertical Takeoff and Landing (eVTOL) jet (the “Lilium Jet”) for production and operation of a regional air mobility service as well as related services. ​ Lilium N.V. is a public company under Dutch law and is registered under the Dutch trade register number 82165874. Lilium N.V. has its activities exclusively in Germany. The registered headquarters is Claude-Dornier Str. 1 , Geb. 335, 82234 Wessling, Germany. The Company is publicly listed and traded on Nasdaq under the symbols “LILM” for its Class A ordinary shares and “LILMW” for its listed redeemable warrants since September 15, 2021. ​ The consolidated financial statements of the Group for the year ended December 31, 2022, were authorized for issue by the Management Board on March 28, 2023. ​ The Reorganization ​ On September 14, 2021, Lilium GmbH consummated the Business Combination Agreement, with Qell Acquisition Corp (“Qell”), Lilium GmbH, Lilium N.V., and Queen Cayman Merger LLC. The transaction was accounted for as a capital reorganization (“Reorganization”) with Lilium GmbH being the accounting acquirer. Lilium N.V. acquired 100% of the share capital of Lilium GmbH in exchange for Class A and Class B shares of Lilium N.V., and Lilium N.V. acquired the net assets of Qell in exchange for the issuance of Class A shares of Lilium N.V. As of the date of Reorganization, Lilium N.V. succeeded Lilium GmbH as the parent company of the Group. The accounting impact of the Reorganization is described in note 21.

Basis of Preparation

Basis of Preparation	12 Months Ended
	Dec. 31, 2022
Basis of Preparation
Basis of Preparation	2. Basis of Preparation The Group’s consolidated financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”) and the related interpretations issued by the IFRS Interpretations Committee. The consolidated financial statements have been prepared on a going concern basis, applying a historical cost convention, unless otherwise indicated. They are prepared and reported in thousands of Euro (“€ thousand”) except where otherwise stated. Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures. Going Concern The financial statements have been prepared on a basis that assumes the Group will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. Management assessed the Group ’ ’ Historically, the Group has funded its operations primarily through capital raises and loans from shareholders. Since its inception, the Group has incurred recurring losses and negative cash flows from operations (accumulated losses of € Lilium ’ The Group ’ ’ There is no certainty that the Group will be successful in obtaining sufficient funding through additional private or public offerings of debt and/or equity. If the Group is unsuccessful in raising sufficient capital, the Group ’ Based on its recurring losses from operations since inception, expectation of continuing operating losses in the future and the need to raise additional capital to finance its future operations, which is not assured yet, the Group has concluded that there is substantial doubt about its ability to continue as a going concern, and, therefore, that it may be unable to realize its assets and discharge its liabilities in the normal course of business. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Despite this substantial doubt, management is continuing to take actions to secure sufficient financing, and thus believes that the application of the going concern assumption for the preparation of these consolidated financial statements is appropriate. Group information Consolidated entities are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Country of ​ Date of ​ % equity interest owned Name Incorporation ​ incorporation 12/31/ 2022 12/31/ 2021 Lilium N.V. ​ Netherlands ​ March 11, 2021 ​ 100.0 % 100.0 % Lilium GmbH Germany February 11, 2015 100.0 % 100.0 % Lilium Schweiz GmbH ​ Switzerland ​ December 8, 2017 ​ 100.0 % 100.0 % Lilium Aviation UK Ltd. ​ United Kingdom ​ December 20, 2017 ​ 100.0 % 100.0 % Lilium Aviation Inc. ​ United States ​ July 1, 2020 ​ 100.0 % 100.0 % Lilium eAircraft GmbH Germany August 17, 2020 100.0 % 100.0 % Stichting JSOP Netherlands September 10, 2021 0.0 % 0.0 % Lilium Aviation Spain SLU Spain April 7, 2022* 100.0 % n/a ​ * date of purchase of a shell company (company without active business). ​ The Netherlands trust “Stichting JSOP” (“Stichting”) has been fully consolidated, as Lilium has the right to appoint the members of the board of the trust and therefore controls the trust. Lilium is exposed to a variable return risk due to an interest-bearing loan that was granted to the trust. ​ Principles of consolidation The consolidated financial statements incorporate the financial positions and the results of operations of the Group. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. The financial statements of the subsidiaries are prepared for the same reporting period as Lilium N.V. using consistent accounting policies. Intercompany transactions, balances and unrealized gains on transactions between Group companies are eliminated. ​ Segment The Group operates its business as a single operating segment, which is also its reporting segment. An operating segment is defined as a component of an entity for which discrete financial information is available and whose results of operations are regularly reviewed by the chief operating decision maker. The Group’s chief operating decision maker is the Chief Executive Officer, who reviews results of operations to make decisions about allocating resources and assessing performance based on consolidated financial information. Regarding the geographical split of non-current assets, the investment in a joint venture (2021: investment in an associate) is located in the United States, and the property plant and equipment is disclosed in note 15. Most of the remaining non-current assets are located in Germany. Foreign currency The Group’s consolidated financial statements are presented using the Euro, which is the Group’s functional currency. The functional currency of all foreign consolidated entities included in these consolidated financial statements is their local currency. Lilium translates the financial statements of these subsidiaries to Euro using year-end exchange rates for assets and liabilities, and average exchange rates for income and expenses. Adjustments resulting from translating foreign functional currency financial statements into Euro are recorded as a separate component on the consolidated statements of comprehensive income. ​ Monetary assets and liabilities that are denominated in currencies other than the respective functional currencies are initially recognized at the foreign exchange rate on that date and remeasured at the foreign currency rates as of the reporting date. Foreign currency transaction gains and losses from the remeasurement are included in other income and other expenses, as appropriate, in the consolidated statements of operations for the period. ​ New standards, interpretations and amendments adopted by the Group ​ The accounting policies adopted in the preparation of the consolidated financial statements are consistent with those followed in the preparation of the Group’s annual consolidated financial statements for the year ended December 31, 2021, except for the adoption of new standards effective as of January 1, 2022. The following standards, amendments and interpretations were adopted by the Group for the first time for its annual reporting period commencing January 1, 2022: ​ ​ ​ ​ Standard/amendment/ interpretation Effective date Amendments to IFRS 3, ‘Business combinations’, IAS 16 ‘Property, plant and equipment’ and IAS 37 ‘Provisions, contingent liabilities and contingent assets’ ​ Annual periods on or after January 1, 2022 Annual improvements 2018-2020 ​ Annual periods on or after January 1, 2022 ​ The amendments listed above did not have any impact on the amounts recognized in prior periods and are not expected to significantly affect the current or future periods. ​ The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective (see below). ​ New Standards and Interpretations not yet adopted by the Group ​ Certain new accounting standards and amendments to accounting standards and interpretations have been published that are not mandatory for December 31, 2022 reporting periods and have not been early adopted by the Group. None of these standards is expected to have a material impact on the consolidated financial statements of the Group: ​ ​ ​ ​ Standard/amendment/ interpretation Effective date IFRS 17, ‘Insurance contracts’ as amended in June 2020 by amendments to IFRS 17, Insurance Contracts ​ Annual periods on or after January 1, 2023 Amendment to IAS 1, ‘Presentation of financial statements’, IFRS Practice statement 2 and IAS 8, ‘Accounting policies, changes in accounting estimates and errors’ ​ Annual periods on or after January 1, 2023 Deferred Tax related to Assets and Liabilities arising from a Single Transaction – Amendments to IAS 12 ​ Annual periods on or after January 1, 2023 Amendments to IFRS 17: First-time Adoption of IFRS 17 and IFRS 9 - Comparative Information ​ Annual periods on or after January 1, 2023 Amendment to IAS 1, Non-current liabilities with Covenants ​ Annual periods on or after January 1, 2024 Amendment to IFRS 16 – Leases on sale and leaseback ​ Annual periods on or after January 1, 2024 Amendment to IAS 1, ‘Presentation of financial statements’, on classification of liabilities as current or non-current ​ Annual periods on or after January 1, 2024 ​

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Significant Accounting Policies
Significant Accounting Policies	3. Significant Accounting Policies Intangible assets Research and development costs In developing its novel eVTOL technology, the Group incurs significant research and development costs. The costs for internally generated research and development are expensed when incurred. A portion of costs for internally generated development is capitalized if: ● the product or process is technically feasible; ● adequate resources are available to successfully complete the development; ● the benefits from the assets are demonstrated; ● the costs attributable to the projects are reliably measured; and ● the Group intends to produce and market or use the developed product or process and can demonstrate its market relevance. Management recognizes there is interest for an air mobility service, especially within heavily populated urban areas; however, there is not yet an established market for this new industry. The self-developed eVTOL technology used in the development of the Lilium Jet is highly innovative and there are uncertainties related to successful completion of the development. Consequently, the Group has not yet capitalized development costs. These costs are reflected in the consolidated statement of operations in the period in which the expenditure is incurred. Purchased intangibles Purchased intangible assets are initially measured and recorded at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses. Amortization on intangible assets with a limited useful life is calculated on a straight-line basis over the following periods: ​ ​ ​ ​ ​ Useful life Software 2  –  15 years Purchased concessions, rights and other intangible assets 10  –  20 years ​ Impairment tests At the end of each reporting period, the Group assesses whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Group estimates the asset’s recoverable amount. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. An asset’s recoverable amount is the higher of an asset’s or cash generating unit (“CGU”)’s fair value less costs of disposal and its value in use. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. Property, Plant and Equipment Property, plant and equipment are measured at cost, net of accumulated depreciation and any accumulated impairment losses. Costs of construction recognized include all attributable direct costs including material and production overheads and, where applicable, an initial estimate of the cost of dismantling and removing the item and restoring the site on which it is located. Borrowing costs are capitalized as part of the underlying asset under construction if there is a qualifying asset. Subsequent expenditures on assets are capitalized only when it is probable that future economic benefits associated with the expenditure will flow to the Group and the cost of the item can be measured reliably. Repairs and maintenance are expensed in the period the costs are incurred. If items of property, plant and equipment are sold or disposed of, the gain or loss arising from the disposal is recognized as other operating income or expense in the consolidated statement of operations and other comprehensive income (loss). Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows: ​ ​ ​ ​ ​ Useful life Rights to land and buildings including leasehold improvements 2  –  9 years Technical equipment and machinery 3  –  25 years Office and other equipment 3  –  13 years Vehicles 5  –  11 years ​ Assets qualifying as low value assets with a value of up to €1 thousand are aggregated into groups and depreciated over a useful life of 5 years . Leasehold improvements are amortized over the unexpired portion of the lease term or the estimated useful life of the improvements, whichever is shorter. The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate. Assets under construction are presented net of additions and transfers during the financial period in the property, plant and equipment movement schedule in the notes to the consolidated financial statements. Leases The Group’s lease obligations primarily relate to rights to buildings mainly for its office and research and development premises. As lease contracts are negotiated on an individual basis, lease terms contain a range of different terms and conditions. Lease contracts are typically entered for a period of 2 - 9 years and regularly include renewal and termination options, which provide operational flexibility to Lilium. Contracts may contain both lease and non-lease components. The Group allocates the consideration in the contract to the lease and non-lease components based on their relative stand-alone prices. As a lessee, at the inception of a contract, the Group assesses whether the contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. At the commencement date of the lease, which is the date at which the leased asset is available for use, the Group recognizes a right-of-use asset, which represents a right to use the underlying leased asset, and a corresponding lease liability, which represents the present value of future lease payments, in the consolidated statement of financial position. Short-term leases (leases with lease term of 12 months or less from lease commencement and that do not contain a purchase options) and leases of low value assets are not capitalized. Payments associated with short-term leases and leases of low-value assets are recognized on a straight-line basis as an expense in the consolidated statement of operations. Liabilities arising from a lease are initially measured at the present value of the remaining lease payments discounted using the interest rate implicit in the lease or the incremental borrowing rate in case the interest rate implicit in the lease is not readily determinable. The main components of the lease payments included in the measurement of the lease liability comprise the following: ● fixed lease payments; ● variable lease payments that are linked to an index (consumer price index); and ● lease payments in an optional renewal period if the Group is reasonably certain to exercise an extension option. Lease payments contain two elements, principal and interest. Interest expense is presented as part of finance costs in the consolidated statements of operations and other comprehensive income and measured using the effective interest method. Principal and interest portions of lease payments have been presented within financing activities in the consolidated statement of cash flows. The carrying amount of lease liabilities is remeasured if there is change in the future lease payments due to change in index or rate. At lease commencement right-of-use assets are initially measured at cost and are subsequently measured at cost less any accumulated depreciation and impairment losses and adjusted for any remeasurement of lease liabilities recognized. Cost of right-of-use assets includes lease liabilities, initial direct costs, prepayments made on or before the commencement date and less any lease incentives received. Right-of-use assets are depreciated on a straight-line basis from the commencement date to the earlier of the end of the useful life of the right-of-use asset and the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of the leased property and equipment. The right-of-use asset is periodically assessed for impairment. The Group has presented right-of-use assets within “Property, plant and equipment.” Assets related to retirement obligations for leased buildings are included in the cost of right-of-use assets for the respective underlying building lease. The Group does not have any contracts as a lessor as of the date of the consolidated statement of financial position. Investment in joint venture / associate company Under the equity accounting method, the investment in a joint venture or an associate is initially recognized at cost. The carrying amount of the investment is subsequently adjusted to recognize changes in the Group’s share of net assets of the joint venture or associate since the acquisition date. On acquisition of the investment, any difference between the cost of the investment and the entity’s share of the net fair value of the investee’s identifiable assets and liabilities is accounted for as follows: (a) Goodwill relating to a joint venture or associate is included in the carrying amount of the investment. Amortization of that goodwill is not permitted. (b) Any excess of the entity’s share of the net fair value of the investee’s identifiable assets and liabilities over the cost of the investment is included as income in the determination of the entity’s share of the joint venture or associate’s profit or loss in the period in which the investment is acquired. The consolidated statement of operations and other comprehensive income (loss) reflects the Group’s share of the results of operations of the joint venture or associate. Any change in other comprehensive income (loss) (“OCI”) of those investees is presented as part of the Group’s OCI. Gains and losses resulting from transactions between the Group and the joint venture or associate would be eliminated to the extent of the interest in the joint venture or associate. After application of the equity method, the Group determines whether it is necessary to recognizse an impairment loss on its investment in joint venture or associate. At each reporting date, the Group determines whether there is objective evidence that the investment in joint venture or associate is impaired. If there is such evidence, the Group calculates the amount of impairment as the difference between the recoverable amount of the joint venture or associate and its carrying value, and then recognizes the loss within ‘Share of profit/loss in a joint venture/ associate’ in the consolidated statements of operations. Upon loss of joint control or significant influence over the joint venture or the associate, the Group measures and recognizes any retained investment at its fair value. Any difference between the carrying amount of the joint venture or associate upon loss of joint control or significant influence and the fair value of the retained investment and proceeds from disposal is recognized consolidated statements of operations. Non-financial Assets Insurance recoveries are recognized for virtually certain reimbursements for damaged assets from the insurers. Other non-financial assets are recognized at cost. Cash and Cash Equivalents Cash and cash equivalents in the consolidated statement of financial position and consolidated statement of cash flows comprise cash at banks and on hand and short-term highly liquid deposits with an initial maturity of three months or less that are readily convertible to a known amount of cash and subject to an insignificant risk of changes in value. Depending on the classification, these financial assets are measured at amortized cost or fair value with changes through profit or loss – see financial instruments, note 28. Treasury Shares The treasury shares represent the consideration paid or payable for own shares held in treasury. The nominal value of the shares is shown in the treasury share reserve, which is part of the capital reserves. Acquisition values higher or lower than the nominal value are reduced from or added to the share premium reserve. Financial Instruments Financial instruments are contracts that give rise to a financial asset for one entity and to a financial liability or equity instrument for another entity. Financial instruments are recognized when the Group becomes a counterparty to it. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the marketplace (regular way trades) are recognized on the settlement date. Financial assets and financial liabilities are offset, and the net amount is reported in the consolidated statement of financial position, if there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis or to realize the assets and settle the liabilities simultaneously. The Group has no such assets and liabilities. Financial assets The Group’s financial assets include cash and cash equivalents and other financial assets. Other financial assets consist of security deposits for leases, fixed-term deposits and money market funds. Financial assets are initially measured at fair value plus, in the case of a financial asset not measured at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset. As an exception to this general rule, trade receivables are measured at their transaction price. Transactions costs are expensed as incurred for financial assets initially measured at fair value through profit or loss (“FVTPL”). Financial assets are classified at initial recognition as either measured at amortized cost (“AC”), fair value through other comprehensive income (“FVOCI”), or FVTPL depending on the contractual cash flows and the Group’s business model for managing them. For all financial assets, the Group has the objective to hold financial assets in order to collect the contractual cash flows. If the contractual terms of the financial assets give rise on specified dates to cash flows that are solely payments of principal and interest on the principal outstanding amount, the Group will measure these financial assets at AC under consideration of impairment (see following section). All financial assets are measured at AC, with the exception of money market funds, which are required to be measured at FVTPL because their cash flows are not solely payments of principal and interest on the principal outstanding amount. Gains and losses from financial assets measured at FVTPL are presented in the consolidated statements of operations in finance income and finance expense. Gains and losses from financial assets measured at AC including effects resulting from impairment are also presented in finance income and finance expense. Generally, the gains and losses from foreign currency translation effects are presented in other income / other expense. A financial asset is derecognized (i.e., removed from the Group’s consolidated statement of financial position) when the rights to receive cash flows from the asset have expired or have been transferred. Impairment of financial assets – expected credit losses (“ECL”) All financial assets measured at AC are required to be impaired at initial recognition in the amount of their expected credit loss (“ECL”). ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive. Lilium recognizes an allowance for ECLs for cash and cash equivalents and other financial assets according to the “general approach”. This means that ECLs are recognized in three stages. For credit exposures at initial recognition, ECLs are provided for credit losses that result from default events which may be possible within the next 12-months (Stage 1: a 12-month ECL). For credit exposures for which there has been a significant increase in credit risk since initial recognition (which is deemed to have occurred if a payment is more than 30 days past due), a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (Stage 2: a lifetime ECL). The same applies if objective indications exist that a default event has occurred (Stage 3: an incurred loss). In this case, any interest income is measured on the basis of the net carrying amount, while for stage 1 and 2 the basis is the gross carrying amount. Examples of objective evidence are significant financial difficulties experienced by the debtor, payment default or delays, a lowering of the credit rating, insolvency or where measures are taken to secure a debtor’s financial situation, or if other observable data indicates that expected cash flows deriving from financial assets may be appreciably reduced. For cash and cash equivalents as well as other financial assets, the simplification available for financial instruments with a low credit risk (“low credit risk exemption”) is applied as of the reporting date. Factors that can contribute to a low credit risk assessment are debtor-specific rating information and related outlooks. The requirement for classification with a low credit risk is deemed to be fulfilled for counterparties that have at least an investment grade rating; in this case there is no need to monitor credit risks for financial instruments with a low credit risk. The default probabilities applied to determine the ECL for cash and cash equivalents and other financial assets are based on credit default swap spreads that are quoted on markets, which take future-oriented macroeconomic data into account. In general, Lilium defines a default event as a situation in which the debt is no longer recoverable. If the financial instrument is perceived to be unrecoverable, then the expectation is that future contractual cash flows will not occur. At this point in time, the balance is written off after giving consideration to any possible collateral that is available. Impairment losses (including reversals of impairment losses on financial assets) are not presented as a separate item in accordance with IAS 1.82(ba) as they are considered immaterial. Impairment losses or income from the reversal of impairment losses on financial assets are reported net under finance income or finance expenses. Financial liabilities The Group’s financial liabilities include warrants, lease liabilities (see note 16), derivatives, trade and other payables, and other financial liabilities. Financial liabilities are classified as measured at AC or FVTPL. All financial liabilities are recognized initially at fair value less, in the case of a financial liability not at FVTPL, directly attributable transaction costs. Transactions costs are expensed as incurred for financial liabilities initially measured at FVTPL. Financial liabilities at FVTPL are measured at fair value and gains and losses resulting from changes in fair value are recognized in finance income / expenses. The Group only accounts for separated embedded derivatives of convertible loans and warrants as well as for other derivatives as a financial liability measured at FVTPL. All other financial liabilities are subsequently measured at AC using the effective interest rate (“EIR”) method. When applying the EIR method, the Group generally amortizes any fees, points paid or received, transaction costs and other premiums or discounts that are included in the calculation of the EIR over the expected life of the financial instrument. Gains and losses are recognized in interest expense when the liabilities are derecognized as well as through the EIR amortization process. For financial liabilities subsequently measured at AC, the foreign currency translation effects are presented in other income or expense. Foreign currency translation effects on financial liabilities at FVTPL are recognized in the finance income / expenses. Where there are hybrid instruments, transaction costs are apportioned between the liability and equity components based on the allocation of proceeds to the liability and equity components when the instruments are initially recognized. An embedded derivative in a hybrid contract, with a financial liability or a non-financial host, is separated from the host and accounted for as a separate derivative if: the economic characteristics and risks are not closely related to the host; a separate instrument with the same terms as the embedded derivative would meet the definition of a derivative; and the hybrid contract is not measured at FVTPL. The assessment whether to separate an embedded derivative is done only once at initial recognition of the hybrid contract. Reassessment only occurs if there is a change in the terms of the contract that significantly modifies the cash flows. A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expired. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The resulting gain or loss is recognized in the consolidated statement of other comprehensive income. Convertible Loans Convertible loans are assessed at issuance for any components of equity and liability. Convertible loans are bifurcated into a debt component and an equity instrument if there is a conversion right. The conversion right of a convertible loan is classified as a liability if some conversion features of the loan lead to a conversion into a variable number of shares. Embedded derivatives are assessed and, if needed, are separated from the host contract. The remaining host contract is measured at AC and the separated embedded derivative is measured at FVTPL until the loan is converted into equity or becomes due for repayment. If there are other derivative features provided for in the contract besides the conversion right, they are treated as a combined embedded derivative if they share the same risk exposure and are interdependent. Derivative Warrant Liabilities The Group evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to “IFRS 9 Financial Instruments” (“IFRS 9”). Warrants are recognized as derivative financial liabilities in accordance with IFRS 9. Accordingly, the Group classifies warrants as financial liabilities at FVTPL. The liabilities are subject to remeasurement at each balance sheet date until exercised or expired, and any change in fair value is recognized in the finance income/ expenses. Income Taxes Current income taxes Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date in the countries where the Group operates and generates taxable income. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate. Deferred taxes The Group uses the liability method of accounting for income taxes. Deferred income tax assets and liabilities represent temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and their corresponding tax basis used in the computation of taxable income. Deferred tax, however, is not recognized on the initial recognition of goodwill or the initial recognition of an asset or liability (other than in a business combination) in a transaction that affects neither tax nor accounting income. Deferred tax assets are in principle recognized for all deductible temporary differences, carry forward of unused tax credits and any unused tax losses. However deferred tax assets are only recognized to the extent it is sufficiently probable that taxable profit will be available against which the deductible temporary differences, the carry forward of unused tax credits and the unused tax losses can be utilized. Deferred tax liabilities are recognized for all taxable temporary differences associated with investments in subsidiaries and associates, except where the Group is able to control the reversal of the temporary differences and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year in which the asset is realized, or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. Deferred tax liabilities and assets are offset when there is a legally enforceable right to offset current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Group intends to settle its current tax assets and liabilities on a net basis. Current and deferred tax items are recognized similar to the underlying transaction either in profit or loss, other comprehensive income or directly in equity. Changes in deferred tax assets or liabilities are recognized as a component of tax expense (benefit) in the consolidated statement of operations, except where they relate to items that are recognized in other comprehensive income or directly in equity, in which case the related deferred tax is also recognized in other comprehensive income or equity, respectively. Where deferred tax arises from the initial accounting for a business combination, the tax effect is included in the accounting for the business combination. Deferred tax assets and deferred tax liabilities are not discounted. Deferred taxes are always classified as non-current. Provisions Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Fair Values of Assets and Liabilities Fair value is a market-based measurement. For some assets and liabilities, observable market transactions or market information is available. For other assets and liabilities, observable market transactions or market information might not be available. When a price for an identical asset or liability is not observable, another valuation technique is used. To increase consistency and comparability in fair value measurements, there are three levels of the fair value hierarchy: ● Level 1: contains the use of unadjusted quoted prices in active markets for identical assets or liabilities ● Level 2: inputs are other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly ● Level 3: inputs are based on unobservable market data If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, the fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement. The Group recognizes transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred. Further information about the assumptions made in measuring fair values of financial instruments is included in note 28.1. In cases where a gain or loss arises on initial recognition of a financial asset or a financial liability because the fair value deviates from the transaction price and is neither evidenced by a quoted price in an active market for an identical asset (i.e., a Level 1 input) nor based on a valuation technique that uses only data from observable markets (i.e., a Level 2 input), this gain or loss remains unrecognized until all market inputs become observable. In case such gain or loss results from a transaction with shareholders, this amount is to be considered as capital contribution to the Group and is therefore to be recognized in equity. Share-based Payments General accounting principles The Group grants certain share-based payment awards to the Group’s employees, advisors and vendors in exchange for their service. These share-based payment awards qualify either as cash-settled or equity-settled transactions depending on the terms of settlement. When the settlement choice (i.e. cash versus shares) lies with the participant, awards are classified as compound financial instruments. Only in the case the equity component is zero, the award is accounted for as a cash-settled option. When the settlement choice lies with the Group, the award is classified as an equity-settled grant unless the Group has a present obligation to settle in cash. For cash-settled awards a liability is recognized at fair value. The fair value is measured initially and at each reporting date up to and including the settlement date, with changes in fair value recognized in profit or loss for the period. An equity-settled award is measured based on the fair value determined at grant date. The fair value usually remains unchanged after the grant date. In case of a modification of an award after grant date, an incremental fair value is determined at the modification date for modifications that are beneficial to the participants. The Group grants several share-based awards under several different plans, which are described below. Refer to note 22 for the measurement approach of the fair value of options. Due to the Reorganization, the Group has granted certain nonrecurring share-based awards to external consultants. The expenses for services received are recognized when the participant renders services over the applicable vesting period with a corresponding increase of either the liability or equity, depending on the classification of the awards. The related share-based payment awards expense is recorded in the functional cost category to which the participant’s costs are classified. Employee Stock Option Program (“ESOP”) The Group maintains an Employee Stock Option Program (“ESOP”), originally established in 2017, which allows for the issuance of options to purchase ordinary shares to its employees, executives and certain advisors. Share options typically follow a vesting schedule over a four-year period. 25% will vest after the one-year anniversary of the applicable vesting commencement data (the “Cliff Period”) and then monthly thereafter on a graded vesting basis through the end of the vesting period. Individuals must continue to provide services to a Group entity to vest. Upon termination, all unvested options are forfeited . There is no contractual life for the share options provided in the contract. In October 2021, Lilium GmbH sent letters to all employees under the current ESOP plan to modify certain terms of the agreement. As per the modification agreement, an employee’s vested options shall now be exclusively settled in shares of Lilium N.V. instead of shares of Lilium GmbH in consideration for the participant’s claim for settlement under the ESOP conditions (as amended) to Lilium N.V. Options which are unvested at the time of the modification shall continue to vest in accordance with the regular vesting schedule. Vested options became exercisable after expiration of a lock-up period of 180 calendar days from the date of listing of Lilium N.V. on the Nasdaq Stock Market. Vested options must be exercised during certain exercise windows during each quarter of the fiscal year of the Group, with the exact dates during each such quarterly period being determined by the Group. The options will expire on the 10 th anniversary of the date on which vested options became exercisable. All the holders of the options have signed the modification agreement. By signing this modification, the illiquid sha

Significant Accounting Judgment

Significant Accounting Judgments, Estimates and Assumptions	12 Months Ended
	Dec. 31, 2022
Significant Accounting Judgments, Estimates and Assumptions
Significant Accounting Judgments, Estimates and Assumptions	4. Significant Accounting Judgments, Estimates and Assumptions The preparation of the Group’s consolidated financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the consolidated financial statements. In preparing these consolidated financial statements, management exercises its best judgement based upon its experience and the circumstances prevailing at that time. The estimates and assumptions are based on available information and conditions at the end of the financial period presented and are reviewed on an ongoing basis. Actual results may differ from these estimates under different assumptions and conditions and may materially affect the financial results or the financial position reported in future periods. Assumptions and estimates relating to the Group’s ability to continue as a going concern are described in note 2. Key estimates and judgements that have a significant influence on the amounts recognized in the Group’s consolidated financial statements are described below: Leases – Lease Term The Group has lease agreements for rental properties with material renewal options. The Group applies judgement in evaluating whether it is reasonably certain to exercise the option to extend or terminate the lease. The Group considers all relevant factors that create an economic incentive for it to exercise the respective extension option. After the commencement date, the Group reassesses the lease term if there is a significant event or change in circumstances that is within its control and affects whether the Group is reasonably certain to exercise or not to exercise the option to extend or terminate the lease (e.g., more than insignificant penalty, construction of significant leasehold improvements or significant customization to the leased asset). Leases – Incremental Borrowing Rate The Group cannot readily determine the interest rate implicit in the majority of its leases, therefore, it uses its incremental borrowing rate (“IBR”) to measure lease liabilities. The IBR is the rate of interest that the Group would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment. The IBRs used by the Group are calculated based on the risk-free rate, individual country risk premiums of underlying country and credit spread. The weighted average IBR in 2022 is 3.53% (2021: 3.75%). Investment in joint venture/ associate – Purchase Price Allocation The Group holds 27.7 % of Ionblox, Inc (formerly known as Zenlabs Energy, Inc or “Zenlabs”) (“Ionblox”), described in detail in note 17. Management calculated the goodwill acquired during purchase by performing a purchase price allocation, allocating the total consideration between the fair value of the identified net assets acquired and the goodwill acquired upon purchase. Assessing the fair value of the identified net assets acquired requires significant judgement. Management concluded that the fair value of the technology portfolio and the brand value acquired significantly exceeded their carrying value. ​ Management used the Multi-Period Excess Earnings Method (MPEEM) for the valuation of the technology portfolio. The MPEEM estimates the fair value of an intangible asset as a residual value after deducting charges for all other assets. It is assumed that the Group holds only the intangible asset to be valued and leases all other assets necessary to operate the business. Contributory asset charges (CACs) reflect all return on and of the supporting assets and are deducted for the use of all other assets. The Remaining Useful Life for the technology portfolio is estimated to be 15 years . Management used the Relief-from-Royalty (RfR) method for valuation of the Ionblox brand. This method is based on the assumption that if the Group did not own the brand, it would be willing to enter a licensing agreement for the brand. As part of this hypothetical licensing transaction, the licensee would have to pay royalty fees to the licensor. The value of the brand can thus be estimated as the present value of all future royalty payments in a hypothetical licensing transaction. Management has applied a hypothetical royalty rate of 0.93 % based on comparable industry peers. The remaining useful life for the brand asset is estimated to be 15 years . Share-based Payments An option pricing model (Black-Scholes) has been used for the determination of the fair value of awards. A simplified approach has been used in cases where share options have been deep in the money, so that the intrinsic value could serve as an approximation for the value of the option. Estimates also require the determination of the most appropriate inputs to the valuation model when calculating the fair value of the share option, such as the volatility of stock price. Note 22 describes the parameters used to calculate the fair value within 2022. For cash-settled share-based payment award transactions, the liability must be remeasured at the end of each reporting period until the date of settlement, with any changes in fair value recognized in profit or loss. This requires a reassessment of the estimates used at the end of each reporting period. Performance-based Stock Options For the performance-based stock options, the service-based vesting condition is predetermined and does not require any assumptions or estimates. For valuation purposes the performance-based vesting condition is assumed to be fulfilled by September 30, 2026. This date is reassessed at every reporting date. Success Fees In 2021, the number of financing rounds with expected amounts raised and their probabilities were the significant estimates for the valuation of the success fees. The weighted average expected timing of fulfillment of the performance condition was 20 months with a weighted average probability of 69 %. In 2022, all amounts under the success fees contracts entered into in previous years were settled and the contracts were terminated. A new success fee contract was entered into with a related party that is accounted for under IAS 37 as a contingent liability disclosed in note 29 and note 30. No conditions for payment have been met as of December 31, 2022. Share listing expense For the share listing expense, the Group has assessed the discount for lack of marketability on 5% for the transfer restrictions imposed on certain shares transferred to Qell shareholders. Warrants ​ Warrants are described in note 23. ​ Private Warrants & Public Warrants (“Reorganization Warrants”) ​ The fair value of the Private Warrants is deemed to be equal to the fair value of the Public Warrants. The Private Warrants are identical to the Public Warrants, except that the Private Warrants were not transferable, assignable or salable until 30 days after the completion of the Business Combination. Additionally, the Private Warrants will not be redeemable by Lilium so long as they are held by the initial purchasers or such purchasers’ permitted transferees. If the Private Warrants are held by holders other than the initial purchaser or their permitted transferees, the Private Warrants will be redeemable by Lilium and exercisable by such holders on the same basis as the Public Warrants. ​ The Group has certain redemption rights depending on the share price of which one only relates to the Public Warrants, but given the other elements in the agreement, the Group has a certain economic incentive to call for redemption of all Warrants before a certain share price. Consequently, management has applied the same valuation to both the Private Warrants and Public Warrants (collectively, hereinafter also known as “Reorganization Warrants”). ​ The Reorganization Warrants were considered to be part of the net assets acquired and therefore, management applied the provisions of debt and equity classification under IAS 32 Financial Instruments: Presentation (“IAS 32”) and management has concluded that these are current liabilities. As the Reorganization Warrants include contingent settlement provisions that introduce potential variability to their settlement amounts and are dependent on the occurrence of some uncertain future events, the Reorganization Warrants are accounted for as derivative financial liabilities at fair value, with changes in FVTPL. The Private Warrants are Level 2 in the fair value hierarchy. ​ Registered Direct Offering (“RDO”) Warrants & Private Placement (“2022 PIPE”) Warrants ​ The fair value of the RDO Warrants is deemed equal to the fair value of the 2022 PIPE Warrants. The RDO Warrants are identical to the 2022 PIPE Warrants as these share the same terms except that the RDO Warrants and the underlying shares are registered securities and the 2022 PIPE Warrants and the underlying shares are unregistered and would need an effective registration statement for resale. Subsequent to the issuance of the 2022 PIPE Warrants, the Group registered the securities underlying the 2022 PIPE Warrants on December 13, 2022. The Group has certain redemption rights on the RDO & 2022 PIPE Warrants if the share price exceeds a certain threshold and meets certain conditions as described in the RDO & 2022 PIPE Warrant agreements. ​ Management determined that the RDO & 2022 PIPE Warrants have all the characteristics of a derivative liability under IFRS 9. As RDO & 2022 PIPE Warrants are unlisted, these were categorized in Level 3 of the fair value hierarchy, due to the inputs used to determine the fair value of these warrants. Fair value has been determined using a Monte Carlo simulation in a risk neutral framework. The primary inputs into the simulation included the following: closing Lilium N.V. stock price as of December 31, 2022, expected stock price volatility, term, risk-free rate and dividend yield. The expected stock price volatility was based on Lilium N.V. implied volatilities calculated over a period matching the remaining life of these warrants. The term input is equal to the warrants’ remaining contractual term. The risk-free interest rate is based on interpolated U.S. Constant Maturity Treasury rates for a maturity equal to the remaining life of the RDO & 2022 PIPE Warrants. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero. ​ Covid-19 Risks and Uncertainties ​ The Group continues to closely monitor developments with respect to COVID-19 that could potentially impact the business. The Group had implemented logistical and organizational changes to consolidate the Group’s resilience to COVID-19. The Group expects that the impact of the pandemic would be minimal to none for the foreseeable future, ​ War in Ukraine The Board is actively monitoring the impact on the Russia & Ukraine war. The Group does not and does not intend to engage in any transactions that involve Russian, Ukrainian, or Belarusian entities nor any Politically Exposed Persons (“PEPs”) from those countries. There is currently no direct or indirect impact on the Group from the war in Ukraine and sanctions imposed on Russia and Belarus as the Group does not have any operations or direct suppliers located in these jurisdictions. ​ The Group continues to closely monitor the impact of the war in Ukraine on general economic factors, including the impact of inflation, as these factors put pressure on the Group’s costs for employees, raw materials and other parts provided by suppliers.

Revenue from Contracts with Cus

Revenue from Contracts with Customers and Cost of Sales	12 Months Ended
	Dec. 31, 2022
Revenue from Contracts with Customers and Cost of Sales
Revenue from Contracts with Customers and Cost of Sales	5. Revenue from Contracts with Customers and Cost of Sales Lilium is currently not generating revenues from mobility services. In rolling-out the business, Lilium is engaged in infrastructure and mobility consultancy services provided to airport authorities with which future collaborations are planned. No revenue was recognized during the current year. In 2021, revenue amounting to €47 thousand was recognized from one customer at a point in time upon receipt of acceptance (2020: €97 thousand). The geographic region which recognized revenues was Germany based on the Group location which bills the customer. ​ Related costs are captured in costs of sales and comprise personnel expenses.

Research and Development Expens

Research and Development Expenses	12 Months Ended
	Dec. 31, 2022
Research and Development Expenses.
Research and Development Expenses	6. Research and Development Expenses Research and development expenses consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 2020 Salaries and social security 77,455 75,672 66,536 Professional services 72,840 49,421 8,448 Materials 7,808 9,009 8,253 Depreciation/amortization/impairment 6,386 4,541 2,829 IT and communication expense 3,709 1,248 1,857 Other research and development expenses 7,420 4,667 2,422 Total research and development expenses 175,618 144,558 90,345 ​ Expenses for salaries and social security mainly include salary, salary-related expenses and share-based payment awards recognized from the Group’s share-based payment award programs (note 22). Professional services include €54,734 thousand (2021: €31,576 thousand; 2020: €3,732 thousand) for consulting services and €18,105 thousand (2021: €17,845 thousand; 2020: €4,716 thousand) for contractors. Consulting and contractor services have increased due to the ramp up of research and development activities being conducted with suppliers and partners in readiness for entry into service (EIS). Materials include various components used in development of the Lilium Jet.

General and Administrative Expe

General and Administrative Expenses	12 Months Ended
	Dec. 31, 2022
General and Administrative Expenses.
General and Administrative Expenses	7. General and Administrative Expenses General and administrative expenses consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 2020 Share listing expense — 111,109 — Professional services 28,851 70,380 8,483 Salaries and social security 30,187 35,395 20,926 IT and communication expense 20,374 12,391 2,255 Depreciation/amortization 1,816 1,870 1,289 Insurances 6,457 1,698 73 HR related expenses (training, recruitment) 1,466 1,617 1,026 Other administrative expenses 4,736 4,633 1,354 Total administrative expenses 93,887 239,093 35,406 ​ Professional services are related to general legal and tax advice, external contractors, consultants, audit expense, staff lease and bookkeeping services. In 2022, professional services expenses are partially reduced by €4,435 thousand (2021: €5,438 thousand expense; 2020: nil ) in relation to a reduction of the fair value of the JSOP (note 22). In 2021, professional services included Lilium’s consulting and legal fees in relation to the Reorganization which are not capitalizable, investor relations costs not deducted from capital reserves (in total €33,127 thousand), and €13,030 thousand for the issue of Azul Warrants (see note 22). Expenses for salaries and social security include employee remunerations, benefits and share-based payment awards recognized from the Group’s share-based payment award programs (note 22). IT and communication expense relate to ongoing ERP costs and other IT maintenance and development costs for general tools used by all functions in the Group. In 2022, these expenses include €13,527 thousand (2021: €6,590 thousand; 2020: nil ) incurred for a cloud-based data analytics tool. Insurance expenses mainly due to Directors & Officers liability insurance. Other administrative expenses include occupancy costs, travel expenses, membership fees and other operating expenses. In 2021 the share listing expense was the fair value of the shares issued by Lilium N.V. in excess of the net assets acquired from Qell as a result of the Reorganization (see note 1 for details).

Selling Expenses

Selling Expenses	12 Months Ended
	Dec. 31, 2022
Selling Expenses.
Selling Expenses	8. Selling Expenses Selling expenses consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 2020 Salaries, social security 8,915 11,971 13,115 Professional services 1,690 1,983 1,196 Marketing 1,448 2,059 613 Travel 523 626 167 Depreciation/amortization 65 65 41 Other selling expenses 288 485 140 Total selling expenses 12,929 17,189 15,272 ​ The Group recognizes costs related to the commercialization of the Lilium Jet as selling expenses. Expenses for salaries and social security mainly include employee remunerations, benefits and share-based payment awards recognized from the Group’s share-based payment award programs (note 22). In 2021, marketing costs mainly related to the Reorganization.

Other Income

Other Income	12 Months Ended
	Dec. 31, 2022
Other Income
Other Income	9. Other Income Other income consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 2020 Foreign currency gains 3,842 1,689 19 Insurance recoveries 483 456 1,906 Grants received from the German government 1,038 51 307 Income from other grants — — 42 At-equity income from dilution ​ 1,179 ​ — ​ — Other miscellaneous income 266 78 72 Total other income 6,808 2,274 2,346 ​ Foreign currency gains of €3,842 thousand (2021: €1,689 thousand; 2020: €19 thousand) are primarily derived from favorable exchange rate movements on the Group’s cash holdings denominated in US Dollar. In 2022 insurance recoveries of €483 thousand are for damage to equipment sustained in transit. In 2021, insurance recoveries of €456 thousand (2020: €1,906 thousand) are for damage which occurred as a result of an accident during maintenance work. Lilium has been granted government funds for conducting research on future mobility infrastructure and technology. The conditions connected with the grants have been fulfilled by the Group and therefore, have been recognized in other income. At-equity income from dilution of €1,179 thousand relates to the Group’s gain on dilution in the investment in Ionblox (see note 17). Other miscellaneous income is primarily made up of €167 thousand (2021 and 2020: nil) of health insurance reimbursements.

Other Expenses

Other Expenses	12 Months Ended
	Dec. 31, 2022
Other Expenses
Other Expenses	10. Other Expenses Other expenses consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 2020 Foreign currency losses 3,264 1,054 107 Miscellaneous other items 4 982 23 Total other expenses 3,268 2,036 130 ​ Foreign currency losses of €3,264 thousand in 2022 (2021: €1,054 thousand; 2020: €107 thousand) are primarily derived from unfavorable exchange rate movements on the Group’s cash holdings denominated in US Dollar and from currency losses on foreign trade payables.

Financial Result

Financial Result	12 Months Ended
	Dec. 31, 2022
Financial Result
Financial Result	11. Financial Result Financial result is comprised of the following: ​ ​ ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 2020 Finance income 30,322 11,288 80 thereof: fair value changes 29,922 11,280 58 thereof: impairment loss net of reversal ​ 125 ​ — ​ — Finance expenses (1,995) (20,201) (49,741) thereof: fair value changes (763) (15,645) (15,222) thereof: interest portion of lease payments (443) (437) (450) thereof: impairment loss net of reversal — (260) — thereof: interest on convertible loans ​ — ​ (3,483) ​ (33,960) Financial result 28,327 (8,913) (49,661) ​ Finance income mainly resulted from changes in fair value of warrants of €29,688 thousand (2021: €4,454 thousand; 2020: nil) consisting of fair value changes in the price of warrants of €30,196 thousand (2021: €5,492 thousand; 2020: nil) and the gain on foreign exchange conversion of RDO & 2022 PIPE Warrants of €1,116 thousand (2021: nil; 2020: nil) offset by the loss on foreign exchange conversion of Reorganization Warrants of €1,624 thousand (2021: €1,038 thousand; 2020: nil). Finance income fair value changes also consisted of gain on foreign currency contract of €234 thousand (2021 and 2020: nil). Finance income also consisted of the impairment losses net of reversal of €125 thousand (2021 and 2020: nil) made in the previous year. Finance expenses that resulted from fair value changes consist of fair value changes in money market funds of €67 thousand (2021: €87 thousand; 2020: nil ) and fair value changes in the ELOC purchased put option of €696 thousand (2021 and 2020: nil ) (see note 21). In 2021 fair value changes also included foreign currency exchange contract loss of €15,532 thousand. In 2020 fair value changes consisted of fair value changes from the embedded derivatives of the convertible loans of €15,222 thousand. In 2021, the foreign currency exchange contract was related to the funds from the Reorganization expected to be received in USD. There are no convertible loans or investments in money market funds outstanding as of December 31, 2022.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Taxes
Income Taxes	12. Income Taxes Income Tax Expenses/ Benefits The expenses/ benefits for income taxes is comprised of the following: ​ ​ ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 2020 Current income tax charge (169) (556) (46) Current income tax related to prior years 495 (143) — Current taxes ​ 326 ​ (699) ​ (46) Deferred taxes — (10) — Income tax benefits / (expense) 326 (709) (46) ​ The income tax expenses/ benefits mainly relate to foreign subsidiaries. At German companies, a corporate tax rate of 15 % was used for the calculation of deferred taxes. In addition, a solidarity surcharge of 5.5 % on corporate tax and a trade tax rate of 11.73 % were taken into account. This resulted in an overall tax rate of 27.55 % for German companies, which is also the group tax rate (previous year: 27.55%). At international group companies, the respective country-specific tax rates were used for the calculation of current and deferred taxes. Tax Rate Reconciliation The following table presents the reconciliation of expected tax expense and recorded tax expense. Expected tax expense is determined by multiplying consolidated profit before tax from continuing operations by the total group tax rate of 27.55%: ​ ​ ​ ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 2020 Profit (Loss) before income tax (253,390) (410,327) (188,381) ​ Income tax rate 27.55 % 27.55 % 27.55 % Expected income taxes on this 69,809 113,045 51,899 ​ Effects deriving from differences to the expected tax rate 9 40 54 ​ Taxes for prior years ​ 495 ​ (143) ​ — ​ Other non-deductible expenses and taxes (59) (66) (238) ​ Changes in the realization of deferred tax assets (76,356) (67,465) (22,371) ​ Other 6,428 (46,120) (29,390) ​ Income tax as per consolidated statement of operations 326 (709) (46) ​ Effective tax rate in % ​ 0.1 % (0.2) % 0.0 % ​ The other effects in 2022 mainly relate to share-based payments (€22,817 thousand; resulting in a reconciliation effect of (€6,286 thousand), fair value adjustments of Reorganization Warrants and RDO & 2022 PIPE Warrants (€29,689 thousand; resulting in a reconciliation effect of €8,179 thousand) and transaction costs deducted from equity (€7,402 thousand, resulting in a reconciliation effect of €2,039 thousand). The other effects in 2021 mainly relate to expenses resulting from non-cash share listing expense (€111,109 thousand; resulting in a reconciliation effect of €30,610 thousand), equity settled share-based payments (€40,321 thousand; resulting in a reconciliation effect of €11,108 thousand) and fair value adjustments of the Azul Warrants (€13,030 thousand; resulting in a reconciliation effect of €3,590 thousand) as well as finance income resulting from the embedded derivatives of the convertible loans (€6,351 thousand; resulting in a reconciliation effect of €1,750 thousand) and fair value adjustments of Qell warrants (€4,454 thousand; resulting in a reconciliation effect of €1,227 thousand). Deferred Taxes Deferred taxes relate to the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Deferred tax assets Deferred tax liabilities In € thousand ​ 12/31/2022 ​ 12/31/2021 ​ 12/31/2022 ​ 12/31/2021 Non-current assets 2,378 3,010 2,913 3,099 Intangible assets 2,341 2,995 — — Property, plant and equipment 37 15 2,903 3,088 Financial assets — — 10 11 Current assets 149 14 — 286 Inventories 123 11 — — Receivables and other assets 26 3 — 286 Non-current liabilities 446 645 — 167 Provisions 10 24 — 3 Liabilities 436 621 — 163 Current liabilities 138 222 208 631 Provisions — 91 47 — Liabilities 138 131 161 631 Loss carryforwards — 282 — — Total value 3,111 4,173 3,121 4,183 Netting (3,111) (4,173) (3,111) (4,173) Recognition in the consolidated statement of financial position — — 10 10 ​ As of December 31, 2022, and 2021, there were the following tax attributes (gross): ​ ​ ​ ​ ​ ​ In € thousand 12/31/2022 12/31/2021 Corporation tax loss carryforwards 661,501 388,980 Trade tax loss carryforwards 659,161 387,524 Interest carryforwards 15,348 15,846 ​ ​ The reported tax loss and interest carryforwards mainly relate to the German Lilium entities and can be carried forward indefinitely. Tax loss carryforwards in the amount of €56,891 thousand can’t be used during the time of the tax group between Lilium GmbH as controlling entity and eAircraft as controlled entity. German minimum taxation rules and interest stripping rules apply. These tax attributes may be subject to restrictions of the German change in ownership rules (Sec. 8c KStG) going forward. The closing of the de-SPAC transaction did not result in the forfeiture of the tax loss carryforwards. These tax attributes relate to entities that have a history of losses which have been accumulated in the previous years. The respective entities neither have any taxable temporary difference exceeding the deductible temporary differences nor any tax planning opportunities and documentation available that could partly support the recognition of these tax attributes as deferred tax assets. On this basis, the Group has determined that it cannot recognize deferred tax assets on the tax attributes carried forward. For the following deductible temporary differences and tax loss and interest carryforwards, no deferred tax assets were recognized in the consolidated financial statements: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Deferred tax assets on ​ ​ ​ ​ ​ ​ Interest ​ ​ ​ ​ Temporary ​ Tax ​ carry ​ ​ In € thousand ​ differences ​ losses ​ forward ​ Total Unrecognized deferred tax assets as of January 1, 2021 17,276 35,639 3,663 56,578 Addition — 70,625 266 70,891 Deductions (3,426) — — (3,426) Unrecognized deferred tax assets as of December 31, 2021 13,850 106,264 3,929 124,043 Addition 1,541 75,705 436 77,682 Deductions — — (137) (137) Unrecognized deferred tax assets as of December 31, 2022 15,391 181,969 4,228 201,588 ​

Loss per Share

Loss per Share	12 Months Ended
	Dec. 31, 2022
Loss per Share
Loss per Share	13. Loss per Share Basic loss per share (EPS) is calculated by dividing the net loss for the year by the weighted average number of ordinary shares outstanding during the year. Diluted EPS is calculated by dividing the net loss for the year by the weighted average number of ordinary shares outstanding during the year plus the ordinary shares that would be issued upon conversion of all outstanding stock options and warrants into ordinary shares. For the periods included in these consolidated financial statements, the Group incurred net losses; therefore, anti-dilutive stock options, outstanding equity awards during the period (as described in note 22), the Reorganization Warrants and RDO & 2022 PIPE Warrants as well as the 1,800,000 Azul Warrants issued in 2021 The following table reflects the income and share data used in the basic and diluted EPS calculations: ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 2021 2020 Comprehensive loss attributed to equity shareholders (253,003) (410,830) (188,435) (in € thousand) ​ ​ ​ ​ ​ ​ Weighted average number of shares outstanding Basic and diluted 316,474,576 214,858,203 193,722,062 Basic and diluted EPS (in €) (0.80) (1.91) (0.97) ​

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2022
Intangible Assets
Intangible Assets	14. Intangible Assets Intangible assets comprise the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Purchased concessions, ​ ​ ​ ​ ​ rights and other ​ ​ In € thousand ​ Software ​ intangible assets ​ Total Costs of acquisition ​ ​ ​ January 1, 2022 3,998 108 4,106 Additions 163 37 200 Transfer from property, plant and equipment — — — December 31, 2022 4,161 145 4,306 Accumulated amortization/write downs ​ ​ ​ January 1, 2022 2,694 18 2,712 Amortization 717 7 724 December 31, 2022 3,411 25 3,436 Carrying amount: ​ ​ ​ December 31, 2021 1,304 90 1,394 December 31, 2022 750 120 870 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Purchased concessions, ​ ​ ​ ​ ​ rights, and other ​ ​ In € thousand ​ Software ​ in-tangible assets ​ Total Costs of acquisition ​ ​ ​ January 1, 2021 2,401 108 2,509 Additions 1,586 — 1,586 Transfer from property, plant and equipment 11 — 11 December 31, 2021 3,998 108 4,106 Accumulated amortization/write downs ​ ​ ​ January 1, 2021 1,125 12 1,137 Amortization 1,569 6 1,575 December 31, 2021 2,694 18 2,712 Carrying amount: ​ ​ ​ December 31, 2020 1,276 96 1,372 December 31, 2021 1,304 90 1,394 ​ There were no indicators of impairment which would have required intangible assets to be tested for impairment in the financial years ended December 31, 2022 and 2021.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment
Property, Plant and Equipment	15. Property, Plant and Equipment Property, plant and equipment is comprised of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Rights to ​ ​ ​ ​ ​ ​ ​ land and ​ ​ ​ Technical ​ ​ ​ ​ ​ ​ ​ ​ buildings ​ ​ ​ equipment ​ Office ​ Assets ​ ​ ​ ​ and leasehold ​ ​ ​ and ​ and other ​ under ​ ​ In € thousand ​ improvements ​ Vehicles ​ machinery ​ equipment ​ construction ​ Total Costs of acquisition or construction: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1, 2022 19,903 166 10,738 8,243 2,611 41,661 Additions 2,366 67 6,328 1,519 2,894 13,174 Disposals — (94) (12) (95) — (201) Transfers 130 — 2,466 22 (2,618) — Transfer to intangible assets — — — — — — Indexation impact 488 — — — — 488 Foreign exchange — — — (6) ​ — (6) December 31, 2022 22,887 139 19,520 9,683 2,887 55,116 Accumulated depreciation: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1, 2022 5,438 82 1,669 3,862 — 11,051 Depreciation 3,642 64 2,168 1,617 — 7,491 Disposals ​ — ​ (94) ​ (12) ​ (68) ​ — ​ (174) Impairment ​ — ​ — ​ 52 ​ — ​ — ​ 52 Transfer — — — — — — Foreign exchange — — — (3) — (3) December 31, 2022 9,080 52 3,877 5,408 — 18,417 Carrying amount: ​ ​ ​ ​ ​ ​ December 31, 2021 14,465 84 9,069 4,381 2,611 30,610 December 31, 2022 13,807 87 15,643 4,275 2,887 36,699 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Rights to ​ ​ ​ ​ ​ ​ ​ land and ​ ​ ​ Technical ​ ​ ​ ​ ​ ​ ​ ​ buildings ​ ​ ​ equipment ​ Office ​ Assets ​ ​ ​ ​ and leasehold ​ ​ ​ and ​ and other ​ under ​ ​ In € thousand ​ improvements ​ Vehicles ​ machinery ​ equipment ​ construction ​ Total Costs of acquisition or construction: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1, 2021 15,774 160 6,195 5,590 1,144 28,863 Additions 3,444 6 2,532 2,644 4,200 12,826 Disposals — — — (1) — (1) Transfers 711 — 2,009 2 (2,722) — Transfer to intangible assets — — — — (11) (11) Indexation impact (26) — — — — (26) Foreign exchange — — 2 8 — 10 December 31, 2021 19,903 166 10,738 8,243 2,611 41,661 Accumulated depreciation: ​ ​ ​ ​ ​ ​ January 1, 2021 3,057 40 640 2,411 — 6,148 Depreciation 2,381 42 1,028 1,450 — 4,901 Transfer — — 1 (1) — — Foreign exchange — — — 2 — 2 December 31, 2021 5,438 82 1,669 3,862 — 11,051 Carrying amount: ​ ​ ​ ​ ​ ​ December 31, 2020 12,717 120 5,555 3,179 1,144 22,715 December 31, 2021 14,465 84 9,069 4,381 2,611 30,610 ​ Property, plant and equipment includes right-of-use assets for an amount of €10,499 thousand as of December 31, 2022 (December 31, 2021: €11,525 thousand). For further information refer to note 16. The transfers from assets under construction mainly relate to leasehold improvements and equipment which are required for construction of the Lilium Jet prototype. There are no security pledges. The Group test for impairment on an annual basis. During the year, an impairment loss of €52 thousand (2021 and 2020: nil) relating to assets that were obsolete and in the process of being disposed of was recognized as research and development expenses in profit or loss. Property, plant and equipment is distributed among geographical areas as follows: ​ ​ ​ ​ ​ ​ In € thousand 12/31/2022 12/31/2021 Property, plant and equipment ​ ​ ​ ​ Germany 26,063 18,933 United Kingdom 97 100 United States 23 38 Switzerland 12 14 Spain ​ 5 ​ — Right-of-use assets ​ ​ ​ ​ Germany ​ 10,033 ​ 11,525 Spain ​ 466 ​ — Total 36,699 30,610 ​

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Leases
Leases	16. Leases The Group has lease contracts for facilities, which contain variable lease payments and for vehicles, equipment and other assets which contain fixed-rate payment terms. The carrying amounts of right-of-use assets recognized and the movements during the period were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Technical ​ ​ ​ ​ ​ ​ ​ ​ equipment ​ Office ​ ​ ​ ​ Rights ​ ​ ​ and ​ and other ​ ​ In € thousand ​ to buildings ​ Vehicles ​ machinery ​ equipment ​ Total January 1, 2021 10,375 77 461 28 10,941 Additions to right-of-use assets 2,369 — 29 170 2,568 Transfer ​ — ​ — ​ (17) ​ — ​ (17) Depreciation (1,808) (34) (45) (54) (1,941) Indexation impact (26) — — — (26) December 31, 2021 10,910 43 428 144 11,525 Additions to right-of-use assets 1,526 63 23 — 1,612 Transfer — — — (144) (144) Disposal of right-of-use assets ​ — ​ (3) ​ (1) ​ — ​ (4) Depreciation (2,889) (49) (39) — (2,977) Indexation impact 488 — — — 488 December 31, 2022 10,034 54 411 — 10,499 ​ Some lease payments for rights to buildings are indexed to the German consumer price index, which is adjusted on a yearly basis. The carrying amounts of lease liabilities and the movements during the period were as follows: ​ ​ ​ In € thousand Lease Liability January 1, 2021 11,118 Additions 2,512 Interest 437 Payments (2,218) Indexation impact (26) December 31, 2021 11,823 Additions 1,385 Accrued interest ​ (7) Interest 443 Payments (3,163) Indexation impact 488 December 31, 2022 10,969 ​ The current and non-current portion of lease liabilities are as follows: ​ ​ ​ ​ ​ ​ In € thousand 12/31/2022 12/31/2021 Current ​ 2,616 ​ 1,962 Non-current 8,353 9,861 Total lease liabilities 10,969 11,823 ​ The consolidated statement of operations and other comprehensive income (loss) include the following amounts of lease related expense: ​ ​ ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 ​ 2020 Depreciation of right of-use-assets 2,977 1,941 ​ 1,631 Interest expense on lease liabilities 443 437 ​ 450 Short-term lease expenses 6 488 ​ 108 Lease expenses for low-value assets 137 220 ​ 80 Total amount recognized in expense 3,563 3,086 ​ 2,269 ​ Variable lease payments result from indexed rental payments for facility leases and are included in lease liabilities. The following table provides further information about the composition of the lease payments as included in the above movement schedule of lease liabilities: ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Fixed lease payments 1,212 204 Variable lease payments 1,951 2,014 Total amount of lease payments 3,163 2,218 ​ The below table provides information on the total cash outflow from all leases during the year: ​ ​ ​ ​ ​ ​ ​ ​ In € thousand 2022 ​ 2021 2020 Principal paid 2,720 ​ 1,781 1,439 Interest paid 443 ​ 437 450 Short term and low value leases 143 ​ 708 188 Total amount paid 3,306 ​ 2,926 2,077 ​

Investment in a Joint Venture _

Investment in a Joint Venture / Associate	12 Months Ended
	Dec. 31, 2022
Investment in a Joint Venture / Associate
Investment in a Joint Venture / Associate	17. Investment in a Joint Venture / Associate Investment in Ionblox On March 10, 2021, the Group entered into a Stock Purchase Agreement in which the Group acquired 25.7% of the shares of Ionblox for a purchase price of €8,502 thousand ($10,054 thousand), including transactions costs (see note 4 for additional information on Ionblox, formerly known as Zenlabs). Ionblox is a supplier of battery technology for Lilium. The principal place of business for Ionblox is the United States of America. On July 15, 2021, the Group entered into an additional Stock Purchase Agreement in which the Group acquired a further 9.1% of the shares of Ionblox across two transactions on July 16, 2021 and September 27, 2021, for a total consideration of €7,400 thousand ($8,716 thousand). The consideration included the conversion of outstanding promissory notes at a fair value of €2,222 thousand ($2,629 thousand), including a €1,051 thousand ($1,250 thousand) promissory note purchased on March 19, 2021. Lilium holds preferred stock in Ionblox, which give Lilium preferred dividend rights as well as rights of preferential payments in certain events. Preferred dividends are not cumulative, and payment is at the discretion of the Board of Directors of Ionblox out of any funds and assets legally available. In a deemed liquidation event, which is defined in the preferred stock purchase agreement as mergers and consolidations and certain asset sales, Lilium is entitled to redeem cash or other assets from Ionblox which provides Lilium a share in Ionblox net assets. In the event of liquidation, dissolution or winding up or deemed liquidation event, Lilium is entitled to preferential payments if there are sufficient funds in Ionblox to pay the preferred stockholders. The preferred stocks carry the same shareholder voting rights as holders of equivalent common stock. The preferred stocks also entitle the Group to nominate two directors to the Board of Directors of Ionblox. As such, the Group is considered to have significant influence over Ionblox. The significant influence together with other features of the preferred stock result in Lilium participating in a share of gains or losses from Ionblox; as such, the investment was initially recognized as an investment in associate and accounted for at-equity under IAS 28 ‘Investment in associates and joint ventures’. For each date of acquisition of Ionblox, the fair value of Ionblox’s identifiable net assets and liabilities were identified, and the difference between the purchase price and the fair value of identified net assets has been accounted for as goodwill. The goodwill is included within the carrying value of the Investment in Associate. The total fair value of the identifiable net assets acquired is €8,344 thousand ($9,843 thousand), generating goodwill upon purchase of €7,558 thousand ($8,927 thousand). The fair value of the identifiable net assets acquired includes a carrying value of €2,248 thousand ($2,652 thousand) and a fair value step-up of €8,688 thousand ($10,250 thousand) for Ionblox’s brand and technology portfolio, offset by €2,592 thousand ($3,059 thousand) for deferred taxation. In 2022, the Group’s share in Ionblox was diluted to 27.7% share of outstanding capital, representing 31.4% of the shareholder voting rights, through the issuance of 1,092,908 series B preferred stock by Ionblox to other investors, offset by a share buyback of 273,227 common stock, resulting in a gain on dilution of €1,179 thousand in other income. As part of the transactions, Lilium signed new Investors’ Agreements in May and November 2022, under which management have concluded that Lilium has joint control of Ionblox with another Preferred Stock investor. Lilium subsequently accounts for Ionblox as a Joint Venture, continuing to apply the equity method of accounting. As of December 31, 2022, there were no indicators that an impairment expense (2021: Nil) should be recognized on the carrying value of the investment in a joint venture (2021: associate). Shares in Ionblox are currently unquoted, hence there is no quoted price to determine the fair value of the investment in Ionblox. The following table illustrates the summarized valuation of the Group’s investment in Ionblox: ​ ​ ​ ​ ​ ​ ​ Carrying Value In € thousand ​ 2022 ​ 2021 January 1 15,054 ​ — Initial recognition ​ — ​ 8,502 Conversion of promissory notes (July 2021) — ​ 2,222 Capital increases (July and September 2021) ​ — ​ 5,178 Gain on dilution ​ 1,179 ​ — Share of loss in a joint venture/ associate (2,823) ​ (848) December 31 13,410 ​ 15,054 ​ The following is the summarized financial information for Ionblox, based on their consolidated financial statements prepared in accordance with IFRS, modified for fair value adjustments on acquisition. The numbers presented reflect the amounts in Ionblox’s IFRS consolidated financial statements, not of Lilium’s ownership share in these amounts. Ionblox, Inc. - Consolidated Statement of Operations for the year ended December 31, 2022 ​ ​ ​ ​ ​ ​ In € thousand 01/01/2022 – 12/31/2022 3/10/2021 – 12/31/2021 Revenue 1,927 806 Loss from continued operations ​ (7,777) (3,482) Net loss for the year/ period (7,369) (2,907) ​ Ionblox, Inc. - Consolidated Statement of Financial Position as of December 31, 2022 ​ ​ ​ ​ ​ ​ In € thousand 12/31/2022 12/31/2021 Non-current assets 1 25,438 ​ 24,255 Current assets 13,487 ​ 6,724 Preferred stock reclassification 2 ​ 21,619 ​ 20,283 Non-current liabilities (31,482) ​ (28,200) Current liabilities (933) ​ (756) Shareholders’ equity 28,129 ​ 22,306 ​ ​ ​ ​ ​ ​ ​ ​ Reconciliation to carrying amounts of Lilium’s Interest in Ionblox ​ ​ ​ ​ ​ Group’s effective interest in the joint venture / associate 27.7 % 34.8 % Group’s share in shareholders’ equity 7,780 ​ 7,762 ​ Goodwill 8,370 ​ 7,558 ​ Currency translation difference (2,740) ​ (266) ​ Investment in a joint venture / associate 13,410 ​ 15,054 ​ 1 As the purchase price allocation is performed at each acquisition date (as of March 10, July 16 and September 27, 2021), differences occur due to the different ownership rates used in purchase price allocation and equity accounting. These differences are adjusted in Ionblox’s summary consolidated financial statements. ​ 2

Other Financial Assets

Other Financial Assets	12 Months Ended
	Dec. 31, 2022
Other Financial Assets
Other Financial Assets	18. Other Financial Assets Other financials assets are as follows: ​ ​ ​ ​ ​ ​ In € thousand 12/31/2022 12/31/2021 Security deposits 3,386 3,779 Total non-current financial assets 3,386 3,779 Fixed term deposits 19,987 119,664 Money market funds — 99,919 Security deposits 2,594 42 Total current other financial assets 22,581 219,625 Total other financial assets 25,967 223,404 ​ Security deposits include €50 thousand (December 31, 2021: €400 thousand) pledged as collateral for customs, €182 thousand (December 31, 2021: €253 thousand) pledged as collateral for a furniture lease and €427 thousand (December 31, 2021: €196 thousand) pledged as collateral for use of credit card facilities. Additional deposits in the amount of €2,941 thousand (December 31, 2021: €2,942 thousand) are pledged as collaterals for facility leases, and €2,530 thousand (December 31, 2021: €30 thousand) refer to deposits to suppliers. The Group has invested in a fixed term deposit amounting to €20,000 thousand with a term of 4 months. The Group recognized an increase of principal amount by €17 thousand due to positive interest rates and the Group recognized an expected credit loss of €30 thousand. The deposits were not redeemable before maturity. In October 2021, the Group had invested a total €120,000 thousand into fixed term deposits with terms of 6, 9 and 12 months, €40,000 thousand each respectively. The Group recognized a reduction of principal amount by €336 thousand due to negative interest rates of €80 thousand and an expected credit loss of €257 thousand. The Group did not hold any investment in money market funds as of year end. In November 2021, the Group has invested €100,006 thousand into money market funds. During the year, the Group sold all investments in money market funds for total proceeds of €99,853 thousand (2021: nil). The Group terminated its investment in March 2022.

Non-Financial Assets

Non-Financial Assets	12 Months Ended
	Dec. 31, 2022
Non-Financial Assets
Non-Financial Assets	19. Non-Financial Assets ​ Non-financial assets are as follows: ​ ​ ​ ​ ​ ​ In € thousand 12/31/2022 12/31/2021 Advance payments 4,069 8,113 Prepaid expenses ​ 9,418 ​ — Total non-current non-financial assets 13,487 8,113 Value added tax claims 1,696 12,602 Prepaid expenses 16,241 9,924 Miscellaneous other current non-financial assets 711 468 Total current non-financial assets 18,648 22,994 Total non-financial assets 32,135 31,107 ​ Advance payments are payments made for the acquisition of fixed assets €4,069 thousand (2021: €8,113 thousand). Non-current prepaid expenses mainly consist of multi-year supplier contracts which have required upfront prepayments due to necessary investments by the suppliers €9,418 thousand (2021: nil). Current prepaid expenses mainly relate to manufacturing costs prepaid €16,241 thousand (2021: €9,924 thousand). Miscellaneous other current non-financial assets relate mainly to receivables from suppliers amounting to €374 thousand (2021: €372 thousand).

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Dec. 31, 2022
Cash and Cash Equivalents
Cash and Cash Equivalents	20. Cash and Cash Equivalents ​ Cash and cash equivalents are as follows: ​ ​ ​ ​ ​ ​ In € thousand 12/31/2022 12/31/2021 Petty cash — 2 Short-term fixed deposits ​ 49,385 ​ — Cash at banks 130,196 129,854 Total cash and cash equivalents 179,581 129,856 ​

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2022
Shareholders' Equity
Shareholders' Equity	21. Shareholders’ Equity On September 14, 2021, upon the Reorganization, all outstanding Lilium GmbH shares (Common shares, Seed shares, Series A, Series B1 and Series B2) have been transferred to Class A shares in the relationship 1 : 2,857 , except for 8,545 shares which have been transferred into 24,413,065 Class B shares. Class A shares have a nominal value of €0.12 per share and are freely transferrable (subject to any lock-up as may be contractually agreed from time to time) and each Class A share confers the right to cast twelve (12) votes in Lilium’s shareholders meeting, subject to a so-called voting cap as defined in Article 1 of Lilium’s articles of association and as may be elected by a certain shareholder to apply it. Class B shares have a nominal value of €0.36 and may only be transferred to (i) permitted transferees or (ii) Lilium. One Class B share will be converted into one Class A share and one Class C ordinary share, nominal value €0.24 per share (a “Class C share”) upon the occurrence of certain conversion events. A conversion event is triggered in respect of Class B shares (i) at the discretion of the Class B holder or (ii) in case the holder of Class B shares is not qualified to hold such Class B shares anymore as defined in Lilium’s articles of association. Each Class B share confers the right to cast thirty-six (36) votes and each Class C share confers the right to cast twenty-four (24) votes in Lilium’s shareholders meeting. As of year-end 525,000 (2021: nil) Class C shares were issued and held in treasury. If a Class C share is held by anyone else other than Lilium (regardless of the consequence of conversion), such holder of Class C shares (a transferor) must notify Lilium of this fact by written notice within three days after the occurrence of such event, following the failure of which Lilium is irrevocably empowered and authorized to offer and transfer the relevant Class C shares. The transferor, other than Lilium itself, must transfer such Class C shares to Lilium for no consideration. The result of the conversion of Class B shares is that a Lilium shareholder acquires one Class A share for each converted Class B share. During the year the conversion of 525,000 Class B shares (2021: nil ) and the transfer of 525,000 Class C shares (2021: nil ) to the Group were conducted. The holders of Class A shares and Class B shares shall be entitled pari passu pro rata ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Supervoting ​ Ordinary ​ ​ ​ ​ Common shares ​ shares ​ shares ​ ​ (in units) (Class A) (Class B) (Class C) Total Issued at January 1, 2020, as adjusted 130,596,327 24,413,065 — 155,009,392 Issued shares – convertible loans 19,156,185 — — 19,156,185 Issued shares – capital increase 23,261,694 — — 23,261,694 Issued as of December 31, 2020, as adjusted 173,014,206 24,413,065 — 197,427,271 Treasury shares – share buy-back ​ (205,704) ​ — ​ — ​ (205,704) Outstanding as of December 31, 2020, as adjusted ​ 172,808,502 ​ 24,413,065 ​ — ​ 197,221,567 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Common shares Supervoting shares Ordinary shares (in units) ​ (Class A) ​ (Class B) ​ (Class C) ​ Total Issued at January 1, 2021 ​ 173,014,206 ​ 24,413,065 ​ — ​ 197,427,271 Issued shares – convertible loans 20,533,259 — — 20,533,259 Reorganization as of September 14, 2021 22,697,450 — — 22,697,450 Treasury shares Lilium GmbH not exchanged into Lilium N.V. shares — — — — Capital increase 2021 PIPE 45,000,000 — — 45,000,000 Issued as of December 31, 2021 261,244,915 24,413,065 — 285,657,980 Treasury shares (375,000) — — (375,000) Treasury shares (due to consolidation) (879,691) — — (879,691) Outstanding as of December 31, 2021 259,990,224 24,413,065 — 284,403,289 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Common shares Supervoting shares Ordinary shares (in units) ​ (Class A) ​ (Class B) ​ (Class C) ​ Total Issued at January 1, 2022 261,244,915 24,413,065 — 285,657,980 Issued shares for share-based payment awards exercised 10,857,264 ​ — ​ — ​ 10,857,264 Warrants exercised 10 — — 10 Issued shares – ELOC 5,618,697 — — 5,618,697 Capital increase RDO & 2022 PIPE 91,524,935 — — 91,524,935 Conversion of Class B Shares 525,000 (525,000) 525,000 525,000 Repurchase of Class B Shares 50,000 — — 50,000 Issued as of December 31, 2022 369,820,821 23,888,065 525,000 394,233,886 Treasury shares — (425,000) (525,000) (950,000) Outstanding as of December 31, 2022 369,820,821 23,463,065 — 393,283,886 ​ As of December 31, 2022, there were 196,385,439 (2021: 152,054,830) shares with a par value each of €0.12 authorized for issue by the management. In March 2020, the 2019 convertible loans were converted into 19,156,185 shares, increasing subscribed capital by €2,299 thousand, share premium by €65,824 thousand and other capital reserves by €34,084 thousand (retrospectively adjusted). For the convertible loan, the €34,084 thousand exceeded the initial fair value of the convertible loan by this amount. Since the lender of this convertible loan was also a shareholder, this difference has been considered as a capital contribution; it was reclassified into share premium in March 2021 due to the conversion of the convertible loan. Share premium represents additional consideration for shares above the nominal value of shares in issue less transaction cost that incurred for the share issuance. During 2020, there was a net increase in shareholders’ equity of €96,810 thousand from the issuance of 23,261,694 shares (retrospectively adjusted) as a result of a capital increase, adding €2,791 thousand to subscribed capital and €94,019 thousand to share premium (retrospectively adjusted). Transaction costs of €503 thousand have been deducted from the share premium. These increases in 2020 were offset by a decrease of €763 thousand as a result of the buyback of 205,704 shares, €738 thousand have reduced share premium and (€25) thousand have been put into the reserve for treasury shares (retrospectively adjusted). On March 26, 2021 the convertible loan of €85,900 thousand and the accrued interest were converted into shares. In order to facilitate the transaction, the Group issued 20,533,259 shares, subscribed capital increased by €2,464 thousand, share premium by €127,813 thousand (retrospectively adjusted) and other capital reserves decreased by €34,084 thousand due to the conversion as described above. On March 30, 2021, Lilium entered into the Business Combination Agreement leading to the Reorganization, as described in note 1. Concurrently, Lilium entered into Subscription Agreements with certain investors for PIPE Financing (“2021 PIPE”). As a result of the Reorganization and the 2021 PIPE, the Group has increased shareholders’ equity by €164,868 thousand and €381,208 thousand, respectively. Subscribed capital increased by €2,724 thousand, share premium by €51,116 thousand (net of €2,227 thousand transaction costs) and other capital reserves by the IFRS 2 share listing expense of €111,109 thousand. The amounts related to the Reorganization also reflect the impact of (i) the conversion of the convertible loan (CLA4) into 274,272 Lilium N.V. shares, which increased subscribed capital by €33 thousand and share premium by €2,023 thousand, and (ii) the additional 293,230 Lilium N.V. shares related to the success fee, which increased subscribed capital by €35 thousand and share premium by €1 thousand. Additionally, the reserve for treasury shares decreased by €81 thousand. From the 2021 PIPE capital increase, subscribed capital increased by €5,400 thousand and share premium by €375,808 thousand. For the Reorganization, Lilium’s total transaction costs amount to €29,029 thousand. During the year ended December 31, 2022, a total of 10,857,264 (2021: Nil) shares have been issued due to the exercise of vested share-based payment awards; €1,303 thousand (2021: nil) have been added to subscribed capital, thereof €1,227 thousand (2021: nil) is transferred from other capital reserves, and €207 thousand (2021: nil) to share premium. A further €845 thousand (2021: nil) is deducted from other capital reserves in relation to net settlement of employee income taxation obligations. During the year ended December 31, 2022, €27,380 thousand (2021: €53,350 thousand) was recognized in other capital reserves in relation to equity-settled share-based payment arrangements, as described in note 22. Share Purchase Agreement (“ELOC”) On June 3, 2022, the Group had entered into a Share Purchase Agreement and a Registration Rights Agreement with Tumim Stone Capital LLC (“Tumim Stone”), pursuant to which (a) the Group agreed to issue 262,697 (the “Commitment Shares”) of the Group’s Class A shares to Tumim Stone and (b) Tumim Stone had committed to purchase, subject to certain limitations, up to $75 million of Class A shares. While the Group had the right, but not the obligation, to sell the Class A shares to Tumim Stone, the latter was obligated to purchase the Class A shares up to the total committed amount as and when the Group required funding via a purchase notice to Tumin Stone. Under this Agreement, the Group issues Class A shares at a discount to the volume-weighted average price on the date of the purchase notice. The Group determined that the right to issue Class A shares represents a freestanding purchased put option, and the purchased put option was classified as a derivative asset with a fair value at the inception of €696 thousand equal to the market value of the Commitment Shares paid as consideration. The issuance of the Commitment Shares resulted in a €31 thousand increase in subscribed capital and a €665 thousand increase in share premium. As all shares were issued at a discount to the market value, the put option was immediately considered to have a fair value of nil and a €696 thousand fair value loss was recognized in financial expenses. Between July 5, 2022 and October 31, 2022, Lilium N.V. issued 5,356,000 Class A shares under this Share Purchase Agreement for cash proceeds of €12,498 thousand. Lilium N.V. recorded the issued Class A shares at fair value net of equity issuance cost (represented by the discount) by increasing subscribed capital by €643 thousand and share premium by €11,855 thousand. The agreement was terminated on November 17, 2022. Registered Direct Offering (“RDO”) On November 18, 2022, the Group entered into securities purchase agreements (“RDO Securities Purchase Agreement”) with certain investors in a registered direct offering for the purchase and sale of 22,499,997 Class A shares and warrants to purchase up to 11,249,997 Class A shares for aggregate gross cash proceeds of €28,217 thousand (the “Registered Direct Offering”). €8,541 thousand are recognized as a liability to issue the warrants. Details of the warrants (“RDO Warrants”) are disclosed in note 23. The closing of the RDO occurred on November 22, 2022. 2022 Private Placement (“2022 PIPE”) In November 2022, the Group entered into securities purchase agreements (“2022 PIPE Securities Purchase Agreement”) with certain investors for the purchase and sale of 69,024,938 Class A shares and warrants to purchase up to 34,512,464 Class A shares at $1.30 per share for aggregate cash proceeds of €85,754 thousand and a non-cash contribution of €975 thousand. Each Class A Share sold in the 2022 PIPE will also be accompanied by a 2022 PIPE Warrant to purchase 0.5 Class A Share. Under the 2022 PIPE agreement, the 2022 PIPE transaction will conclude concurrently with the RDO transaction and the purchase price of the 2022 PIPE transaction was determined in connection with the pricing of the RDO transaction. The terms and pricing of the 2022 PIPE transaction is similar with the RDO transaction. The contribution from two investors, who are also suppliers of the Group, was accounted for as an IFRS 2 share-based payment in exchange for non-recurring cost (“NRC”) supplies. The share-based payments resulted in €11,916 thousand recognized in other capital reserves. The closing of the 2022 PIPE occurred on November 22, 2022 and a portion of the Class A shares and warrants closed on November 29, 2022. €26,009 thousand are recognized as a liability to issue the warrants. Details of the 2022 PIPE Warrants are disclosed in note 23. Class B share transactions In July 2022, the Company agreed that up to 375,000 Class B shares could be returned by a member of Key Management Personnel of the Group for no consideration against the transfer of 375,000 Class A shares held in Lilium’s treasury. In August 2022, 375,000 Class B shares were returned, and accordingly, 375,000 Class A shares were transferred from Lilium’s treasury to the shareholder who is a member of Key Management Personnel of the Group. Treasury Shares The reserve for treasury shares represents the nominal amount of own shares held in treasury. Payments for treasury shares above or below nominal value are deducted from or added to share premium, respectively. The movement of treasury shares during years are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Common shares Supervoting shares Ordinary shares (in units) ​ (Class A) ​ (Class B) ​ (Class C) ​ Total At January 1, 2021 205,704 — — 205,704 Treasury shares of Lilium GmbH not exchanged into Lilium N.V. shares (205,704) — — (205,704) Treasury shares acquired upon Reorganization 375,000 — — 375,000 Treasury shares from consolidation of Stichting JSOP 879,691 — — 879,691 At December 31, 2021 1,254,691 — — 1,254,691 Repurchase of Class B shares for Class A shares held in treasury (375,000) 375,000 — — Repurchase of Class B shares for newly issued Class A shares — 50,000 — 50,000 Conversion of Class B shares — — 525,000 525,000 Treasury shares sold by Stichting JSOP (879,691) — — (879,691) At December 31, 2022 — 425,000 525,000 950,000 ​ During 2022, the Group repurchased 375,000 class B shares for no consideration against the transfer of 375,000 class A shares held in treasury, increasing the treasury share reserve by €90 thousand due to the difference in nominal capital between class B and class A shares. Additionally, the Group repurchased 50,000 Class B shares for no consideration and issued and transferred 50,000 Class A shares, increasing treasury reserve by € 18 thousand. As there was no consideration paid by the Group the share premium increased by €108 thousand and the subscribed capital increased by €6 thousand. During 2022, a shareholder converted 525,000 class B shares into 525,000 class A shares and 525,000 class C shares and transferred the class C shares back to the Group for no consideration in line with the articles of association, increasing treasury share reserve by €126 thousand. As no consideration was paid for these class C shares by the Group, the nominal amount of €126 thousand has been recorded in share premium. In December 2022, the Group sold 879,691 shares held in treasury resulting in total consideration of €983 thousand of which €877 thousand was recognized in share premium. The sale was triggered due to the settlement of JSOP with a related party. Further details are in note 30.

Share-based Payments

Share-based Payments	12 Months Ended
	Dec. 31, 2022
Share-based Payments
Share-based Payments	22. Share-based Payments ​ Overview ​ Lilium offers several share-based plans as summarized in the table below. All plans are equity-settled, except for new success fees and JSOP (including bonus) which are treated as cash-settled. Refer to note 3 for the general accounting principles of share-based payment awards. ​ The ESOP plan started in 2017, initial success fees started in 2020, while all other plans such as RSU, performance-based stock option, time-based stock option, new success fees, presence bonus and JSOP came into place in 2021. During 2022, each of the previously mentioned plans were still in place, with the exception of the JSOP and presence bonus, which were closed during 2022 with no plans to replace these specific programs. The remaining liability for the JSOP is due to be paid out in early 2023, the presence bonus was settled during 2022. ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 General population and executives – standard ESOP 7,942 29,286 General population - RSU 4,977 77 Executives – ESOP special vesting 1,101 2,135 Executives – RSU 3,259 1,178 Executives – Performance-based stock options (375) 2,296 Executives – Time-based stock options 2,200 3,505 Executives – Success fees (cash-settled) (134) 2,590 Executives – Success fee (equity-settled) — 1,844 Joint stock ownership Plan (JSOP) incl. bonus (4,435) 5,438 Share-based payment – Vendors 9,726 — Total expense 24,261 48,349 ​ General population and Executives – standard Employee Stock Option Program (“ESOP”) ​ The expense recognized for participant services received during the year is shown in the following table: ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Expense arising from equity-settled share-based payment awards 7,942 29,286 ​ The total fair value of options granted during the year was €17,483 (2021: €23,061). ​ On October 8, 2021, Lilium has offered ESOP participants to settle their vested options exclusively in shares of Lilium N.V. instead of Lilium GmbH. As all participants have accepted, they now can exercise vested options at a conversion rate of 1 ESOP in Lilium GmbH into 2,857 options in Lilium N.V. in accordance with the relevant exercise windows. No accounting effects resulted from this conversion. The exercise price is €1 for 2,857 shares in Lilium N.V. ​ Movements during the year ​ The following table illustrates the number and weighted average exercise prices (“WAEP”) of, and movements in, Lilium N.V. share options during the years: ​ Equity-settled options: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ Number of ​ 2022 ​ Number of ​ 2021 (in units) options WAEP options WAEP Outstanding at January 1 19,573,307 € 0.00 13,962,159 € 0.00 Granted during the year 5,714 € 0.00 4,019,799 € 0.00 Forfeited during the year (1,188,512) € 0.00 (757,105) € 0.00 Exercised during the year ​ (10,318,085) ​ € 0.00 ​ — ​ ​ — Transferred (to)/ from cash-settled (22,856) € 0.00 2,348,454 € 0.00 Outstanding at December 31 8,049,568 € 0.00 19,573,307 € 0.00 ​ Cash-settled options: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ 2021 ​ ​ ​ ​ Number of ​ 2022 ​ Number of ​ 2021 (in units) ​ options ​ WAEP ​ options ​ WAEP Outstanding at January 1 — ​ — 2,348,454 ​ — Exercised during the year ​ (17,142) ​ € 0.00 ​ — ​ ​ — Transferred from/ (to) equity-settled 22,856 € 0.00 (2,348,454) € 0.00 Outstanding at December 31 5,714 € 0.00 — ​ — ​ The exact WAEP for all options is €1 divided by 2,857, which is 0.00035 and rounded to nil. The Group waived the employee’s liability for the share capital. ​ The weighted-average remaining contractual life is 10.37 years for equity-settled options and 10.13 years for cash-settled options. ​ Total options that vested during the year were 979,661 options (2021: 3,300,960 options). The weighted average share price for options exercised during 2022 was €2.52 (2021: not applicable). ​ In 2021, none of the options granted under the ESOP were exercisable and/or eligible to be settled because of the waiting period of 180 calendar days after the Reorganization on September 14, 2021. As of December 31, 2022, 7,043,620 options are vested and are exercisable at the request of the employee with a WAEP of €0.00. ​ Measurement of fair values ​ For grant dates on and after September 15, 2021, the fair value of the ESOP has been set equal to the actual share price using a simplified approach. ​ For grant dates prior to September 15, 2021, the inputs to the option pricing model includes the probability of indirect IPO and other scenarios, discount for the lack of marketability and the expected volatility. The expected volatility was based on an evaluation of the historical volatilities of comparable listed peer group companies. It reflects the assumption that the historical volatility is indicative of future trends, which may not necessarily be the actual outcome. Other common inputs to option pricing models such as discount rate, dividends expected and expected term are not significant due to the low exercise price. ​ The fair value of the options was derived from the estimated equity value of Lilium on that date because the beneficiary is entitled to shares of Lilium for a nominal amount in the case of an exit event. The value of the common shares was derived by applying a market approach on the basis of external financing rounds and an expected financing round valuation. With regards to the financing rounds, the liquidation preferences of the Seed shares, Series A, B1 and B2 shares were taken into account. A hybrid model between option pricing method and probability-weighted expected return method was used for the valuation. ​ Retrospectively adjusted, the fair value has developed as follows: ​ ​ ​ ​ ​ ​ ​ ​ Price of one share in in € ​ Valuation methodology ​ Lilium N.V. December 31, 2020 Hybrid model 6.05 March 31, 2021 Hybrid model 7.13 June 30, 2021 Hybrid model 7.05 July 31, 2021 Hybrid model 7.36 August 31, 2021 Hybrid model 7.71 September 15, 2021 Actual share price 7.89 December 31, 2021 ​ Actual share price ​ 6.12 March 31, 2022 Actual share price 3.59 ​ General population – Restricted Stock Units to new hires ​ The expense recognized for participant services received during the years is shown in the following table: ​ ​ ​ ​ ​ ​ In € thousand ​ 2022 ​ 2021 Expense arising from equity settled RSU 4,977 77 ​ Movements during the year ​ The following table illustrates the number and weighted average exercise prices (“WAEP”) of, and movements in, RSU during the years ended December 31, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ 2021 ​ ​ ​ ​ Number of ​ 2022 ​ Number of ​ 2021 (in units) ​ RSU ​ WAEP ​ RSU ​ WAEP Outstanding at January 1 162,800 € 0.12 — ​ — Assigned during the year 4,886,077 ​ € 0.12 162,800 € 0.12 Exercised during the year ​ (638,470) ​ € 0.12 ​ — ​ ​ — Forfeited during the year (135,309) ​ € 0.12 — ​ — Outstanding at December 31 4,275,098 ​ € 0.12 162,800 € 0.12 ​ 4,886 thousand RSU (2021: nil ) were granted during the year of which 162 thousand were recognized in 2021 due to explicit intention to grant the RSU to new hires. As RSU are exercised on vesting, none of the RSU were exercisable as of December 31, 2022 and 2021. The weighted average remaining contractual life of RSU outstanding at the end of 2022 is 0.58 years (2021: 1.7 years). ​ Measurement of fair values ​ The RSU are equity settled and have an exercise price of nominal €0.12 per share. The exercise price is significantly lower than the share price at grant date. Accordingly, the intrinsic value of the RSU has been used, i.e. the share price at grant date less the exercise price. The weighted average fair value of RSU granted during the year is €1.92 (2021: €5.97). ​ Executives – Employee Stock Option Program (“ESOP”) special vesting ​ Some executives have received ESOP comparable with the general ESOP program, but with individual conditions in respect to the vesting scheme and with different exercise prices. ​ The expense recognized for participant services received during the year is shown in the following table: ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Expense arising from equity-settled share-based payment awards 1,101 2,135 ​ The following table illustrates the number and weighted average exercise prices (“WAEP”) of, and movements in, Lilium N.V. equity-based share options during the years: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ 2021 ​ ​ ​ Number of ​ 2022 ​ Number of ​ 2021 (in units) ​ options ​ WAEP ​ options ​ WAEP Outstanding at January 1 1,888,477 7.90 — — Granted during the year — — 1,888,477 7.90 Forfeited during the year (1,160,457) 8.50 — — Outstanding at December 31 728,020 6.94 1,888,477 7.90 ​ Total options in Lilium N.V. shares vested during the year were 430,431 options (2021: 101,018 options). As of December 31, 2022, 531,449 (2021: none ) of the options granted under the ESOP plan have vested and are available to be exercised, with a WAEP of €0.00. The weighted average remaining contractual life of the ESOP option outstanding at the end of 2022 is 11.4 years (2021: 12.4 years). ​ Measurement of fair values ​ For grant dates on and after September 15, 2021, the fair value of the ESOP has been derived from the actual share price, using an option price model (Black-Scholes). There were no Executive ESOPs granted during the year (2021: €11,229 thousand). ​ Executives – Restricted Stock Units (“RSU”) ​ The expense recognized for participant services received during the year is shown in the following table: ​ ​ ​ ​ ​ ​ In € thousand ​ 2022 ​ 2021 Expense arising from equity–settled RSU 3,259 1,178 ​ Movements during the year ​ The following table illustrates the number and weighted average exercise prices (“WAEP”) of, and movements in, RSU during the years ended December 31, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ Number of ​ 2022 ​ Number of ​ 2021 (in units) ​ RSU ​ WAEP ​ RSU ​ WAEP Outstanding at January 1 1,050,913 € 0.12 — ​ — Granted during the year 1,699,411 ​ € 0.12 1,050,913 € 0.12 Forfeited during the year ​ (134,400) ​ € 0.12 ​ — ​ ​ — Exercised during the year (291,199) ​ € 0.12 — ​ — Outstanding at December 31 2,324,725 ​ € 0.12 1,050,913 € 0.12 ​ In the table above, assigned rights include granted rights as well as rights explicitly expected to be granted in the future. The weighted average remaining contractual life of RSU outstanding at the end of 2022 is 1.5 years (2021: 2.7 years). ​ Measurement of fair values ​ Similar to the RSU for the general population, the exercise price is significantly below the share price at grant. While a Black-Scholes model was used to determine the RSU fair market value, the outcome of the valuation basically reflects the intrinsic value of the RSU. Accordingly, the input assumptions other than the share price are not material. ​ For fair value calculations the share price was taken as the closing price at grant date of Lilium N.V. share. The weighted average fair value of options granted during the period was €1.67 (2021: €7.09). ​ Executives – Performance-based stock options ​ The (income) / expense recognized for participant services received during the years is shown in the following table: ​ ​ ​ ​ ​ ​ In € thousand ​ 2022 ​ 2021 (Income) / expense arising from performance-based stock option (375) 2,296 ​ Movements during the year ​ The following table illustrates the number and weighted average exercise prices (“WAEP”) of, and movements in, share options during the years ended December 31, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ 2021 ​ ​ ​ ​ Number of ​ 2022 ​ Number of ​ 2021 (in units) ​ options ​ WAEP ​ options ​ WAEP Outstanding at January 1 7,036,501 € 8.15 — ​ — Granted during the year 1,272,059 ​ € 9.45 7,036,501 € 8.15 Forfeited during the year (4,711,839) ​ € 8.66 — ​ — Outstanding at December 31 3,596,721 ​ € 7.94 7,036,501 € 8.15 ​ No options (2021: Nil options) are exercisable as of December 31, 2022. The weighted average remaining contractual life of performance-based stock options outstanding at the end of 2022 is 9.5 years (2021: 9.9 years). ​ For a member of key management, all 4,341 thousand originally granted performance stock options were forfeited as of June 1, 2022, and the expense already recognized from prior years (€1,553 thousand) has been released in general and administrative expense. The forfeiture was the result of a change in responsibilities which result in a different remuneration. In total, 1,006 thousand options were newly granted to a member of key management, and an expense of €121 thousand has been recognized for the period January 1 – December 31, 2022. The reason for the grant of the new options was partially as ex-gratia benefit for his services rendered in his former role as well as an incentive for his new role. The number of options therefore take into account the 681 thousand options under the former arrangement, for which the service condition was already fulfilled. The remaining 325 thousand options must fulfill the service vesting condition until 2025 and all options remain subject to the previously agreed performance vesting condition and the exercise price is unchanged. ​ Measurement of fair values ​ The following table lists the inputs to the Black-Scholes model used for the fair market value calculation for performance-based stock options for the year ended December 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ 2021 Risk free rate range (0.69%) – 2.01% ​ (0.69 %) – (0.66 %) ​ Expected dividend yield ​ — ​ — ​ Expected exercise term 3.3 – 3.4 years ​ 4 years ​ Expected volatility 108.86% - 121.91% ​ 121.8 % ​ The expected volatility was based on an evaluation of the historical volatilities of comparable listed peer group companies. It reflects the assumption that the historical volatility is indicative of future trends, which may not necessarily be the actual outcome. For fair value calculation the share price was taken as the closing price at grant date of Lilium N.V. The weighted average fair value of options granted during the year was €1.14 (2021: €5.68). The exercise prices are €9.45 (2021: the exercise prices are €7.11 or €8.80). ​ The ex-gratia grants are included in the new options above, based on market conditions at June 1, 2022. ​ Executives – Time-based stock options ​ The expense recognized for participant services received during the years is shown in the following table: ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Expense arising from time-based stock options 2,200 3,505 ​ Movements during the year ​ The following table illustrates the number and weighted average exercise prices (“WAEP”) of, and movements in, share options during the years ended December 31, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ 2021 ​ ​ ​ ​ Number of ​ 2022 ​ Number of ​ 2021 (in units) ​ options ​ WAEP ​ options ​ WAEP Outstanding at January 1 2,951,000 € 7.25 — ​ — Granted during the year 2,199,488 ​ € 2.76 2,951,000 € 7.25 Forfeited during the year (2,043,000) ​ € 7.25 — ​ — Outstanding at December 31 3,107,488 ​ € 4.07 2,951,000 € 7.25 ​ 908 thousand stock options (2021: Nil options) are exercisable as of December 31, 2022. The weighted average remaining contractual life of time-based stock options outstanding at the end of 2022 is 9.5 years (2021: 9.9 years). ​ Measurement of fair values ​ The following table lists the inputs to the Black-Scholes model used for the fair market value calculation for time-based stock options as of the grant date: ​ ​ ​ ​ ​ ​ ​ 2022 2021 Risk free rate range (0.69 %) – 2.05 % ​ (0.69 %) Expected dividend yield 0 ​ 0 Expected exercise term 1.1 – 1.8 years ​ 4 years Expected volatility 118.97 % – 124.10 % ​ 121.9 % ​ The expected volatility was based on an evaluation of the historical volatilities of comparable listed peer group companies. It reflects the assumption that the historical volatility is indicative of future trends, which may not necessarily be the actual outcome. Other common inputs to option pricing models such as discount rate, dividends expected and expected term. For fair value calculation the share price was taken as the closing price at grant date of Lilium N.V. share. The weighted average fair value of options granted during the year was €1.21 (2021: €5.31). The exercise price of the option is €2.76 (2021: €7.25). ​ Executives – Success fees ​ The expense recognized for participant services received during the years is shown in the following table: ​ ​ ​ ​ ​ ​ In € thousand ​ 2022 ​ 2021 (Income)/expense for success fees cash-settled (134) 2,590 Expense for success fee equity-settled — 1,844 Total (income)/expense (134) 4,434 ​ These expenses do not include the success fee that was converted to the JSOP and bonus arrangement; those expenses are disclosed in the corresponding section below. As of December 31, 2022, no (2021: €2,590 thousand) provisions were recorded in the consolidated statement of financial position. The 2021 provision was partly reversed and partly consumed in 2022, and the success fees were subsequently settled as cash during the year, resulting in a payment of €2,457 thousand. ​ In 2021, the equity-settled success fee was determined as a 0.5 % percentage of the proceeds from the Reorganization, which was subsequently converted into 293,230 Lilium N.V. shares at a share price of $10.00 (€8.47) as of September 14, 2021. ​ Measurement of success fees ​ The success fees were measured as discounted expected cash flows for the success fee arrangements. ​ All amounts under the former success fees contract were settled and the contracts were terminated on November 30, 2022. ​ A new contract was entered with a related party and was accounted for under IAS 37 as contingent liability as disclosed in note 29. No conditions for payment have been met as of December 31, 2022. ​ Executives - Joint Stock Ownership Plan (JSOP) and bonus ​ (Income)/ expense related to and the liability from the JSOP and the bonus are shown in the following table, the award is fully vested: ​ ​ ​ ​ ​ ​ In € thousand ​ 2022 ​ 2021 (Income)/ expense for JSOP (3,762) 3,762 (Income)/ expense for bonus (673) 1,676 Total (income)/ expense (4,435) 5,438 ​ Measurement of the JSOP and the bonus ​ In December 2022, the recipient exercised the option to settle the JSOP. The remaining liability amounting to €1,003 thousand (2021: €3,762 thousand and €1,676 for the JSOP and bonus respectively) at year end for the JSOP relates to the bonus due to be paid in early 2023. As of December 31, 2022, the liability is measured at the value of the cash received from the sale of the shares held by Stitching JSOP (see note 30). ​ The remaining contractual life is nil years (2021: 4.7 years). ​ Share-based payment – Vendors ​ In November 2022, the Group entered into a Share Issuance Agreement with a third-party vendor, with the option at the Group’s discretion to pay for the IT services to be rendered by the vendor either via the issuance of 3,101,523 units of Class A shares of Lilium N.V. or cash of US$4,500 thousand. The Group has opted to settle the invoiced amount via issuance of shares and have recognized an expense amounting to €4,558 thousand. ​ As of year end, €3,757 thousand (2021: nil) is recognized in the other capital reserves for services rendered by the vendor but yet to be settled by the Group for which the Group has the option to settle via equity or cash. ​ In November 2022, the Group entered into share-based payment arrangements with two third-party vendors as part of the 2022 PIPE transaction in exchange for prepayment of the goods and services to the vendors amounting to €19,502 thousand (2021: nil). The prepayment value was deemed to be the fair value of the securities issued. As of December 31, 2022, services rendered by one vendor resulted in the release of €1,114 thousand (2021: nil) from the prepayment and recorded as a share-based payment expense. ​ ​ Advisors – Strategic collaboration agreement (Azul Warrants) ​ The Azul Warrants (refer to note 30) entitle Azul to purchase 1,800,000 Class A shares at an exercise price of €0.12 per share. The Azul Warrants will expire on October 22, 2026 (“Expiration Date”), five years after their issuance. The warrants and any Class A shares issuable upon exercise of the warrants may not be transferred until the twelve-month anniversary of issuance (the “Lockup”). ​ Lilium has the option to settle the awards in shares or cash. The Azul Warrants are accounted for as equity-settled awards, as Lilium had no present obligation to settle the awards in cash. They are considered fully vested once both parties signed the term sheet, which occurred on July 31, 2021. After that date, no services were required to be provided by Azul for the warrants to vest thereafter. Due to the unique nature of the services provided by Azul, Lilium considered direct measurement of the services provided unreliable and referred to the fair value of the Azul Warrants to indirectly measure the compensation arrangement. The 1,800,000 warrants have been expensed as of July 31, 2021 based on a hybrid valuations model, using different scenarios and a deduction of 5 % for the lack of marketability at this point of time. For the valuation of the share price, multiple connected Black-Scholes models have been used and for the IPO scenario a simplified valuation based on past financing rounds. The General & Administration expense (professional fees) amount of €13,030 thousand was posted directly into capital reserves (see note 7). ​ The Azul Warrants have not been exercised by Azul as of December 31, 2022.

Warrants and Other Financial Li

Warrants and Other Financial Liabilities	12 Months Ended
	Dec. 31, 2022
Warrants and Other Financial Liabilities
Warrants and Other Financial Liabilities	23. Warrants and Other Financial Liabilities ​ Warrants and other financial liabilities are as follows: ​ ​ ​ ​ ​ ​ in € thousand 12/31/2022 12/31/2021 Other non-current financial liabilities 21 — Other current financial liabilities 4 — Reorganization Warrants 1,811 21,405 RDO & 2022 PIPE Warrants 24,456 — Warrants 26,267 21,405 ​ Warrants ​ Reorganization Warrants ​ Upon the Reorganization, 12,649,946 Public Warrants and 7,060,000 Private Warrants (collectively the “Reorganization Warrants”) were assigned from Qell to Lilium. The terms of the Reorganization Warrants remain unchanged following the assignment. During the year 10 (2021: nil) Public Warrants were exercised. As of December 31, 2022, 12,649,936 Public Warrants (2021: 12,649,946) and 7,060,000 Private Warrants (2021: 7,060,000) were outstanding. ​ The Reorganization Warrants give the holder the right, but not the obligation, to subscribe to Lilium’s shares at a fixed or determinable price for a specified period of time subject to the provision of the warrant agreement. The Reorganization Warrants became exercisable 30 days after the consummation of the Reorganization. The Reorganization Warrants will expire five years after the completion of the Reorganization or earlier upon redemption, liquidation or expiration in accordance with their terms. ​ Public Warrants are listed and publicly traded on the Nasdaq stock exchange. Private Warrants share the same characteristics as Public Warrants and the same price has been used to calculate the fair value as described in note 28. ​ RDO Warrants & 2022 PIPE Warrants As part of the RDO & 2022 PIPE transaction as described in note 21, the Company also entered into a warrant agreement dated November 18, 2022 (the “RDO & 2022 PIPE Warrants”) with each of the RDO & 2022 PIPE investors. The RDO & 2022 PIPE Warrants entitles each whole RDO & 2022 PIPE Warrant holder to purchase 0.5 Class A Share of the Company for $1.30 per share with a minimum of the USD equivalent of the nominal value of €0.12 per share . ​ The RDO Warrants are identical to the 2022 PIPE Warrants as these share the same terms except that the RDO Warrants and the underlying shares are registered securities and the 2022 PIPE Warrants and the underlying shares are unregistered and would need an effective registration statement for resale. Subsequent to the issuance of the 2022 PIPE Warrants, the Group registered the securities underlying the 2022 PIPE Warrants on December 13, 2022. The RDO & 2022 PIPE Warrants are unlisted warrants. ​ The RDO & 2022 PIPE Warrants are exercisable for a four -year period at an exercise price of $ 1.30 per share and contain customary anti-dilution adjustments, including adjustments in connection with the issuance of Class A shares at a price below $1.30 , subject to exceptions. Beginning on November 22, 2024, the Group can redeem the warrants for $0.01 per share if the market price of the Class A shares is equal or exceeds $2.60 per share as reported by Nasdaq, for at least twenty (20) trading days (whether or not consecutive) during a thirty (30) consecutive trading day period by giving at least twenty ( 20 ) trading days’ prior written notice to the registered holders of the warrants. As of December 31, 2022, 11,249,997 (2021: nil) RDO Warrants and 34,512,464 (2021: nil) 2022 PIPE Warrants were outstanding.

Provisions

Provisions	12 Months Ended
	Dec. 31, 2022
Provisions
Provisions	24. Provisions The movement in provisions during the year is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unwinding of ​ ​ ​ ​ ​ ​ ​ discount and ​ ​ ​ ​ ​ ​ Additions/ ​ changes in ​ ​ In € thousand ​ 01/01/2022 ​ Reversals ​ discount rate ​ 12/31/2022 Asset retirement obligations 233 66 3 302 Post-employment benefits (note 25) 84 (9) — 75 Record retention obligations 56 22 (10) 68 Total non-current provisions 373 79 (7) 445 Year-end audit 1,067 (1,067) — — Legal Claims — 420 — 420 Severance payments 619 (505) — 114 Other 736 (540) — 196 Total current provisions 2,422 (1,692) — 730 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unwinding ​ ​ ​ ​ ​ ​ ​ of discount ​ ​ ​ ​ ​ ​ ​ ​ and changes ​ ​ ​ ​ ​ ​ Additions/ ​ in discount ​ ​ In € thousand ​ 01/01/2021 ​ Reversals ​ rate ​ 12/31/2021 Asset retirement obligations 175 54 4 233 Post-employment benefits (note 25) 193 (109) — 84 Record retention obligations 43 13 — 56 Total non-current provisions 411 (42) 4 373 Year-end audit — 1,067 — 1,067 Severance payments 80 539 — 619 Other — 736 — 736 Total current provisions 80 2,342 — 2,422 ​ Asset retirement obligations originate from the Group’s lease rental contracts (removal of tenant fixtures – refer to note 16) and they are expected to be settled in May 2027 at the lease contract end. Accrued severance payments from prior year have been paid. Other provisions closing balance relates to social security provisions with reversals during the year primarily relating to board remuneration, payroll, social security, and HR provisions. ​ Legal claims relate to the expected legal fees in relation to US litigation proceedings. On April 18, 2022, a putative class action was filed against Lilium N.V., Daniel Wiegand, Geoffrey Richardson, and Barry Engle for purported violations of United States securities laws. This lawsuit was filed in the U.S. District Court for the Central District of California. On February 10, 2023, the U.S. District Court for the Central District of California transferred the action to the U.S. District Court for the Southern District of Florida. The lawsuit is presently captioned as: Maniraj Ashirwad Gnanaraj v. Lilium N.V. et al., 2:22-CV-80232-Rosenberg/Reinhart. On February 15, 2023, the court entered an order appointing Jonathan Coon as Lead Plaintiff. On March 10, 2023, Lead Plaintiff filed an amended complaint that adds additional defendants and asserts additional claims for purported violations of the United States securities laws. The Group’s management believes the claims are without merit and intend to vigorously defend this litigation. The lawsuit is currently at a preliminary stage and the Group cannot predict its outcome, so the Group therefore cannot determine the likelihood of loss or estimate a range of possible loss.

Post-Employment Benefits

Post-Employment Benefits	12 Months Ended
	Dec. 31, 2022
Post-Employment Benefits
Post-Employment Benefits	25. Post-Employment Benefits Defined contribution plans The Group participates in defined contribution plans in the UK and Germany that are funded through payments by employees and by the Group to funds administered by third parties. The Group’s expenses for these plans were €635 thousand (2021: €465 thousand). No assets or liabilities are recognized in the Group’s balance sheet in respect of such plans, apart from regular prepayments and accruals of the contributions withheld from employees’ wages and salaries and of the Group’s contributions. Contributions totaling €1 thousand (2021: €28 thousand) were payable to the fund at the reporting date and are included in creditors. Defined benefit plans Corporate post-retirement benefits are provided by the Group to employees in Switzerland in accordance with local law through defined benefit plans. Current pension arrangements for employees in Switzerland are made through plans governed by the Swiss Federal Occupational Old Age, Survivors and Disability Pension Act (‘BVG’). The Group’s pension plans are administered by separate legal foundations, which are funded by regular employee and company contributions. The final benefit is contribution based with certain guarantees regarding the benefits provided. Due to these guarantees, such Swiss pension plans are treated as defined benefit plans. In case the pension foundation becomes underfunded, the employer together with the employees can be obliged to refinance a plan until the funding level has reached 100% again. Such measures might include increasing employee and company contributions, lowering the interest rate on retirement account balances, reducing prospective benefits and a suspension of the early withdrawal facility. The Group in Switzerland is currently affiliated to a fully reinsured collective pension foundation which cannot become underfunded as all risks are reinsured with a life insurance company. However, the Group is exposed to certain refinancing risk in the future as the current affiliation contract can be cancelled or amended by both contractual parties. The present value of the defined benefit obligations and the fair value of the plan assets is as follows: ​ ​ ​ ​ ​ ​ In € thousand 12/31/2022 12/31/2021 Present value of funded obligations 487 155 Fair value of plan assets (411) (71) Net defined benefit liability 76 84 ​ Reconciliation of the net defined benefit liability: ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Net defined liability at January 1 84 193 Defined benefit cost recognized in consolidated statement of operations 101 117 Defined benefit cost recognized in other comprehensive income (28) (162) Employer contributions (85) (74) Currency effects 4 10 Net defined liability at December 31 76 84 ​ Reconciliation of the amount recognized in the consolidated statement of financial position: ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Employee benefit obligations as of January 1 155 433 Actuarial adjustments (14) (233) thereof: experience adjustments 94 (202) thereof: demographic adjustments — (25) thereof: adjustments for financial assumptions (108) (6) Current service cost 95 112 Past service credit — (1) Interest expense 1 1 Currency effects 14 19 Employee contributions 85 74 Benefits recovered / (paid) 151 (250) Employee benefit obligations as of December 31 ​ 487 ​ 155 ​ Reconciliation of the plan assets: ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Fair value of plan assets as of January 1 71 240 Employer contributions 85 74 Employee contributions 85 74 Benefits recovered / (paid) 151 (250) Administration expenses (6) (5) Return on asset excl. interest income 14 (71) Interest income 1 0 Currency effects 10 9 Fair value of plan assets as of December 31 411 71 ​ The plan assets are primarily comprised of retirement savings accounts of participants. These retirement savings are 100% funded with qualifying insurance policies as the foundation has reinsured all of its liabilities with a life insurer. The expense / (income) recognized in the consolidated statements of operations and other comprehensive income is made up as follows: ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Actuarial losses (+) / gains (-) deriving from experience adjustments 94 (202) Actuarial gains (-) / losses (+) deriving from changes in demographical assumptions — (25) Actuarial gains (-) / losses (+) deriving from changes in financial assumptions (108) (6) Return on plan assets etc., interest (expense) / income (14) 71 Included in other comprehensive income (28) (162) Current service cost 95 112 Past service (credit) / cost — (1) Interest income (1) 0 Administrative expenses (effective) 6 5 Interest expense 1 1 Included in the consolidated statements of operations 101 117 Total expense / (income) included in the consolidated statements of operations and other comprehensive income 73 (45) ​ The current service cost is included as part of personnel costs within the respective functional area; interest cost relating to the obligation is a component of the result from financing activities. For the years ended December 31, 2023 and 2024, the Group expects to make future payment contributions of €84 thousand (2021: €56 thousand for years ended December 31, 2022 and 2023). The following were the principal actuarial assumptions as of: ​ ​ ​ ​ ​ ​ ​ ​ 12/31/2022 12/31/2021 Future salary increases 3.00 % 1.00 % Inflation rate 1.60 % 0.60 % Future pension increases 0.00 % 0.00 % Discount rate 2.20 % 0.35 % ​ Sensitivity Analysis The main actuarial assumptions that are used to calculate the provisions for post-employment benefits are the discount rate and the trend for future increases in post-employment benefit obligations. A reasonably possible increase, or respectively decrease, in the significant actuarial assumptions would have had the following impact on the present value of the post-employment benefit obligations as of the respective reporting dates: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 2021 2022 2021 Discount rate 0.25 % 0.25 % ​ (0.25) % (0.25) % Present value of the post-employment benefit obligations (in € thousand) 472 149 ​ 503 163 ​ Salary increase 0.25 % 0.25 % ​ (0.25) % (0.25) % Present value of the post-employment benefit obligations (in € thousand) 490 156 ​ 480 155 ​ Pension increase 0.25 % 0.25 % ​ (0.25) % (0.25) % Present value of the post-employment benefit obligations (in € thousand) 495 159 ​ n/a n/a ​ ​ Duration The average duration of the obligations is 15 years (December 31, 2021: 18 years ). Expected Benefit Payments ​ ​ ​ ​ ​ ​ ​ ​ (in € thousand) ​ December 31, 2022 Financial years 2023 2024-2027 2028-2032 Expected benefit payments 29 161 280 Total expected benefit payments 29 161 280 ​ ​ ​ ​ ​ ​ ​ ​ ​ (in € thousand) December 31, 2021 Financial years ​ 2022 ​ 2023-2026 ​ 2027-2031 Expected benefit payments 18 95 147 Total expected benefit payments 18 95 147 ​

Trade and other Payables

Trade and other Payables	12 Months Ended
	Dec. 31, 2022
Trade and other Payables
Trade and other Payables	26. Trade and other Payables Trade and other payables are as follows: ​ ​ ​ ​ ​ In € thousand 12/31/2022 12/31/2021 Long term accruals 3,483 2,906 Non-current trade and other payables 3,483 2,906 Trade payables 19,195 14,936 Accruals for outstanding invoices 14,463 20,399 Current trade and other payables 33,658 35,335 Total trade and other payables 37,141 38,241 ​ Long term accruals consist of non-recurring cost (NRC’s) arrangements with suppliers. These costs relate to research and development costs that have taken place and which payment will be due upon delivery of future shipments.

Other Non-Financial Liabilities

Other Non-Financial Liabilities	12 Months Ended
	Dec. 31, 2022
Other Non-Financial Liabilities
Other Non-Financial Liabilities	27. Other Non-Financial Liabilities Other non-financial liabilities are as follows: ​ ​ ​ ​ ​ ​ In € thousand 12/31/2022 12/31/2021 Vacation accruals 2,474 2,488 Value added tax payables — 242 Payroll tax and social security 3,497 2,992 Miscellaneous other current non-financial liabilities 2,596 338 Total other non-financial liabilities 8,567 6,060 ​ Payroll tax and social security mainly comprise of personnel-related taxes. Miscellaneous other non-financial liabilities mainly result from personnel-related liabilities.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2022
Financial Instruments
Financial Instruments	28. Financial Instruments 28.1 Carrying Amounts and Fair Value The following tables disclose the carrying amounts of each class of financial instruments together with its corresponding fair value and the aggregated carrying amount per category: Financial instruments, analyzed by classes and categories ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 12/31/2022 In € thousand Category Carrying amount Fair value Financial assets, by class ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ AC 179,581 n/a Fixed term deposit ​ AC ​ 19,987 ​ n/a Non-current security deposits ​ AC 3,386 3,265 Security deposits ​ AC 2,594 n/a Total financial assets ​ ​ 205,548 ​ ​ Financial liabilities, by class ​ ​ ​ ​ ​ ​ Non-current trade and other payables ​ AC 3,483 3,239 Current trade and other payables ​ AC 33,658 n/a Non-current other liabilities ​ AC ​ 21 ​ 21 Current other financial liabilities ​ AC 4 ​ n/a Warrants ​ FVTPL 26,267 ​ 26,267 Total financial liabilities ​ ​ 63,433 ​ ​ ​ ​ ​ ​ ​ Thereof aggregated to categories according to IFRS 9 ​ Carrying ​ amount Financial assets measured at AC ​ 205,548 Financial assets measured at FVTPL — Financial liabilities measured at FVTPL 26,267 Financial liabilities measured at AC 37,166 ​ Financial instruments, analyzed by classes and categories ​ ​ ​ ​ ​ ​ ​ ​ ​ 12/31/2021 In € thousand Category Carrying amount Fair value Financial assets, by class Cash and cash equivalents AC 129,856 n/a Money market fund FVTPL 99,919 99,919 Fixed term deposit AC 119,664 n/a Non-current security deposits AC 3,779 3,787 Security deposits AC 42 n/a Total financial assets ​ 353,260 Financial liabilities, by class Non-current trade and other payables AC 2,906 2,868 Current trade and other payables AC 35,335 n/a Warrants FVTPL 21,405 21,405 Total financial liabilities ​ 59,646 ​ ​ ​ ​ ​ Carrying Thereof aggregated to categories according to IFRS 9 ​ amount Financial assets measured at AC 253,341 Financial assets measured at FVTPL 99,919 Financial liabilities measured at FVTPL 21,405 Financial liabilities measured at AC 38,241 ​ ​ The Public Warrants are traded in an active market and are therefore classified as level 1 of the fair value hierarchy. The Private Warrants have been classified as level 2 of the fair value hierarchy, however as the Private Warrants have the same characteristics as the Public Warrants, the same price has been used to calculate their fair value (see note 4 on Warrants). In addition, money market funds are also classified as level 1 as traded in an active market. The fair values of non-current financial instruments measured at AC are in level 2 and are determined as expected cash flows discounted using market-based credit risk adjusted interest rate curves that are applicable for the Group and specific for the residual term of each financial instrument. The fair values of the non-current security deposits measured at AC are in level 2 and are determined as the principal balance discounted using market-based credit risk adjusted interest rate curves that are applicable for the Group. The Group’s trade and other payables would be classified in level 3 due to the Group’s risk profile. This has no impact on the valuation as trade and other payables were measured at AC. RDO & 2022 PIPE Warrants were classified as level 3 of the fair value hierarchy, due to the inputs used to determine the fair value of the Warrants. Fair value has been determined using a Monte Carlo simulation in a risk neutral framework. The primary inputs into the simulation included the following: closing Lilium N.V. stock price as of the December 31, 2022, expected stock price volatility, term, risk-free rate and dividend yield. The expected stock price volatility was based on Lilium N.V. implied volatilities of 70%. The term input is equal to the Warrants’ remaining contractual term of 4 years. The risk-free interest rate is based on interpolated U.S. Constant Maturity Treasury rates for a maturity equal to the remaining life of the Warrants. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero. The below tables show the effect that an increase or decrease of the Lilium N.V. share price, $1.14 as of the December 31, 2022, or the volatility would have on the fair value of the RDO & 2022 PIPE Warrants. ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2022 ​ ​ Effect on financial in € thousand ​ Shift in share price ​ Fair Value warrant ​ result Base — ​ (24,455) ​ — Up 10 % (28,316) (3,861) Down (10) % (21,023) 3,432 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Effect on financial in € thousand ​ Shift in volatility ​ Fair Value warrant ​ result Base — ​ (24,455) — Up 10 % (27,029) (2,574) Down (10) % (21,881) 2,575 ​ The fair value of the promissory notes are calculated using a trinomial tree approach, set to optional conversion at an expected date. The primary inputs used in the model included the borrower’s share price at valuation date, probability of occurrence of each possible conversion and termination event, borrower-specific credit risk and risk-free interest rate. While the risk-free interest rate was based on currency specific time congruent IBOR and swap rates, the credit risk and stock prices of the borrower were not observable in a market and therefore highly judgmental. As of December 31, 2021, all promissory notes have been converted so that the Group is no longer exposed to equity price risk in relation to the promissory notes as of year-end. The fair value of the embedded derivative that was bifurcated from the convertible loan issued in 2021 is determined by aggregating the valuations for the various expected conversion and termination events. Since all events would lead to a conversion for a set fixed conversion price (however, for a variable number of shares), the value is derived as a forward contract embedded in the loan contract. The primary inputs used in the model include probability of occurrence of each possible conversion and termination event, borrower-specific credit spread and risk-free interest rate. Credit risk is model-implied and adjusted for movement in credit spreads to consider the investor’s higher risk in connection with this convertible instrument at each valuation date, and the risk-free interest rate is based on currency specific time congruent IBOR and swap rates. As credit spreads and stock prices are not observable in a market, especially these input parameters are highly judgmental. The convertible loan was converted to equity during 2021 and no further gains or losses were recognized in finance income / (expenses) in the Statement of Operations. ​ The movements in level 3 fair values are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Convertible loan – ​ RDO and 2022 In € thousand Promissory Notes embedded derivative PIPE Warrants January 1, 2021 676 ​ 14,948 — Purchases / issuances 1,051 ​ 312 — Changes from fair value remeasurement 475 ​ (6,326) — Foreign exchange effects ​ 20 ​ — ​ — Conversion (2,222) ​ (8,934) — December 31, 2021 — ​ — — Initial recognition — ​ — 34,550 Changes from fair value remeasurement — ​ — (8,979) Foreign exchange effects — ​ — (1,116) December 31, 2022 — ​ — 24,455 ​ The net gains and losses for each of the financial instrument measurement categories were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ Subsequent measurement ​ ​ ​ ​ Foreign ​ ​ ​ Impairment ​ ​ ​ ​ ​ ​ exchange ​ ​ ​ losses net of ​ Total per In € thousand Interest conversion Fair value reversal category Financial assets measured at amortized cost (412) 1,147 — 125 860 Financial liabilities measured at amortized cost (236) (560) — — (796) Financial assets and liabilities measured at fair value through profit or loss — (508) 29,667 — 29,159 Total (648) 79 29,667 125 29,223 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2021 ​ Subsequent measurement ​ ​ ​ ​ Foreign ​ ​ ​ Impairment ​ ​ ​ ​ ​ ​ exchange ​ ​ ​ losses net of ​ Total per In € thousand ​ Interest ​ conversion ​ Fair value ​ reversal ​ category Financial assets measured at amortized cost (364) 1,061 — (260) 437 Financial liabilities measured at amortized cost (3,483) (446) — — (3,929) Financial assets and liabilities measured at fair value through profit or loss — (1,018) (3,327) — (4,345) Total (3,847) (403) (3,327) (260) (7,837) ​ The total interest income for financial assets that are not measured at FVTPL is €145 thousand (2021: €5 thousand), while the total interest expense for these financial assets is €557 thousand (2021: €369 thousand). The total interest expense for financial liabilities that are not measured at FVTPL is €236 thousand (2021: €3,483 thousand). 28.2 Financial Instrument Risk Management Objectives and Policies The Group is exposed to market risk (especially foreign exchange risk) and liquidity risk. The Group’s senior management oversees the management of these risks. The CFO in combination with Treasury provides assurance to the Group’s senior management that the Group’s financial risk activities are governed by appropriate procedures and that financial risks are identified, measured and managed in accordance with the Group’s risk objectives. The Executive Board reviews and agrees on procedures for managing each of these risks, which are summarized below. Management regularly reviews the Group’s risk management objectives to ensure that risks are identified and managed appropriately. The Executive Board is made aware of and reviews management’s risk assessments prior to entering into significant transactions. Credit Risk The following tables provide information about the exposures to credit risk for all financial assets that are not measured at fair value through profit or loss and therefore are generally subject to the impairment regulations of IFRS 9. The most significant part of the impairment loss allowance relates to the fixed-term deposits and cash balances. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 12/31/2022 ​ ​ Equivalent to ​ ​ ​ ​ ​ ​ ​ external Gross Impairment ​ ​ credit rating carrying loss ​ Credit- in € thousand [S&P] amount allowance impaired Grades 1–6: Low risk BBB- to AAA 205,683 (135) No Of which: ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ ​ ​ 179,640 ​ (59) ​ No Fixed-term deposits ​ ​ ​ 20,017 ​ (30) ​ No Security deposits ​ ​ ​ 6,026 ​ (46) ​ No ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 12/31/2021 ​ Equivalent to ​ ​ ​ ​ external Gross Impairment ​ ​ credit rating carrying loss ​ Credit- in € thousand [S&P] ​ amount ​ allowance ​ impaired Grades 1–6: Low risk BBB- to AAA 253,601 (260) No Of which: ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ ​ ​ 129,859 ​ (3) ​ No Fixed-term deposit ​ ​ ​ 119,920 ​ (256) ​ No Security deposits ​ ​ ​ 3,822 ​ (1) ​ No ​ The above financial assets are primarily held with reputable financial institutions with high credit ratings. As of December 31, 2022, 52% (2021: 83%) of the Group’s cash and cash equivalents and fixed term deposits are held with a single financial institution. The Group regularly monitors its cash and cash equivalents and takes corrective actions should it identify any possible changes in creditworthiness of these financial institutions. ​ As of December 31, 2021, the total impairment loss allowance was €260 thousand. During the year, certain fixed-term deposits matured, resulting in a reversal of impairment loss allowance of €256 thousand (2021: nil), and impairment loss of €131 thousand was recognized (2021: €260 thousand). As of December 31, 2022, the impairment loss allowance was €135 thousand (2021: €260 thousand). ​ Foreign Currency Risk ​ The Group operates globally and is exposed to foreign currency risk arising from exposure to various currencies in the ordinary course of business. The Group’s foreign currency exposures primarily consist of the British pound (“GBP”), Japanese Yen (“JPY”) and US Dollar (“USD”). Foreign currency exchange risk mainly arises from commercial and financing transactions that resulted in recognized financial assets and liabilities denominated in a currency other than the local functional currency. ​ The following table demonstrates the Group’s exposure to possible appreciation and depreciation in foreign currency. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ USD JPY GBP Total exposure At December 31, 2022 ​ (in € thousand) ​ (in € thousand) ​ (in € thousand) ​ (in € thousand) Cash and cash equivalents ​ 17,927 ​ — ​ — ​ 17,927 Current financial assets 2,158 — 3,793 5,951 Non-current financial assets 5,424 — 6,369 11,793 Non-current trade and other payables ​ (2,885) ​ (901) ​ — ​ (3,786) Current trade and other payables (7,097) — (138) (7,235) Current financial liabilities (8,358) — (10,107) (18,465) Warrants (26,267) — — (26,267) ​ (19,098) (901) (83) (20,082) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ USD GBP Total exposure At December 31, 2021 ​ (in € thousand) ​ (in € thousand) ​ (in € thousand) Cash and cash equivalents 18,174 8 18,182 Current trade and other payables (4,916) (402) (5,318) Warrants (21,405) — (21,405) ​ (8,147) (394) (8,541) ​ The following table demonstrates the sensitivity of the Group to a reasonably possible appreciation and depreciation of the foreign exchange rates consisting of USD, GBP, and JPY towards the EUR by 10 %, with all other variables held constant. The impact on the Group’s profit or loss before tax is due to changes in the carrying amount of monetary assets and liabilities as of December 31, 2022: ​ ​ ​ ​ ​ ​ ​ Effect of EUR appreciation on Effect of EUR depreciation on ​ ​ profit before tax ​ profit before tax Currency ​ (in € thousand) ​ (in € thousand) USD 1,736 (2,122) GBP 8 (9) JPY 82 (100) ​ The impact on the Group’s profit or loss before tax is due to changes in the carrying amount of monetary assets and liabilities as of December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ Effect of EUR appreciation on ​ Effect of EUR depreciation on profit ​ ​ profit before tax ​ before tax Currency (in € thousand) (in € thousand) USD 735 (898) GBP 15 (19) ​ Interest Rate Risk ​ Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Interest rate risks from financial instruments can in general arise in connection with financial liabilities. Fixed rate securities may have their market value adversely impacted due to a rise in interest rates. Our cash equivalents and investment portfolio can also be subject to market risk due to changes in interest rates. Banks are adjusting the interest rate depending on changes of the respective reference rates set by central banks. The carrying value of variable interest bearing cash at banks is €82,128 thousand (2021: €130,000 thousand). Considering existing thresholds, a hypothetical reasonable increase / decrease of 50 basis points (2021: 10 basis points) in interest rates would have an effect on the Group’s consolidated financial statements of € 411 / (€ 411 ) thousand (2021: € 130 / (€ 130 ) thousand) arising from cash at banks. ​ Other Price Risk In 2021 during the Reorganization, the Group entered into obligations to settle Reorganization Warrants for a total number of 19,710 thousand (please refer to note 23). In 2022, the Group entered into further obligations to settle RDO & 2022 PIPE Warrants bringing the total number of outstanding warrants to 65,472 thousand. The value of the Reorganization Warrants is based on a publicly traded price. A reasonably possible increase or decrease in the warrant price by 10 %, with all other variables held constant, would have led to a loss or gain before tax of €181 thousand (2021: €2,140 thousand) with a corresponding effect in the financial result. The value of the RDO & 2022 PIPE Warrants is estimated using implied volatility based on the closing price of the Reorganization Warrants calculated using Monte-Carlo simulation in a risk-neutral framework with its key parameters including the risk-free rate and the closing stock price of Lilium N.V.’s publicly traded Class A shares (refer to note 28.1 for share price sensitivity analysis). In 2021, the Group invested into a money market fund with a total market value as of December 31, 2021 of €99,919 thousand. The value of the money market fund is based on a publicly traded price. A reasonable possible increase or decrease in the market price by 10 % would lead to a gain / (loss) before tax of €9,992 thousand. In 2022, the group sold all holdings in the money market fund so the Group is no longer exposed to equity price risk in relation to the money market fund. In 2021, the Group invested in one further promissory note for a nominal amount of €1,051 thousand ($1,250 thousand). As of December 31, 2021, all promissory notes have been converted so that the Group is no longer exposed to equity price risk in relation to the promissory notes as of year-end. Liquidity Risk Liquidity risk is the risk that the Group will encounter difficulty in meeting its obligations associated with its financial liabilities as they fall due. The Group is expanding very rapidly which results in increasingly stringent requirements regarding the corporate planning for budgeting and procuring of financial resources in such a way that the development program of the Lilium Jet is not delayed. Consequently, the continuation of development is based on the Group’s ability to raise financing from investors in the form of various financing rounds. The Group ensures that the supply of liquidity is always sufficient to settle financial liabilities that are due for payment. Liquidity is evaluated and maintained using forecasts based on fixed planning horizons covering several months and through the cash and cash equivalent balances that are available. The following table provides details of the (undiscounted) cash outflows of financial liabilities (including interest payments). Note that the Group expects to settle the Warrants in own equity instruments. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 12/31/2022 ​ ​ ​ ​ ​ 2028 and in € thousand ​ 2023 ​ 2024 2025 to 2027 ​ thereafter Lease liabilities 2,970 2,457 6,463 — Trade and other payables 33,658 1,974 2,770 — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 12/31/2021 ​ ​ ​ ​ ​ ​ ​ ​ 2027 and in € thousand ​ 2022 ​ 2023 ​ 2024 to 2026 ​ thereafter Lease liabilities 2,356 2,705 8,001 2,187 Trade and other payables 35,335 29 3,498 — ​ Capital Management For the purpose of the Group’s capital management, capital includes all share capital and other equity reserves attributable to the equity holders. The primary objectives of capital management are to support operating activities and maximize the shareholder value through investment in the development activities of the Group. Based on the ongoing development of the Lilium Jet, the Group has to rely almost exclusively on equity funding by its shareholders and debt financing until the Group can refinance itself in the future from marketable products as a result of successful development projects. The Group’s finance department reviews the total amount of cash of the Group on a monthly basis. As part of this review, management considers the total cash and cash equivalents, the cash outflow, currency translation differences and funding activities. The Group monitors cash using a burn rate. The cash burn rate is defined as the average monthly operational net cash flow. The Group is not subject to externally imposed capital requirements. The objectives of the Group’s capital management were achieved in the reporting year. No changes were made in the objectives, policies or processes for managing cash during the years ended December 31, 2022 and 2021. 28.3 Reconciliation of Changes in Liabilities arising from Financing Activities ​ ​ ​ ​ ​ ​ ​ ​ In € thousand ​ Lease liabilities ​ Warrants Total Statement of Financial Position as of December 31, 2021 11,823 21,405 33,228 Principal elements of lease payments (2,720) — (2,720) Interest paid (443) — (443) Change in the cash flow from financing activities (3,163) — (3,163) Additions to lease liabilities due to new lease contracts 1,873 — 1,873 Additions to warrants — 34,550 34,550 Fair value changes — (30,196) (30,196) Effects of foreign exchange conversion — 508 508 Interest expenses 436 — 436 Capital contributions — — — Statement of Financial Position as of December 31, 2022 10,969 26,267 37,236 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Convertible ​ Lease ​ ​ In € thousand ​ loans ​ liabilities ​ Warrants ​ Total Statement of Financial Position as of December 31, 2020 99,235 ​ 11,118 — 110,353 Proceeds from convertible loans 1,850 ​ — — 1,850 Principal elements of lease payments — ​ (1,781) — (1,781) Interest paid — ​ (437) — (437) Change in the cash flow from financing activities 1,850 ​ (2,218) — (368) Additions to lease liabilities due to new lease contracts — ​ 2,486 ​ 2,486 Additions to warrants ​ — ​ ​ ​ 25,859 ​ 25,859 Fair value changes (6,326) ​ — (5,492) (11,818) Effects of foreign exchange conversion ​ ​ ​ 1,038 1,038 Interest expenses ​ 3,483 ​ 437 ​ ​ ​ 3,920 Capital contributions (98,242) ​ — ​ (98,242) Statement of Financial Position as of December 31, 2021 — ​ 11,823 21,405 33,228 ​

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies.
Commitments and Contingencies	29. Commitments and Contingencies The Group has various lease contracts as of December 31, 2022. The future lease payments for these lease contracts are €400 thousand (2021: Nil) within one year, €1,601 thousand (2021: €1,601 thousand) between one and five years and nil (2021: €400 thousand) thereafter. The Group has commitments under operating contracts. The future payments for the operating contracts are €73,779 thousand (2021: €2,175 thousand) within one year, €100,177 thousand (2021: €37,517 thousand) between one and five years and €18,558 thousand (2021: €7,063 thousand) thereafter. ​ Further, the Group has commitments of €5,016 thousand (2021: €12,003 thousand) to acquire items of property, plant & equipment and commitments of €4,344 thousand (2021: €2,731 thousand) to acquire items of intangible assets. ​ The Group is required to issue, subject to the execution of definitive agreements, Azul Additional Warrants, which are expected to vest in three tranches upon achieving certain performance and market conditions. Please refer to the Strategic Commercial Collaboration with Azul in note 30. On April 18, 2022, a putative class action was filed against Lilium N.V., Daniel Wiegand, Geoffrey Richardson, and Barry Engle for purported violations of United States securities laws. This lawsuit was filed in the U.S. District Court for the Central District of California. On February 10, 2023, the U.S. District Court for the Central District of California transferred the action to the U.S. District Court for the Southern District of Florida. The lawsuit is presently captioned as: Maniraj Ashirwad Gnanaraj v. Lilium N.V. et al., 2:22-CV-80232-Rosenberg/Reinhart. On February 15, 2023, the court entered an order appointing Jonathan Coon as Lead Plaintiff. On March 10, 2023, Lead Plaintiff filed an amended complaint that adds additional defendants and asserts additional claims for purported violations of the United States securities laws. The Group’s management believes the claims are without merit and intend to vigorously defend this litigation. The lawsuit is currently at a preliminary stage and the Group cannot predict its outcome, so the Group therefore cannot determine the likelihood of loss or estimate a range of possible loss. In November 2022, the Group entered into a new success fee arrangement with an entity controlled by a former member of key management personnel shortly after cessation of employment, in which the Company will pay a percentage of future fundraising up to a cap of €9,300 thousand ($9,900 thousand). As of December 31, 2022, no conditions for payment had been met.

Related Party Disclosures

Related Party Disclosures	12 Months Ended
	Dec. 31, 2022
Related Party Disclosures
Related Party Disclosures	30. Related Party Disclosures The Group has no parent and no ultimate controlling party. Furthermore, the management holds shares. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Shares (in thousand units) Ownership Interest (%) Function ​ 12/31/2022 ​ 12/31/2021 ​ 12/31/2022 ​ 12/31/2021 Key management 28,302 25,743 7.2 % 9.1 % Other related parties 128,679 121,389 32.7 % 42.7 % Total 156,981 147,132 39.9 % 51.8 % ​ 2022 PIPE participation Members of key management personnel and other related parties participated in the November 2022 2022 PIPE transaction described in note 21. The related parties contributed €15,461 thousand in exchange for 12,192,306 shares and 6,096,151 warrants, acquiring additional beneficial ownership of 3.1% based on outstanding shares after the transaction. Subsidiaries Interests in subsidiaries are set out in note 2. ​ Transactions with Key Management Key management personnel have been defined as the members of the Board of Directors and Senior Leadership Team of Lilium. The annual remuneration and related compensation costs recognized as expense during the reporting period is comprised of the following: ​ ​ ​ ​ ​ ​ In € thousand ​ 2022 ​ 2021 1 Short-term employee benefits 4,657 3,607 Termination remuneration 52 619 Post-employment benefits 45 27 Share-based payment award remuneration 7,364 19,910 Success fees and JSOP (4,568) 9,872 Total 7,550 34,035 ​ 1 ​ During the year €320 thousand (2021: €72 thousand) were recognized as expense for cash remuneration of the board members of Lilium N.V. ​ Short-term benefits ​ Short-term benefits include salaries, bonuses and other benefits such as medical, death and disability coverage, company car and other usual facilities as applicable. ​ Share-based payment award remuneration ​ The share-based payment award remuneration represents the compensation cost of the equity-settled award schemes operated by Lilium during the period. Refer to note 22. ​ During the year, 3,557 thousand options (2021: 14,964 thousand options) were granted to key man-agement personnel. 1,872 thousand options (2021: no options) were exercised, 6,553 thousand options (2021: no options) were forfeited and 12,437 thousand options (2021: 19,204 thousand options) were held as of December 31, 2022 by key management personnel. ​ Success fees and JSOP ​ JSOP and bonus ​ Success fee remuneration includes the creation of the Joint Stock Ownership Plan (Stichting JSOP) and the bonus issued to one member of key management personnel, as described in notes 2 and 22. ​ The Stichting JSOP is a trust entity incorporated solely for the purpose of settling the transaction bonus to the member of key management personnel and is 100 % controlled by the Group. Under the JSOP arrangement, the Stichting JSOP held 879,691 Class A shares in the Group. As of December 31, 2021, these were recognized in treasury shares in the consolidated statement of financial position. ​ In December 2022, the recipient triggered the option to sell the shares, and Stichting JSOP sold all the Class A shares to third parties. ​ An income of €3,762 thousand (2021: €3,762 thousand expense) is recognized in General & Administrative expenses in relation to the JSOP and a credit of €673 thousand (2021: €1,676 thousand expense) in General & Administrative expenses in relation to the bonus. As of December 31, 2022 a share-based payment awards liability of nil (2021: €3,762 thousand) is recognized on the JSOP and €1,003 thousand (2021: €1,676 thousand) is recognized on the bonus. Success fees and related arrangements ​ In November 2022, the success fee award for one member of key management personnel was replaced with a cash bonus agreement conditional on certain liquidity targets being met during the period which resulted in a payment in December 2022. Subsequently, in December 2022 the member signed a separation agreement with the Group and the liquidity bonus was terminated. ​ In November 2022, a success fee arrangement was cancelled upon the recipient leaving the employment of Lilium. A new arrangement was signed with an entity controlled by the former member of key management personnel shortly after cessation of employment, in which Lilium will pay a percentage of some future fundraising up to a cap of €9.3m ($9.9m). As of December 31, 2022 no conditions have been met for payment under the arrangement and no liability recorded. ​ During the year Lilium made cash payments of €2,457 thousand (2021: nil) in relation to success fees and related arrangements. ​ Other transactions with Key Management Personnel The following transactions occurred with entities controlled or significantly influenced by members of key management personnel: ​ ​ ​ ​ ​ ​ (in € thousand) 2022 2021 1 Research and development expenses 17 14 General and administration expenses — 96 Selling expenses 289 167 Finance income 7 — Finance expenses 6 — Purchase of property, plant and equipment 24 1 ​ 1 ​ Lilium have committed to indemnification agreements for several of its directors and executive officers of the Group in relation to any possible claims, suits or proceedings arising from their service to Lilium. ​ As of December 31, 2022 the Group recognized €20 thousand (2021: €10 thousand) in current trade payables, €149 thousand (2021: €150 thousand) in non-current trade payables, and prepaid expenses of €1 thousand (2021: nil) in non-financial assets in relation to transactions with entities controlled or significantly influenced by members of key management personnel. ​ A member of key management personnel returned 950,000 Lilium N.V. Class B shares in exchange for 950,000 Class A shares in a series of transactions in 2022, described in note 21. No further consideration was paid under the transactions. ​ ​ Transactions with other related parties ​ Excluding key management personnel, related parties include entities over which the Group has significant influence and entities that have significant influence over the Group. The following transactions occurred with other related parties: ​ ​ ​ ​ ​ ​ (in € thousand) ​ 2022 ​ 2021 1 Convertible loans Beginning of the year — 99,235 Proceeds from convertible loans — 1,007 Fair value changes of convertible loans — (6,337) Interest expenses (not paid) — 3,400 Subscribed capital — (7) Contribution to capital reserves — (97,298) End of the year — — ​ ​ ​ ​ ​ Azul Warrants ​ — ​ 13,030 Research and development expenses 1,323 347 ​ 1 ​ As of December 31, 2022 the Group recognized €1,226 thousand (2021: €45 thousand) in current trade payables in relation to transactions with other related parties. ​ As part of the Reorganization in 2021, Qell shares have been repurchased by the Group for no consideration from the Qell shareholders. Please see note 21 for additional information. ​ Convertible loans ​ During the year ended December 31, 2021, the convertible loan of €85,900 thousand were converted into 20,533,259 Lilium N.V. shares in March 2021 (retrospectively adjusted). In January 2021, the Group entered into another loan convertible to equity of €1,000 thousand with a significant shareholder which has been converted into 148,564 Lilium N.V. Class A shares in September 2021. No further convertible loan arrangements were entered into in 2022. ​ Investment in Joint Venture ​ In June 2021, Lilium closed a licensing agreement for the use of Ionblox’s intellectual property, to be paid as a royalty rate on battery capacity manufactured for the Lilium Jet. The licensing agreement stipulates a minimum fee to be paid from 2026 onward for use of Ionblox’s battery technology. In the same month, Lilium signed an amendment to an existing Development agreement with Ionblox, extending an exclusivity period for the use of Ionblox’s licensed technology. ​ During the year, Lilium has incurred Research and Development expenditure of €1,323 thousand (2021: €347 thousand) under the Development Agreement. As of December 31, 2022, a balance of €1,226 thousand (2021: €45 thousand) is held in Trade and other payables. ​ As at December 31, 2022, Lilium has a non-cancelable commitment of €7,702 thousand (2021: €7,946 thousand) on the Development agreement. ​ ​ Strategic Commercial Collaboration ​ On July 31, 2021, Lilium executed a term sheet in which Lilium agreed to enter into negotiations with Azul to establish a strategic collaboration whereby Azul and Lilium will negotiate contracts to buy a certain number of Lilium Jets. As of the date these consolidated financial statements were approved, no contracts with respect to the acquisition of Lilium Jets or any other collaboration have been executed. Except for the Azul Warrants, the term sheet is legally non-binding. The term-sheet expired on December 31, 2022. The controlling shareholder of Azul is a member of key management personnel; therefore, Azul is a related party as of the date of the Reorganization. For further information on the warrants to Azul, please refer to notes 22 and 28. ​ Transactions with shareholders ​ Cloud subscription ​ In 2021, the Group entered into a non-cancelable purchase obligation for a cloud subscription with a shareholder (which provides advanced data analytics capability), including support services, updates and related professional services, for €42,433 thousand ($50,000 thousand) payable in increasing annual instalments over five years. This shareholder has no significant influence on Lilium. ​ In November 2022, the Group entered into a contract to increase the scope of services delivered by €4,558 thousand ($4,500 thousand), with a choice of settlement in either cash or Lilium N.V. Class A shares. In December 2022, the Group agreed to settle the balance by issuance of 3,101,523 Class A shares, to be paid out in January 2023 (see note 22). ​ In November 2022, the Group signed a further agreement with the provider that allows payment of €9,376 thousand ($10,000 thousand), due in March 2023, to be settled in either cash or Lilium N.V. Class A shares, at the discretion of Lilium. As of December 31, 2022, the Group had not yet committed to either choice. ​ During the year, €13,527 thousand (2021: €6,590 thousand) expenditure has been incurred under the contract in General and Administration expenses, including €4,558 thousand in relation to the November 2022 scope change to be settled by shares. As of December 31, 2022, the Group has nil prepayment (2021: €2,927 thousand) and recognized €8,315 thousand (2021: nil) in Other Capital Reserves in relation to the share-based payment awards. ​ As of December 31, 2022, the Group has remaining commitments of €26,894 thousand (2021: €34,015 thousand) on the contract.

Events after the Reporting Peri

Events after the Reporting Period	12 Months Ended
	Dec. 31, 2022
Events after the Reporting Period
Events after the Reporting Period	31. Events after the Reporting Period Cancellation of Class B shares ​ In January 2023 the Group cancelled 375,000 Class B shares held in treasury, decreasing treasury shares reserve and subscribed capital in the amount of €135 thousand. ​ AZUL MOU Amendment ​ In January 2023 Lilium and Azul entered into an agreement that extended the term of the term sheet signed on July 31, 2021 that allows for up to 6,200,000 warrants to be issued subject to the execution of definitive agreements (refer to note 22, 29, 30). The new arrangement provides for additional exclusivity rights and a limited Right of First Refusal for Azul over Lilium products and services in Brazil. The remaining terms were legally non-binding. As of the date these consolidated financial statements were approved, no binding contracts with Azul with respect to the acquisition of Lilium Jets or any other collaboration have been executed. ​ Conversion of Class B shares ​ During February 2023, a shareholder who is a member of key management personnel, converted 350,000 Class B shares into 350,000 Class A shares and 350,000 Class C shares and transferred the Class C shares back to the Group for no consideration in line with the articles of association, increasing treasury share reserve by €84 thousand.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Significant Accounting Policies
Intangible assets	Intangible assets Research and development costs In developing its novel eVTOL technology, the Group incurs significant research and development costs. The costs for internally generated research and development are expensed when incurred. A portion of costs for internally generated development is capitalized if: ● the product or process is technically feasible; ● adequate resources are available to successfully complete the development; ● the benefits from the assets are demonstrated; ● the costs attributable to the projects are reliably measured; and ● the Group intends to produce and market or use the developed product or process and can demonstrate its market relevance. Management recognizes there is interest for an air mobility service, especially within heavily populated urban areas; however, there is not yet an established market for this new industry. The self-developed eVTOL technology used in the development of the Lilium Jet is highly innovative and there are uncertainties related to successful completion of the development. Consequently, the Group has not yet capitalized development costs. These costs are reflected in the consolidated statement of operations in the period in which the expenditure is incurred. Purchased intangibles Purchased intangible assets are initially measured and recorded at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses. Amortization on intangible assets with a limited useful life is calculated on a straight-line basis over the following periods: ​ ​ ​ ​ ​ Useful life Software 2  –  15 years Purchased concessions, rights and other intangible assets 10  –  20 years ​
Impairment tests	Impairment tests At the end of each reporting period, the Group assesses whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Group estimates the asset’s recoverable amount. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. An asset’s recoverable amount is the higher of an asset’s or cash generating unit (“CGU”)’s fair value less costs of disposal and its value in use. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are measured at cost, net of accumulated depreciation and any accumulated impairment losses. Costs of construction recognized include all attributable direct costs including material and production overheads and, where applicable, an initial estimate of the cost of dismantling and removing the item and restoring the site on which it is located. Borrowing costs are capitalized as part of the underlying asset under construction if there is a qualifying asset. Subsequent expenditures on assets are capitalized only when it is probable that future economic benefits associated with the expenditure will flow to the Group and the cost of the item can be measured reliably. Repairs and maintenance are expensed in the period the costs are incurred. If items of property, plant and equipment are sold or disposed of, the gain or loss arising from the disposal is recognized as other operating income or expense in the consolidated statement of operations and other comprehensive income (loss). Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows: ​ ​ ​ ​ ​ Useful life Rights to land and buildings including leasehold improvements 2  –  9 years Technical equipment and machinery 3  –  25 years Office and other equipment 3  –  13 years Vehicles 5  –  11 years ​ Assets qualifying as low value assets with a value of up to €1 thousand are aggregated into groups and depreciated over a useful life of 5 years . Leasehold improvements are amortized over the unexpired portion of the lease term or the estimated useful life of the improvements, whichever is shorter. The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate. Assets under construction are presented net of additions and transfers during the financial period in the property, plant and equipment movement schedule in the notes to the consolidated financial statements.
Leases	Leases The Group’s lease obligations primarily relate to rights to buildings mainly for its office and research and development premises. As lease contracts are negotiated on an individual basis, lease terms contain a range of different terms and conditions. Lease contracts are typically entered for a period of 2 - 9 years and regularly include renewal and termination options, which provide operational flexibility to Lilium. Contracts may contain both lease and non-lease components. The Group allocates the consideration in the contract to the lease and non-lease components based on their relative stand-alone prices. As a lessee, at the inception of a contract, the Group assesses whether the contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. At the commencement date of the lease, which is the date at which the leased asset is available for use, the Group recognizes a right-of-use asset, which represents a right to use the underlying leased asset, and a corresponding lease liability, which represents the present value of future lease payments, in the consolidated statement of financial position. Short-term leases (leases with lease term of 12 months or less from lease commencement and that do not contain a purchase options) and leases of low value assets are not capitalized. Payments associated with short-term leases and leases of low-value assets are recognized on a straight-line basis as an expense in the consolidated statement of operations. Liabilities arising from a lease are initially measured at the present value of the remaining lease payments discounted using the interest rate implicit in the lease or the incremental borrowing rate in case the interest rate implicit in the lease is not readily determinable. The main components of the lease payments included in the measurement of the lease liability comprise the following: ● fixed lease payments; ● variable lease payments that are linked to an index (consumer price index); and ● lease payments in an optional renewal period if the Group is reasonably certain to exercise an extension option. Lease payments contain two elements, principal and interest. Interest expense is presented as part of finance costs in the consolidated statements of operations and other comprehensive income and measured using the effective interest method. Principal and interest portions of lease payments have been presented within financing activities in the consolidated statement of cash flows. The carrying amount of lease liabilities is remeasured if there is change in the future lease payments due to change in index or rate. At lease commencement right-of-use assets are initially measured at cost and are subsequently measured at cost less any accumulated depreciation and impairment losses and adjusted for any remeasurement of lease liabilities recognized. Cost of right-of-use assets includes lease liabilities, initial direct costs, prepayments made on or before the commencement date and less any lease incentives received. Right-of-use assets are depreciated on a straight-line basis from the commencement date to the earlier of the end of the useful life of the right-of-use asset and the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of the leased property and equipment. The right-of-use asset is periodically assessed for impairment. The Group has presented right-of-use assets within “Property, plant and equipment.” Assets related to retirement obligations for leased buildings are included in the cost of right-of-use assets for the respective underlying building lease. The Group does not have any contracts as a lessor as of the date of the consolidated statement of financial position.
Investment in joint venture / associate company	Investment in joint venture / associate company Under the equity accounting method, the investment in a joint venture or an associate is initially recognized at cost. The carrying amount of the investment is subsequently adjusted to recognize changes in the Group’s share of net assets of the joint venture or associate since the acquisition date. On acquisition of the investment, any difference between the cost of the investment and the entity’s share of the net fair value of the investee’s identifiable assets and liabilities is accounted for as follows: (a) Goodwill relating to a joint venture or associate is included in the carrying amount of the investment. Amortization of that goodwill is not permitted. (b) Any excess of the entity’s share of the net fair value of the investee’s identifiable assets and liabilities over the cost of the investment is included as income in the determination of the entity’s share of the joint venture or associate’s profit or loss in the period in which the investment is acquired. The consolidated statement of operations and other comprehensive income (loss) reflects the Group’s share of the results of operations of the joint venture or associate. Any change in other comprehensive income (loss) (“OCI”) of those investees is presented as part of the Group’s OCI. Gains and losses resulting from transactions between the Group and the joint venture or associate would be eliminated to the extent of the interest in the joint venture or associate. After application of the equity method, the Group determines whether it is necessary to recognizse an impairment loss on its investment in joint venture or associate. At each reporting date, the Group determines whether there is objective evidence that the investment in joint venture or associate is impaired. If there is such evidence, the Group calculates the amount of impairment as the difference between the recoverable amount of the joint venture or associate and its carrying value, and then recognizes the loss within ‘Share of profit/loss in a joint venture/ associate’ in the consolidated statements of operations. Upon loss of joint control or significant influence over the joint venture or the associate, the Group measures and recognizes any retained investment at its fair value. Any difference between the carrying amount of the joint venture or associate upon loss of joint control or significant influence and the fair value of the retained investment and proceeds from disposal is recognized consolidated statements of operations.
Non-financial Assets	Non-financial Assets Insurance recoveries are recognized for virtually certain reimbursements for damaged assets from the insurers. Other non-financial assets are recognized at cost.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents in the consolidated statement of financial position and consolidated statement of cash flows comprise cash at banks and on hand and short-term highly liquid deposits with an initial maturity of three months or less that are readily convertible to a known amount of cash and subject to an insignificant risk of changes in value. Depending on the classification, these financial assets are measured at amortized cost or fair value with changes through profit or loss – see financial instruments, note 28.
Treasury Shares	Treasury Shares The treasury shares represent the consideration paid or payable for own shares held in treasury. The nominal value of the shares is shown in the treasury share reserve, which is part of the capital reserves. Acquisition values higher or lower than the nominal value are reduced from or added to the share premium reserve.
Financial Instruments	Financial Instruments Financial instruments are contracts that give rise to a financial asset for one entity and to a financial liability or equity instrument for another entity. Financial instruments are recognized when the Group becomes a counterparty to it. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the marketplace (regular way trades) are recognized on the settlement date. Financial assets and financial liabilities are offset, and the net amount is reported in the consolidated statement of financial position, if there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis or to realize the assets and settle the liabilities simultaneously. The Group has no such assets and liabilities. Financial assets The Group’s financial assets include cash and cash equivalents and other financial assets. Other financial assets consist of security deposits for leases, fixed-term deposits and money market funds. Financial assets are initially measured at fair value plus, in the case of a financial asset not measured at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset. As an exception to this general rule, trade receivables are measured at their transaction price. Transactions costs are expensed as incurred for financial assets initially measured at fair value through profit or loss (“FVTPL”). Financial assets are classified at initial recognition as either measured at amortized cost (“AC”), fair value through other comprehensive income (“FVOCI”), or FVTPL depending on the contractual cash flows and the Group’s business model for managing them. For all financial assets, the Group has the objective to hold financial assets in order to collect the contractual cash flows. If the contractual terms of the financial assets give rise on specified dates to cash flows that are solely payments of principal and interest on the principal outstanding amount, the Group will measure these financial assets at AC under consideration of impairment (see following section). All financial assets are measured at AC, with the exception of money market funds, which are required to be measured at FVTPL because their cash flows are not solely payments of principal and interest on the principal outstanding amount. Gains and losses from financial assets measured at FVTPL are presented in the consolidated statements of operations in finance income and finance expense. Gains and losses from financial assets measured at AC including effects resulting from impairment are also presented in finance income and finance expense. Generally, the gains and losses from foreign currency translation effects are presented in other income / other expense. A financial asset is derecognized (i.e., removed from the Group’s consolidated statement of financial position) when the rights to receive cash flows from the asset have expired or have been transferred. Impairment of financial assets – expected credit losses (“ECL”) All financial assets measured at AC are required to be impaired at initial recognition in the amount of their expected credit loss (“ECL”). ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive. Lilium recognizes an allowance for ECLs for cash and cash equivalents and other financial assets according to the “general approach”. This means that ECLs are recognized in three stages. For credit exposures at initial recognition, ECLs are provided for credit losses that result from default events which may be possible within the next 12-months (Stage 1: a 12-month ECL). For credit exposures for which there has been a significant increase in credit risk since initial recognition (which is deemed to have occurred if a payment is more than 30 days past due), a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (Stage 2: a lifetime ECL). The same applies if objective indications exist that a default event has occurred (Stage 3: an incurred loss). In this case, any interest income is measured on the basis of the net carrying amount, while for stage 1 and 2 the basis is the gross carrying amount. Examples of objective evidence are significant financial difficulties experienced by the debtor, payment default or delays, a lowering of the credit rating, insolvency or where measures are taken to secure a debtor’s financial situation, or if other observable data indicates that expected cash flows deriving from financial assets may be appreciably reduced. For cash and cash equivalents as well as other financial assets, the simplification available for financial instruments with a low credit risk (“low credit risk exemption”) is applied as of the reporting date. Factors that can contribute to a low credit risk assessment are debtor-specific rating information and related outlooks. The requirement for classification with a low credit risk is deemed to be fulfilled for counterparties that have at least an investment grade rating; in this case there is no need to monitor credit risks for financial instruments with a low credit risk. The default probabilities applied to determine the ECL for cash and cash equivalents and other financial assets are based on credit default swap spreads that are quoted on markets, which take future-oriented macroeconomic data into account. In general, Lilium defines a default event as a situation in which the debt is no longer recoverable. If the financial instrument is perceived to be unrecoverable, then the expectation is that future contractual cash flows will not occur. At this point in time, the balance is written off after giving consideration to any possible collateral that is available. Impairment losses (including reversals of impairment losses on financial assets) are not presented as a separate item in accordance with IAS 1.82(ba) as they are considered immaterial. Impairment losses or income from the reversal of impairment losses on financial assets are reported net under finance income or finance expenses. Financial liabilities The Group’s financial liabilities include warrants, lease liabilities (see note 16), derivatives, trade and other payables, and other financial liabilities. Financial liabilities are classified as measured at AC or FVTPL. All financial liabilities are recognized initially at fair value less, in the case of a financial liability not at FVTPL, directly attributable transaction costs. Transactions costs are expensed as incurred for financial liabilities initially measured at FVTPL. Financial liabilities at FVTPL are measured at fair value and gains and losses resulting from changes in fair value are recognized in finance income / expenses. The Group only accounts for separated embedded derivatives of convertible loans and warrants as well as for other derivatives as a financial liability measured at FVTPL. All other financial liabilities are subsequently measured at AC using the effective interest rate (“EIR”) method. When applying the EIR method, the Group generally amortizes any fees, points paid or received, transaction costs and other premiums or discounts that are included in the calculation of the EIR over the expected life of the financial instrument. Gains and losses are recognized in interest expense when the liabilities are derecognized as well as through the EIR amortization process. For financial liabilities subsequently measured at AC, the foreign currency translation effects are presented in other income or expense. Foreign currency translation effects on financial liabilities at FVTPL are recognized in the finance income / expenses. Where there are hybrid instruments, transaction costs are apportioned between the liability and equity components based on the allocation of proceeds to the liability and equity components when the instruments are initially recognized. An embedded derivative in a hybrid contract, with a financial liability or a non-financial host, is separated from the host and accounted for as a separate derivative if: the economic characteristics and risks are not closely related to the host; a separate instrument with the same terms as the embedded derivative would meet the definition of a derivative; and the hybrid contract is not measured at FVTPL. The assessment whether to separate an embedded derivative is done only once at initial recognition of the hybrid contract. Reassessment only occurs if there is a change in the terms of the contract that significantly modifies the cash flows. A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expired. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The resulting gain or loss is recognized in the consolidated statement of other comprehensive income. Convertible Loans Convertible loans are assessed at issuance for any components of equity and liability. Convertible loans are bifurcated into a debt component and an equity instrument if there is a conversion right. The conversion right of a convertible loan is classified as a liability if some conversion features of the loan lead to a conversion into a variable number of shares. Embedded derivatives are assessed and, if needed, are separated from the host contract. The remaining host contract is measured at AC and the separated embedded derivative is measured at FVTPL until the loan is converted into equity or becomes due for repayment. If there are other derivative features provided for in the contract besides the conversion right, they are treated as a combined embedded derivative if they share the same risk exposure and are interdependent. Derivative Warrant Liabilities The Group evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to “IFRS 9 Financial Instruments” (“IFRS 9”). Warrants are recognized as derivative financial liabilities in accordance with IFRS 9. Accordingly, the Group classifies warrants as financial liabilities at FVTPL. The liabilities are subject to remeasurement at each balance sheet date until exercised or expired, and any change in fair value is recognized in the finance income/ expenses.
Income Taxes	Income Taxes Current income taxes Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date in the countries where the Group operates and generates taxable income. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate. Deferred taxes The Group uses the liability method of accounting for income taxes. Deferred income tax assets and liabilities represent temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and their corresponding tax basis used in the computation of taxable income. Deferred tax, however, is not recognized on the initial recognition of goodwill or the initial recognition of an asset or liability (other than in a business combination) in a transaction that affects neither tax nor accounting income. Deferred tax assets are in principle recognized for all deductible temporary differences, carry forward of unused tax credits and any unused tax losses. However deferred tax assets are only recognized to the extent it is sufficiently probable that taxable profit will be available against which the deductible temporary differences, the carry forward of unused tax credits and the unused tax losses can be utilized. Deferred tax liabilities are recognized for all taxable temporary differences associated with investments in subsidiaries and associates, except where the Group is able to control the reversal of the temporary differences and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year in which the asset is realized, or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. Deferred tax liabilities and assets are offset when there is a legally enforceable right to offset current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Group intends to settle its current tax assets and liabilities on a net basis. Current and deferred tax items are recognized similar to the underlying transaction either in profit or loss, other comprehensive income or directly in equity. Changes in deferred tax assets or liabilities are recognized as a component of tax expense (benefit) in the consolidated statement of operations, except where they relate to items that are recognized in other comprehensive income or directly in equity, in which case the related deferred tax is also recognized in other comprehensive income or equity, respectively. Where deferred tax arises from the initial accounting for a business combination, the tax effect is included in the accounting for the business combination. Deferred tax assets and deferred tax liabilities are not discounted. Deferred taxes are always classified as non-current.
Provisions	Provisions Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.
Fair Values of Assets and Liabilities	Fair Values of Assets and Liabilities Fair value is a market-based measurement. For some assets and liabilities, observable market transactions or market information is available. For other assets and liabilities, observable market transactions or market information might not be available. When a price for an identical asset or liability is not observable, another valuation technique is used. To increase consistency and comparability in fair value measurements, there are three levels of the fair value hierarchy: ● Level 1: contains the use of unadjusted quoted prices in active markets for identical assets or liabilities ● Level 2: inputs are other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly ● Level 3: inputs are based on unobservable market data If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, the fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement. The Group recognizes transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred. Further information about the assumptions made in measuring fair values of financial instruments is included in note 28.1. In cases where a gain or loss arises on initial recognition of a financial asset or a financial liability because the fair value deviates from the transaction price and is neither evidenced by a quoted price in an active market for an identical asset (i.e., a Level 1 input) nor based on a valuation technique that uses only data from observable markets (i.e., a Level 2 input), this gain or loss remains unrecognized until all market inputs become observable. In case such gain or loss results from a transaction with shareholders, this amount is to be considered as capital contribution to the Group and is therefore to be recognized in equity.
Share-based Payments	Share-based Payments General accounting principles The Group grants certain share-based payment awards to the Group’s employees, advisors and vendors in exchange for their service. These share-based payment awards qualify either as cash-settled or equity-settled transactions depending on the terms of settlement. When the settlement choice (i.e. cash versus shares) lies with the participant, awards are classified as compound financial instruments. Only in the case the equity component is zero, the award is accounted for as a cash-settled option. When the settlement choice lies with the Group, the award is classified as an equity-settled grant unless the Group has a present obligation to settle in cash. For cash-settled awards a liability is recognized at fair value. The fair value is measured initially and at each reporting date up to and including the settlement date, with changes in fair value recognized in profit or loss for the period. An equity-settled award is measured based on the fair value determined at grant date. The fair value usually remains unchanged after the grant date. In case of a modification of an award after grant date, an incremental fair value is determined at the modification date for modifications that are beneficial to the participants. The Group grants several share-based awards under several different plans, which are described below. Refer to note 22 for the measurement approach of the fair value of options. Due to the Reorganization, the Group has granted certain nonrecurring share-based awards to external consultants. The expenses for services received are recognized when the participant renders services over the applicable vesting period with a corresponding increase of either the liability or equity, depending on the classification of the awards. The related share-based payment awards expense is recorded in the functional cost category to which the participant’s costs are classified. Employee Stock Option Program (“ESOP”) The Group maintains an Employee Stock Option Program (“ESOP”), originally established in 2017, which allows for the issuance of options to purchase ordinary shares to its employees, executives and certain advisors. Share options typically follow a vesting schedule over a four-year period. 25% will vest after the one-year anniversary of the applicable vesting commencement data (the “Cliff Period”) and then monthly thereafter on a graded vesting basis through the end of the vesting period. Individuals must continue to provide services to a Group entity to vest. Upon termination, all unvested options are forfeited . There is no contractual life for the share options provided in the contract. In October 2021, Lilium GmbH sent letters to all employees under the current ESOP plan to modify certain terms of the agreement. As per the modification agreement, an employee’s vested options shall now be exclusively settled in shares of Lilium N.V. instead of shares of Lilium GmbH in consideration for the participant’s claim for settlement under the ESOP conditions (as amended) to Lilium N.V. Options which are unvested at the time of the modification shall continue to vest in accordance with the regular vesting schedule. Vested options became exercisable after expiration of a lock-up period of 180 calendar days from the date of listing of Lilium N.V. on the Nasdaq Stock Market. Vested options must be exercised during certain exercise windows during each quarter of the fiscal year of the Group, with the exact dates during each such quarterly period being determined by the Group. The options will expire on the 10 th anniversary of the date on which vested options became exercisable. All the holders of the options have signed the modification agreement. By signing this modification, the illiquid shares of Lilium GmbH have been converted to liquid shares of Lilium N.V. tradable on Nasdaq Stock Market. General population – Restricted Stock Units (“RSU”) The Group started offering Restricted Stock Units to its employees in 2021 based on their grade. Upon vesting, the plan participants are eligible to acquire shares at a nominal value of €0.12 . There are several vesting schedules with differing installment periods. The standard vesting schedule for new grants is vesting taking place a year after grant, with a 12-month cliff period. The RSU are settled in shares of Lilium N.V., and hence are accounted as equity-settled awards. The most common vesting period is 1 year whereby 100% is vested after 1 year , as a cliff period. Upon termination, the employee is entitled to the vested portion of the RSU. All unvested RSU are forfeited. Executives – Restricted Stock Units (“RSU”) The Group offered RSU of Lilium N.V. to executives, they are accounted for as equity-settled awards. RSU are exercisable with a nominal amount of €0.12 per share. All RSU are subject to participants’ continuous service, additionally upon termination of employment, all unvested RSU are forfeited. Specific RSU – The RSU granted to certain executives, which vary according to individual agreements, are subject to participants ’ continuous service. The length of these agreements are on average 4 years and the vesting is split either on a monthly or quarterly basis. Annual Election RSU – Initial RSU – Executives – Performance-based stock options The Group offers performance-based stock options of Lilium N.V. shares to executives. These options are settled in Lilium N.V. shares and can be exercised as soon as they vest until expiration or 90 days after the participant ceases to be an employee of the Group. The performance-based stock options are expected to be settled in shares of Lilium N.V., and hence they are accounted for as equity-settled options. These options vest and are exercisable upon the satisfaction of both the service-based vesting condition and the performance-based vesting condition. Typically, the service-based vesting condition shall be satisfied in 17 quarterly installments between the vesting commencement date and December 31, 2025. The performance-based vesting condition is expected to be satisfied at September 30, 2026 or when the Group earns its first dollar or any equivalent currency of revenue recognized in the Group’s consolidated financial statements directly from providing service to a customer by the operation of its own developed and certified aircraft by either the European Union Aviation Safety Agency or the Federal Aviation Administration and the customer has also paid for such services. The maximum term of options granted is 10 years from the date of grant. If the performance-based vesting condition is satisfied prior to any service-based vesting date, any portion of the option with respect to which the service-based vesting condition has not been satisfied as of the date the performance-based vesting condition is achieved shall remain subject to satisfaction of such service-based vesting condition. Executives – Time-based stock options In addition, there are time-based stock options for three participants. Time-based stock options are settled in shares of Lilium N.V. and are treated as equity-settled. One participant left the Company, and 31 % of this participant’s options had vested by December 31, 2022 and the remainder were forfeited. For the other two participants, the options vest in equal quarterly installments commencing April 19, 2022 (with one year cliff) or October 31, 2022 and ending April 1, 2026 or July 31, 2026, subject to participants’ continuous service in the Group. These options can be exercised until expiration or until 90 days after the participant ceases to be an employee. The maximum term of options granted is 10 years from date of grant. Upon termination, the participant is entitled to the vested portion of the options. All unvested options are forfeited. Executives – Success fees The Group has granted success fees to certain key management personnel for successful fundraising. Initial success fees were granted at the end of 2020 and beginning of 2021. Upon successful fundraising in September 2021, one award was settled in shares while another award was settled by execution of a so-called Joint Stock Ownership Program (“JSOP”) arrangement and a bonus agreement. Please refer to the section below for more details on the JSOP and the bonus. The revised success fees for future fundraising were agreed upon in September 2021, superseding the initial arrangement. Upon successful new financing by December 31, 2025, the participants will receive an agreed percentage of the fundraising in shares or cash capped at specific maximum funding amount. The revised arrangements offer a settlement choice to the participants and are accounted for as cash-settled. The expense for success fees is recognized over the period until a successful financing is expected. The assumption regarding a successful financing is reassessed by management at each reporting date. In case a successful financing is probable, the compensation expense is recognized. In the event the plan participants chose to settle in equity, the participant must pay the nominal share value. These revised success fee arrangements were terminated in the fourth quarter of 2022. The termination was a result of the participants completion of their service with the Group. One of the participants entered into a new success fee arrangement on November 30, 2022. The new success fee arrangement was entered with a related party and was accounted for under IAS 37 as contingent liability as disclosed in note 30. Executives – Presence bonus Additionally, an annual presence bonus award was offered to one individual if the individual performs an agreed percentage of employment services from the base location (Group’s head offices near Munich, Germany). The employee shall be eligible to an annual bonus in each calendar year from 2021 until 2025. The bonus will be accounted for on an annual basis, i.e., the period the respective services are received. Generally, the bonus offers a choice of settlement to the Group. In 2022, the presence bonus was agreed to be settled in cash and terminated. ​ Executives - Joint Stock Ownership plan (JSOP) and bonus The Group entered into a success fee arrangement with a management member of the UK subsidiary (see description on success fees above). Upon successful fundraising the success fee agreement provided the management member remuneration based on JSOP and the bonus. The success fee was invested into shares of Lilium N.V. whereby the participant had the option to determine the timing of the sale of these shares. The cash from the proceeds of selling these shares forms the basis of the payable in 2022 to the participant. Setting-up the JSOP and the bonus according to the arrangements made consists of the following steps: ● Setting up a trust: A Dutch foundation “Stichting JSOP” was incorporated through a deed of incorporation. ● Joint Ownership agreement: Shares in Lilium N.V. with a total value corresponding to the success fee were issued against a fair market value consideration to Stichting which serves as joint owner of the shares together with the management member. The management member has a sell right, which upon exercise, has the effect that all shares held together with Stichting are sold in the market. The sell right needs to be executed before September 14, 2026. If the sell right expires, the Stichting has a buy right buying back the management member’s shares. The buy right needs to be executed before March 14, 2027. In any case, the shares will be sold. The proceeds from the shares will be divided between the Stichting and the manage-ment member according to the respective portion in the shares, also taking into consideration that Stichting is entitled to a carry charge of 7.5% p.a. ● Bonus agreement with Lilium GmbH: Stichting’s portion of the sale of shares are paid to Lilium GmbH and forwarded to the manager after deduction of employment income tax and social security contributions. ● In substance, the management member receives in total the proceeds from the sale of shares after execution of the Sell Right or Buy Right, one part directly from Stichting (“JSOP”) and the other part from the Lilium GmbH as a bonus: o The proceeds directly from the JSOP are the difference between the proceeds from the sale of shares received (treasury shares due to consolidation) and the acquisition cost of the shares received at the time of the setup of the Stichting plus 7.5 % interest p.a.; if this difference is negative, the JSOP is nil. o The bonus is the lower of the proceeds from the sale of shares received (treasury shares due to consolidation) and the acquisition costs of the shares at the time of the setup of the Stichting plus 7.5 % interest p.a. Since the management member received cash from the JSOP and the bonus, both parts of these awards were accounted for as cash-settled. Advisors – Strategic collaboration agreement On July 31, 2021, Lilium executed a term sheet in which Lilium agreed to enter into negotiations with Brazilian airline Azul S.A. and Azul Linhas Aereas Brasileiras S.A. (collectively, “Azul”) to establish a strategic collaboration whereby Azul and Lilium will negotiate contracts to buy a certain number of Lilium Jets. Except for the up-front warrants (“Azul Warrants”), the term sheet is legally non-binding. As of the date these consolidated financial statements were approved, no contracts with respect to the acquisition of Lilium Jets or any other collaboration have been executed. The Azul Warrants are within the scope of IFRS 2 Share-Based Payment as they were granted in contemplation of signing a service agreement to explore the feasibility of eVTOL in Brazil and are expected to be settled in our Class A shares. In consideration of the commercial collaboration, Lilium agreed to use all efforts to grant Azul the warrants to purchase up to 8,000,000 Class A shares at an exercise price of €0.12 per share, consisting of (i) Azul Warrants to purchase 1,800,000 Class A shares, which were issued on a fully vested basis on October 22, 2021, granted upon the signing of term sheet and (ii) subject to the execution of definitive agreements and legally non-binding, warrants to purchase additional 6,200,000 Class A shares (“Azul Additional Warrants”), which are expected to vest in three tranches. These warrants are subject to the execution of the above-mentioned definitive agreements and legally non-binding. As of December 31, 2022 it was not yet probable that they will be granted. As the Azul Warrants are to be settled in shares of Lilium N.V., they are accounted for as equity-settled awards. Share listing expense The Reorganization is accounted for within the scope of IFRS 2. In accordance with IFRS 2, the difference in the fair value of the shares issued to Qell’s former shareholders by Lilium (€165.0 million) and the fair value of the Qell’s identifiable net assets (€53.9 million) represents a service received by Lilium, and thus is recognized as an expense (€111.1 million) upon closing of the Reorganization (“Closing Date”). The determination of the fair value of the shares issued is based on the share price of Lilium N.V.’s publicly traded common stock. As of Closing Date, Lilium N.V. shares issued to Qell shareholders were trading at $9.41 per share. This trading price represents a Level 1 measurement, as it is a quoted price in an active market with sufficient trading volume for identical instruments. Within the Reorganization, Qell shareholders have received 21,080,961 shares in Lilium N.V. some of which are subject to transfer restrictions: 1. Sponsor Lock-Up Shares: 4,595,133 Lilium Class A Shares acquired by Qell Partners LLC (the “Sponsor”) in connection with the Reorganization, having a lock-up period of one year . 2. Sponsor Earnout Shares: 3,063,422 Lilium Class A Shares acquired by the Sponsor in connection with the Reorganization. Pursuant to the Sponsor Support Agreement, concurrently with the clos-ing of the Business Combination, the Sponsor Earnout Shares were imprinted in three tranches ( 1,148,783 , 1,148,783 and 765,856 shares respectively) with a legend to note restrictions on transfer, which will be removed after the occurrence of a certain milestone or a specific date which is between March 2024 and September 2025. For the transfer restrictions, the valuation has been adjusted as follows: ● Qell Sponsor Lock-Up Shares: the closing price of Lilium N.V. shares as of Closing Date has been adjusted for a 5 % discount for lack of marketability due to the one-year lock-up restriction. ● Qell Sponsor Earnout Shares: the closing price of Lilium N.V. shares as of Closing Date has been adjusted for a 5 % discount for lack of marketability. The net assets held by Qell had a fair value upon closing of €53.9 million, comprising of cash and cash equivalents held in Qell’s trust account (€83.3 million), offset by current liabilities (€3.6 million) and financial liabilities for the former Qell Warrants (€25.8 million). As the share listing expense is to be settled in shares of Lilium N.V., it is accounted as equity-settled awards. Share-based payment – Vendors In November 2022, the Group entered into a Share Issuance Agreement with a third-party vendor, with the option at the Group’s discretion to pay certain goods and services to be rendered by the vendor either via the issuance of Class A shares of Lilium N.V. or cash. The Group has accounted for this transaction as an equity-settled share-based payment under IFRS 2 at fair value of the equity instrument with the corresponding increase in equity. ​ The Group also entered into share-based payment arrangements with two other third-party vendors as part of the 2022 PIPE transaction in exchange for the good and services to be rendered by the respective vendors which was deemed to be at fair value of the securities issued to both vendors. The Group has accounted for this transaction as a prepayment with the corresponding increase in equity. The Group also had the discretion to settle an annual instalment either by cash or by issuance of equity subject to a formalized share issuance agreement. The Group concluded that the agreement falls within the scope of IFRS 2.
Pension Benefits	Pension Benefits The Group operates a defined benefit pension plan in Switzerland which requires contributions to be made to a separately administered fund. The cost of providing benefits under the defined benefit plan is determined using the projected unit credit method. The defined benefit obligation is recognized within non-current provisions. Remeasurements, comprising of actuarial gains and losses, the effect of the asset ceiling, and the return on plan assets (excluding amounts included in net interest on the net defined benefit liability), are recognized immediately in the consolidated statement of financial position with a corresponding debit or credit to retained earnings through OCI in the period in which they occur. Past service costs are recognized in profit or loss on the earlier of: ● The date of the plan amendment or curtailment, and ● The date that the Group recognizes related restructuring costs. Net interest is calculated by applying the discount rate to the net defined benefit liability or asset. The Group recognizes the following changes in the net defined benefit obligation under, ‘Research and development’, ‘General and administrative’, and ‘Selling’ expenses’ in the consolidated statement of operations and other comprehensive income (loss) (by function): ● Service costs comprising current service costs, past-service costs, gains and losses on curtailments, ● Non-routine settlements, and ● Net interest expense or income.
Non-financial Liabilities	Non-financial Liabilities Non-financial liabilities are recognized at their nominal amounts.
Revenue Recognition	Revenue Recognition Revenues from contracts are recognized when the customer gains the ability to direct the use of and obtain substantially all the remaining benefits from the services performed. The consideration which the Group expects to receive is allocated to each of the performance obligations, using the relative stand-alone selling price method.
Government Grants	​ Government Grants Grants from governments are recognized at their fair value, when there is reasonable assurance that the grant will be received, and the Group will comply with all attached conditions. Government grants relating to costs are deferred and recognized gross in other operating income over the period necessary to match them with the costs that they are intended to compensate.

Basis of Preparation (Tables)

Basis of Preparation (Tables)	12 Months Ended
	Dec. 31, 2022
Basis of Preparation
Schedule of equity interest owned by the company in subsidiaries	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Country of ​ Date of ​ % equity interest owned Name Incorporation ​ incorporation 12/31/ 2022 12/31/ 2021 Lilium N.V. ​ Netherlands ​ March 11, 2021 ​ 100.0 % 100.0 % Lilium GmbH Germany February 11, 2015 100.0 % 100.0 % Lilium Schweiz GmbH ​ Switzerland ​ December 8, 2017 ​ 100.0 % 100.0 % Lilium Aviation UK Ltd. ​ United Kingdom ​ December 20, 2017 ​ 100.0 % 100.0 % Lilium Aviation Inc. ​ United States ​ July 1, 2020 ​ 100.0 % 100.0 % Lilium eAircraft GmbH Germany August 17, 2020 100.0 % 100.0 % Stichting JSOP Netherlands September 10, 2021 0.0 % 0.0 % Lilium Aviation Spain SLU Spain April 7, 2022* 100.0 % n/a ​ * date of purchase of a shell company (company without active business). ​
Schedule of new standards, interpretations and amendments adopted	​ ​ ​ ​ Standard/amendment/ interpretation Effective date Amendments to IFRS 3, ‘Business combinations’, IAS 16 ‘Property, plant and equipment’ and IAS 37 ‘Provisions, contingent liabilities and contingent assets’ ​ Annual periods on or after January 1, 2022 Annual improvements 2018-2020 ​ Annual periods on or after January 1, 2022 ​
Schedule of new standards and interpretations not yet adopted	​ ​ ​ ​ Standard/amendment/ interpretation Effective date IFRS 17, ‘Insurance contracts’ as amended in June 2020 by amendments to IFRS 17, Insurance Contracts ​ Annual periods on or after January 1, 2023 Amendment to IAS 1, ‘Presentation of financial statements’, IFRS Practice statement 2 and IAS 8, ‘Accounting policies, changes in accounting estimates and errors’ ​ Annual periods on or after January 1, 2023 Deferred Tax related to Assets and Liabilities arising from a Single Transaction – Amendments to IAS 12 ​ Annual periods on or after January 1, 2023 Amendments to IFRS 17: First-time Adoption of IFRS 17 and IFRS 9 - Comparative Information ​ Annual periods on or after January 1, 2023 Amendment to IAS 1, Non-current liabilities with Covenants ​ Annual periods on or after January 1, 2024 Amendment to IFRS 16 – Leases on sale and leaseback ​ Annual periods on or after January 1, 2024 Amendment to IAS 1, ‘Presentation of financial statements’, on classification of liabilities as current or non-current ​ Annual periods on or after January 1, 2024

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Significant Accounting Policies
Schedule of purchase of intangible assets	​ ​ ​ ​ ​ Useful life Software 2  –  15 years Purchased concessions, rights and other intangible assets 10  –  20 years ​
Schedule of estimated useful lives of property plant and equipment	​ ​ ​ ​ ​ Useful life Rights to land and buildings including leasehold improvements 2  –  9 years Technical equipment and machinery 3  –  25 years Office and other equipment 3  –  13 years Vehicles 5  –  11 years ​

Research and Development Expe_2

Research and Development Expenses (Tables)	12 Months Ended
	Dec. 31, 2022
Research and Development Expenses.
Schedule of research and development expenses	​ ​ ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 2020 Salaries and social security 77,455 75,672 66,536 Professional services 72,840 49,421 8,448 Materials 7,808 9,009 8,253 Depreciation/amortization/impairment 6,386 4,541 2,829 IT and communication expense 3,709 1,248 1,857 Other research and development expenses 7,420 4,667 2,422 Total research and development expenses 175,618 144,558 90,345 ​

General and Administrative Ex_2

General and Administrative Expenses (Tables)	12 Months Ended
	Dec. 31, 2022
General and Administrative Expenses.
Schedule of general and administrative expenses	​ ​ ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 2020 Share listing expense — 111,109 — Professional services 28,851 70,380 8,483 Salaries and social security 30,187 35,395 20,926 IT and communication expense 20,374 12,391 2,255 Depreciation/amortization 1,816 1,870 1,289 Insurances 6,457 1,698 73 HR related expenses (training, recruitment) 1,466 1,617 1,026 Other administrative expenses 4,736 4,633 1,354 Total administrative expenses 93,887 239,093 35,406 ​

Selling Expenses (Tables)

Selling Expenses (Tables)	12 Months Ended
	Dec. 31, 2022
Selling Expenses.
Selling Expenses	​ ​ ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 2020 Salaries, social security 8,915 11,971 13,115 Professional services 1,690 1,983 1,196 Marketing 1,448 2,059 613 Travel 523 626 167 Depreciation/amortization 65 65 41 Other selling expenses 288 485 140 Total selling expenses 12,929 17,189 15,272 ​

Other Income (Tables)

Other Income (Tables)	12 Months Ended
	Dec. 31, 2022
Other Income
Schedule of other income	​ ​ ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 2020 Foreign currency gains 3,842 1,689 19 Insurance recoveries 483 456 1,906 Grants received from the German government 1,038 51 307 Income from other grants — — 42 At-equity income from dilution ​ 1,179 ​ — ​ — Other miscellaneous income 266 78 72 Total other income 6,808 2,274 2,346 ​

Other Expenses (Tables)

Other Expenses (Tables)	12 Months Ended
	Dec. 31, 2022
Other Expenses
Schedule of other expenses	​ ​ ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 2020 Foreign currency losses 3,264 1,054 107 Miscellaneous other items 4 982 23 Total other expenses 3,268 2,036 130 ​

Financial Result (Tables)

Financial Result (Tables)	12 Months Ended
	Dec. 31, 2022
Financial Result
Schedule of financial results	​ ​ ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 2020 Finance income 30,322 11,288 80 thereof: fair value changes 29,922 11,280 58 thereof: impairment loss net of reversal ​ 125 ​ — ​ — Finance expenses (1,995) (20,201) (49,741) thereof: fair value changes (763) (15,645) (15,222) thereof: interest portion of lease payments (443) (437) (450) thereof: impairment loss net of reversal — (260) — thereof: interest on convertible loans ​ — ​ (3,483) ​ (33,960) Financial result 28,327 (8,913) (49,661) ​

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Taxes
Schedule of income tax expense	​ ​ ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 2020 Current income tax charge (169) (556) (46) Current income tax related to prior years 495 (143) — Current taxes ​ 326 ​ (699) ​ (46) Deferred taxes — (10) — Income tax benefits / (expense) 326 (709) (46) ​
Schedule of reconciliation of expected tax expense and reported tax expense	​ ​ ​ ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 2020 Profit (Loss) before income tax (253,390) (410,327) (188,381) ​ Income tax rate 27.55 % 27.55 % 27.55 % Expected income taxes on this 69,809 113,045 51,899 ​ Effects deriving from differences to the expected tax rate 9 40 54 ​ Taxes for prior years ​ 495 ​ (143) ​ — ​ Other non-deductible expenses and taxes (59) (66) (238) ​ Changes in the realization of deferred tax assets (76,356) (67,465) (22,371) ​ Other 6,428 (46,120) (29,390) ​ Income tax as per consolidated statement of operations 326 (709) (46) ​ Effective tax rate in % ​ 0.1 % (0.2) % 0.0 % ​
Schedule of deferred taxes	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Deferred tax assets Deferred tax liabilities In € thousand ​ 12/31/2022 ​ 12/31/2021 ​ 12/31/2022 ​ 12/31/2021 Non-current assets 2,378 3,010 2,913 3,099 Intangible assets 2,341 2,995 — — Property, plant and equipment 37 15 2,903 3,088 Financial assets — — 10 11 Current assets 149 14 — 286 Inventories 123 11 — — Receivables and other assets 26 3 — 286 Non-current liabilities 446 645 — 167 Provisions 10 24 — 3 Liabilities 436 621 — 163 Current liabilities 138 222 208 631 Provisions — 91 47 — Liabilities 138 131 161 631 Loss carryforwards — 282 — — Total value 3,111 4,173 3,121 4,183 Netting (3,111) (4,173) (3,111) (4,173) Recognition in the consolidated statement of financial position — — 10 10 ​
Schedule of tax attributes (gross)	​ ​ ​ ​ ​ ​ In € thousand 12/31/2022 12/31/2021 Corporation tax loss carryforwards 661,501 388,980 Trade tax loss carryforwards 659,161 387,524 Interest carryforwards 15,348 15,846 ​
Schedule of deductible temporary differences and tax loss and interest carryforwards	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Deferred tax assets on ​ ​ ​ ​ ​ ​ Interest ​ ​ ​ ​ Temporary ​ Tax ​ carry ​ ​ In € thousand ​ differences ​ losses ​ forward ​ Total Unrecognized deferred tax assets as of January 1, 2021 17,276 35,639 3,663 56,578 Addition — 70,625 266 70,891 Deductions (3,426) — — (3,426) Unrecognized deferred tax assets as of December 31, 2021 13,850 106,264 3,929 124,043 Addition 1,541 75,705 436 77,682 Deductions — — (137) (137) Unrecognized deferred tax assets as of December 31, 2022 15,391 181,969 4,228 201,588

Loss per Share (Tables)

Loss per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Loss per Share
Schedule of income and share data used in the basic and diluted EPS calculations	​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 2021 2020 Comprehensive loss attributed to equity shareholders (253,003) (410,830) (188,435) (in € thousand) ​ ​ ​ ​ ​ ​ Weighted average number of shares outstanding Basic and diluted 316,474,576 214,858,203 193,722,062 Basic and diluted EPS (in €) (0.80) (1.91) (0.97)

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Intangible Assets
Schedule of intangible assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Purchased concessions, ​ ​ ​ ​ ​ rights and other ​ ​ In € thousand ​ Software ​ intangible assets ​ Total Costs of acquisition ​ ​ ​ January 1, 2022 3,998 108 4,106 Additions 163 37 200 Transfer from property, plant and equipment — — — December 31, 2022 4,161 145 4,306 Accumulated amortization/write downs ​ ​ ​ January 1, 2022 2,694 18 2,712 Amortization 717 7 724 December 31, 2022 3,411 25 3,436 Carrying amount: ​ ​ ​ December 31, 2021 1,304 90 1,394 December 31, 2022 750 120 870 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Purchased concessions, ​ ​ ​ ​ ​ rights, and other ​ ​ In € thousand ​ Software ​ in-tangible assets ​ Total Costs of acquisition ​ ​ ​ January 1, 2021 2,401 108 2,509 Additions 1,586 — 1,586 Transfer from property, plant and equipment 11 — 11 December 31, 2021 3,998 108 4,106 Accumulated amortization/write downs ​ ​ ​ January 1, 2021 1,125 12 1,137 Amortization 1,569 6 1,575 December 31, 2021 2,694 18 2,712 Carrying amount: ​ ​ ​ December 31, 2020 1,276 96 1,372 December 31, 2021 1,304 90 1,394 ​

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment
Schedule of Property, plant and equipment	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Rights to ​ ​ ​ ​ ​ ​ ​ land and ​ ​ ​ Technical ​ ​ ​ ​ ​ ​ ​ ​ buildings ​ ​ ​ equipment ​ Office ​ Assets ​ ​ ​ ​ and leasehold ​ ​ ​ and ​ and other ​ under ​ ​ In € thousand ​ improvements ​ Vehicles ​ machinery ​ equipment ​ construction ​ Total Costs of acquisition or construction: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1, 2022 19,903 166 10,738 8,243 2,611 41,661 Additions 2,366 67 6,328 1,519 2,894 13,174 Disposals — (94) (12) (95) — (201) Transfers 130 — 2,466 22 (2,618) — Transfer to intangible assets — — — — — — Indexation impact 488 — — — — 488 Foreign exchange — — — (6) ​ — (6) December 31, 2022 22,887 139 19,520 9,683 2,887 55,116 Accumulated depreciation: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1, 2022 5,438 82 1,669 3,862 — 11,051 Depreciation 3,642 64 2,168 1,617 — 7,491 Disposals ​ — ​ (94) ​ (12) ​ (68) ​ — ​ (174) Impairment ​ — ​ — ​ 52 ​ — ​ — ​ 52 Transfer — — — — — — Foreign exchange — — — (3) — (3) December 31, 2022 9,080 52 3,877 5,408 — 18,417 Carrying amount: ​ ​ ​ ​ ​ ​ December 31, 2021 14,465 84 9,069 4,381 2,611 30,610 December 31, 2022 13,807 87 15,643 4,275 2,887 36,699 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Rights to ​ ​ ​ ​ ​ ​ ​ land and ​ ​ ​ Technical ​ ​ ​ ​ ​ ​ ​ ​ buildings ​ ​ ​ equipment ​ Office ​ Assets ​ ​ ​ ​ and leasehold ​ ​ ​ and ​ and other ​ under ​ ​ In € thousand ​ improvements ​ Vehicles ​ machinery ​ equipment ​ construction ​ Total Costs of acquisition or construction: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1, 2021 15,774 160 6,195 5,590 1,144 28,863 Additions 3,444 6 2,532 2,644 4,200 12,826 Disposals — — — (1) — (1) Transfers 711 — 2,009 2 (2,722) — Transfer to intangible assets — — — — (11) (11) Indexation impact (26) — — — — (26) Foreign exchange — — 2 8 — 10 December 31, 2021 19,903 166 10,738 8,243 2,611 41,661 Accumulated depreciation: ​ ​ ​ ​ ​ ​ January 1, 2021 3,057 40 640 2,411 — 6,148 Depreciation 2,381 42 1,028 1,450 — 4,901 Transfer — — 1 (1) — — Foreign exchange — — — 2 — 2 December 31, 2021 5,438 82 1,669 3,862 — 11,051 Carrying amount: ​ ​ ​ ​ ​ ​ December 31, 2020 12,717 120 5,555 3,179 1,144 22,715 December 31, 2021 14,465 84 9,069 4,381 2,611 30,610 ​
Schedule of Property, plant and equipment is distributed among geographical areas	​ ​ ​ ​ ​ ​ In € thousand 12/31/2022 12/31/2021 Property, plant and equipment ​ ​ ​ ​ Germany 26,063 18,933 United Kingdom 97 100 United States 23 38 Switzerland 12 14 Spain ​ 5 ​ — Right-of-use assets ​ ​ ​ ​ Germany ​ 10,033 ​ 11,525 Spain ​ 466 ​ — Total 36,699 30,610

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Leases
Schedule of right-of-use assets and lease liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Technical ​ ​ ​ ​ ​ ​ ​ ​ equipment ​ Office ​ ​ ​ ​ Rights ​ ​ ​ and ​ and other ​ ​ In € thousand ​ to buildings ​ Vehicles ​ machinery ​ equipment ​ Total January 1, 2021 10,375 77 461 28 10,941 Additions to right-of-use assets 2,369 — 29 170 2,568 Transfer ​ — ​ — ​ (17) ​ — ​ (17) Depreciation (1,808) (34) (45) (54) (1,941) Indexation impact (26) — — — (26) December 31, 2021 10,910 43 428 144 11,525 Additions to right-of-use assets 1,526 63 23 — 1,612 Transfer — — — (144) (144) Disposal of right-of-use assets ​ — ​ (3) ​ (1) ​ — ​ (4) Depreciation (2,889) (49) (39) — (2,977) Indexation impact 488 — — — 488 December 31, 2022 10,034 54 411 — 10,499 ​
Schedule of lease related expense recognised in consolidated statement of operations and comprehensive income	​ ​ ​ In € thousand Lease Liability January 1, 2021 11,118 Additions 2,512 Interest 437 Payments (2,218) Indexation impact (26) December 31, 2021 11,823 Additions 1,385 Accrued interest ​ (7) Interest 443 Payments (3,163) Indexation impact 488 December 31, 2022 10,969 ​ The current and non-current portion of lease liabilities are as follows: ​ ​ ​ ​ ​ ​ In € thousand 12/31/2022 12/31/2021 Current ​ 2,616 ​ 1,962 Non-current 8,353 9,861 Total lease liabilities 10,969 11,823
Schedule of carrying amounts of lease liabilities and the movements	​ ​ ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 ​ 2020 Depreciation of right of-use-assets 2,977 1,941 ​ 1,631 Interest expense on lease liabilities 443 437 ​ 450 Short-term lease expenses 6 488 ​ 108 Lease expenses for low-value assets 137 220 ​ 80 Total amount recognized in expense 3,563 3,086 ​ 2,269 ​
Schedule of information about the composition of the lease payments	​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Fixed lease payments 1,212 204 Variable lease payments 1,951 2,014 Total amount of lease payments 3,163 2,218 ​
Schedule of information on the total cash outflow from all leases	​ ​ ​ ​ ​ ​ ​ ​ In € thousand 2022 ​ 2021 2020 Principal paid 2,720 ​ 1,781 1,439 Interest paid 443 ​ 437 450 Short term and low value leases 143 ​ 708 188 Total amount paid 3,306 ​ 2,926 2,077

Investment in a Joint Venture_2

Investment in a Joint Venture / Associate (Tables)	12 Months Ended
	Dec. 31, 2022
Investment in a Joint Venture / Associate
Schedule of valuation of investment in Zenlabs	​ ​ ​ ​ ​ ​ ​ Carrying Value In € thousand ​ 2022 ​ 2021 January 1 15,054 ​ — Initial recognition ​ — ​ 8,502 Conversion of promissory notes (July 2021) — ​ 2,222 Capital increases (July and September 2021) ​ — ​ 5,178 Gain on dilution ​ 1,179 ​ — Share of loss in a joint venture/ associate (2,823) ​ (848) December 31 13,410 ​ 15,054 ​
Schedule of financial information for Zenlabs	​ ​ ​ ​ ​ ​ In € thousand 01/01/2022 – 12/31/2022 3/10/2021 – 12/31/2021 Revenue 1,927 806 Loss from continued operations ​ (7,777) (3,482) Net loss for the year/ period (7,369) (2,907) ​ ​ ​ ​ ​ ​ ​ In € thousand 12/31/2022 12/31/2021 Non-current assets 1 25,438 ​ 24,255 Current assets 13,487 ​ 6,724 Preferred stock reclassification 2 ​ 21,619 ​ 20,283 Non-current liabilities (31,482) ​ (28,200) Current liabilities (933) ​ (756) Shareholders’ equity 28,129 ​ 22,306 ​ ​ ​ ​ ​ ​ ​ ​ Reconciliation to carrying amounts of Lilium’s Interest in Ionblox ​ ​ ​ ​ ​ Group’s effective interest in the joint venture / associate 27.7 % 34.8 % Group’s share in shareholders’ equity 7,780 ​ 7,762 ​ Goodwill 8,370 ​ 7,558 ​ Currency translation difference (2,740) ​ (266) ​ Investment in a joint venture / associate 13,410 ​ 15,054 ​ 1 As the purchase price allocation is performed at each acquisition date (as of March 10, July 16 and September 27, 2021), differences occur due to the different ownership rates used in purchase price allocation and equity accounting. These differences are adjusted in Ionblox’s summary consolidated financial statements. ​ 2

Other Financial Assets (Tables)

Other Financial Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Other Financial Assets
Schedule of other financials assets	​ ​ ​ ​ ​ ​ In € thousand 12/31/2022 12/31/2021 Security deposits 3,386 3,779 Total non-current financial assets 3,386 3,779 Fixed term deposits 19,987 119,664 Money market funds — 99,919 Security deposits 2,594 42 Total current other financial assets 22,581 219,625 Total other financial assets 25,967 223,404 ​

Non-Financial Assets (Tables)

Non-Financial Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Non-Financial Assets
Schedule of Non-financial assets	​ ​ ​ ​ ​ ​ In € thousand 12/31/2022 12/31/2021 Advance payments 4,069 8,113 Prepaid expenses ​ 9,418 ​ — Total non-current non-financial assets 13,487 8,113 Value added tax claims 1,696 12,602 Prepaid expenses 16,241 9,924 Miscellaneous other current non-financial assets 711 468 Total current non-financial assets 18,648 22,994 Total non-financial assets 32,135 31,107 ​

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Dec. 31, 2022
Cash and Cash Equivalents
Schedule of cash and cash equivalents	​ ​ ​ ​ ​ ​ In € thousand 12/31/2022 12/31/2021 Petty cash — 2 Short-term fixed deposits ​ 49,385 ​ — Cash at banks 130,196 129,854 Total cash and cash equivalents 179,581 129,856

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2022
Shareholders' Equity
Schedule of amount of common and preferred shares	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Supervoting ​ Ordinary ​ ​ ​ ​ Common shares ​ shares ​ shares ​ ​ (in units) (Class A) (Class B) (Class C) Total Issued at January 1, 2020, as adjusted 130,596,327 24,413,065 — 155,009,392 Issued shares – convertible loans 19,156,185 — — 19,156,185 Issued shares – capital increase 23,261,694 — — 23,261,694 Issued as of December 31, 2020, as adjusted 173,014,206 24,413,065 — 197,427,271 Treasury shares – share buy-back ​ (205,704) ​ — ​ — ​ (205,704) Outstanding as of December 31, 2020, as adjusted ​ 172,808,502 ​ 24,413,065 ​ — ​ 197,221,567 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Common shares Supervoting shares Ordinary shares (in units) ​ (Class A) ​ (Class B) ​ (Class C) ​ Total Issued at January 1, 2021 ​ 173,014,206 ​ 24,413,065 ​ — ​ 197,427,271 Issued shares – convertible loans 20,533,259 — — 20,533,259 Reorganization as of September 14, 2021 22,697,450 — — 22,697,450 Treasury shares Lilium GmbH not exchanged into Lilium N.V. shares — — — — Capital increase 2021 PIPE 45,000,000 — — 45,000,000 Issued as of December 31, 2021 261,244,915 24,413,065 — 285,657,980 Treasury shares (375,000) — — (375,000) Treasury shares (due to consolidation) (879,691) — — (879,691) Outstanding as of December 31, 2021 259,990,224 24,413,065 — 284,403,289 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Common shares Supervoting shares Ordinary shares (in units) ​ (Class A) ​ (Class B) ​ (Class C) ​ Total Issued at January 1, 2022 261,244,915 24,413,065 — 285,657,980 Issued shares for share-based payment awards exercised 10,857,264 ​ — ​ — ​ 10,857,264 Warrants exercised 10 — — 10 Issued shares – ELOC 5,618,697 — — 5,618,697 Capital increase RDO & 2022 PIPE 91,524,935 — — 91,524,935 Conversion of Class B Shares 525,000 (525,000) 525,000 525,000 Repurchase of Class B Shares 50,000 — — 50,000 Issued as of December 31, 2022 369,820,821 23,888,065 525,000 394,233,886 Treasury shares — (425,000) (525,000) (950,000) Outstanding as of December 31, 2022 369,820,821 23,463,065 — 393,283,886 ​
Schedule of movement of treasury shares	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Common shares Supervoting shares Ordinary shares (in units) ​ (Class A) ​ (Class B) ​ (Class C) ​ Total At January 1, 2021 205,704 — — 205,704 Treasury shares of Lilium GmbH not exchanged into Lilium N.V. shares (205,704) — — (205,704) Treasury shares acquired upon Reorganization 375,000 — — 375,000 Treasury shares from consolidation of Stichting JSOP 879,691 — — 879,691 At December 31, 2021 1,254,691 — — 1,254,691 Repurchase of Class B shares for Class A shares held in treasury (375,000) 375,000 — — Repurchase of Class B shares for newly issued Class A shares — 50,000 — 50,000 Conversion of Class B shares — — 525,000 525,000 Treasury shares sold by Stichting JSOP (879,691) — — (879,691) At December 31, 2022 — 425,000 525,000 950,000 ​

Share-based Payments (Tables)

Share-based Payments (Tables)	12 Months Ended
	Dec. 31, 2022
Share-based Payments
Schedule of share-based payment arrangement expense	​ ​ ​ ​ ​ ​ In € thousand 2022 2021 General population and executives – standard ESOP 7,942 29,286 General population - RSU 4,977 77 Executives – ESOP special vesting 1,101 2,135 Executives – RSU 3,259 1,178 Executives – Performance-based stock options (375) 2,296 Executives – Time-based stock options 2,200 3,505 Executives – Success fees (cash-settled) (134) 2,590 Executives – Success fee (equity-settled) — 1,844 Joint stock ownership Plan (JSOP) incl. bonus (4,435) 5,438 Share-based payment – Vendors 9,726 — Total expense 24,261 48,349 ​
General population and executives - standard ESOP
Share-based Payments
Schedule of expense from share-based payment arrangement	​ The expense recognized for participant services received during the year is shown in the following table: ​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Expense arising from equity-settled share-based payment awards 7,942 29,286 ​
Schedule of movements	​ Equity-settled options: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ Number of ​ 2022 ​ Number of ​ 2021 (in units) options WAEP options WAEP Outstanding at January 1 19,573,307 € 0.00 13,962,159 € 0.00 Granted during the year 5,714 € 0.00 4,019,799 € 0.00 Forfeited during the year (1,188,512) € 0.00 (757,105) € 0.00 Exercised during the year ​ (10,318,085) ​ € 0.00 ​ — ​ ​ — Transferred (to)/ from cash-settled (22,856) € 0.00 2,348,454 € 0.00 Outstanding at December 31 8,049,568 € 0.00 19,573,307 € 0.00 ​ Cash-settled options: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ 2021 ​ ​ ​ ​ Number of ​ 2022 ​ Number of ​ 2021 (in units) ​ options ​ WAEP ​ options ​ WAEP Outstanding at January 1 — ​ — 2,348,454 ​ — Exercised during the year ​ (17,142) ​ € 0.00 ​ — ​ ​ — Transferred from/ (to) equity-settled 22,856 € 0.00 (2,348,454) € 0.00 Outstanding at December 31 5,714 € 0.00 — ​ — ​
Schedule of fair values	​ ​ ​ ​ ​ ​ ​ ​ Price of one share in in € ​ Valuation methodology ​ Lilium N.V. December 31, 2020 Hybrid model 6.05 March 31, 2021 Hybrid model 7.13 June 30, 2021 Hybrid model 7.05 July 31, 2021 Hybrid model 7.36 August 31, 2021 Hybrid model 7.71 September 15, 2021 Actual share price 7.89 December 31, 2021 ​ Actual share price ​ 6.12 March 31, 2022 Actual share price 3.59 ​
General population - Restricted Stock Units ("RSU")
Share-based Payments
Schedule of expense from share-based payment arrangement	​ ​ ​ ​ ​ ​ In € thousand ​ 2022 ​ 2021 Expense arising from equity settled RSU 4,977 77 ​
Schedule of movements	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ 2021 ​ ​ ​ ​ Number of ​ 2022 ​ Number of ​ 2021 (in units) ​ RSU ​ WAEP ​ RSU ​ WAEP Outstanding at January 1 162,800 € 0.12 — ​ — Assigned during the year 4,886,077 ​ € 0.12 162,800 € 0.12 Exercised during the year ​ (638,470) ​ € 0.12 ​ — ​ ​ — Forfeited during the year (135,309) ​ € 0.12 — ​ — Outstanding at December 31 4,275,098 ​ € 0.12 162,800 € 0.12 ​
Executives - ESOP modified
Share-based Payments
Schedule of expense from share-based payment arrangement	​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Expense arising from equity-settled share-based payment awards 1,101 2,135 ​
Schedule of movements	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ 2021 ​ ​ ​ Number of ​ 2022 ​ Number of ​ 2021 (in units) ​ options ​ WAEP ​ options ​ WAEP Outstanding at January 1 1,888,477 7.90 — — Granted during the year — — 1,888,477 7.90 Forfeited during the year (1,160,457) 8.50 — — Outstanding at December 31 728,020 6.94 1,888,477 7.90 ​
Executives - Restricted Stock Units ("RSU")
Share-based Payments
Schedule of expense from share-based payment arrangement	​ ​ ​ ​ ​ ​ In € thousand ​ 2022 ​ 2021 Expense arising from equity–settled RSU 3,259 1,178 ​
Schedule of movements	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ Number of ​ 2022 ​ Number of ​ 2021 (in units) ​ RSU ​ WAEP ​ RSU ​ WAEP Outstanding at January 1 1,050,913 € 0.12 — ​ — Granted during the year 1,699,411 ​ € 0.12 1,050,913 € 0.12 Forfeited during the year ​ (134,400) ​ € 0.12 ​ — ​ ​ — Exercised during the year (291,199) ​ € 0.12 — ​ — Outstanding at December 31 2,324,725 ​ € 0.12 1,050,913 € 0.12 ​
Executives - Performance-based stock options
Share-based Payments
Schedule of expense from share-based payment arrangement	​ ​ ​ ​ ​ ​ In € thousand ​ 2022 ​ 2021 (Income) / expense arising from performance-based stock option (375) 2,296 ​
Schedule of movements	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ 2021 ​ ​ ​ ​ Number of ​ 2022 ​ Number of ​ 2021 (in units) ​ options ​ WAEP ​ options ​ WAEP Outstanding at January 1 7,036,501 € 8.15 — ​ — Granted during the year 1,272,059 ​ € 9.45 7,036,501 € 8.15 Forfeited during the year (4,711,839) ​ € 8.66 — ​ — Outstanding at December 31 3,596,721 ​ € 7.94 7,036,501 € 8.15 ​
Schedule of inputs used for measurement of fair values	​ The following table lists the inputs to the Black-Scholes model used for the fair market value calculation for performance-based stock options for the year ended December 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ 2021 Risk free rate range (0.69%) – 2.01% ​ (0.69 %) – (0.66 %) ​ Expected dividend yield ​ — ​ — ​ Expected exercise term 3.3 – 3.4 years ​ 4 years ​ Expected volatility 108.86% - 121.91% ​ 121.8 % ​
Executives - Time-based stock options
Share-based Payments
Schedule of expense from share-based payment arrangement	​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Expense arising from time-based stock options 2,200 3,505 ​
Schedule of movements	​ The following table illustrates the number and weighted average exercise prices (“WAEP”) of, and movements in, share options during the years ended December 31, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ ​ 2021 ​ ​ ​ ​ Number of ​ 2022 ​ Number of ​ 2021 (in units) ​ options ​ WAEP ​ options ​ WAEP Outstanding at January 1 2,951,000 € 7.25 — ​ — Granted during the year 2,199,488 ​ € 2.76 2,951,000 € 7.25 Forfeited during the year (2,043,000) ​ € 7.25 — ​ — Outstanding at December 31 3,107,488 ​ € 4.07 2,951,000 € 7.25 ​
Schedule of inputs used for measurement of fair values	​ ​ ​ ​ ​ ​ ​ 2022 2021 Risk free rate range (0.69 %) – 2.05 % ​ (0.69 %) Expected dividend yield 0 ​ 0 Expected exercise term 1.1 – 1.8 years ​ 4 years Expected volatility 118.97 % – 124.10 % ​ 121.9 % ​
Executives - Success fees
Share-based Payments
Schedule of expense from share-based payment arrangement	​ ​ ​ ​ ​ ​ In € thousand ​ 2022 ​ 2021 (Income)/expense for success fees cash-settled (134) 2,590 Expense for success fee equity-settled — 1,844 Total (income)/expense (134) 4,434 ​
Executives - Joint Stock Ownership plan (JSOP) and bonus
Share-based Payments
Schedule of expense from share-based payment arrangement	​ ​ ​ ​ ​ ​ In € thousand ​ 2022 ​ 2021 (Income)/ expense for JSOP (3,762) 3,762 (Income)/ expense for bonus (673) 1,676 Total (income)/ expense (4,435) 5,438 ​

Warrants, Convertible Loans and

Warrants, Convertible Loans and Other Financial Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Warrants and Other Financial Liabilities
Summary of warrants, convertible loans and other financial liabilities	​ ​ ​ ​ ​ ​ in € thousand 12/31/2022 12/31/2021 Other non-current financial liabilities 21 — Other current financial liabilities 4 — Reorganization Warrants 1,811 21,405 RDO & 2022 PIPE Warrants 24,456 — Warrants 26,267 21,405 ​

Provisions (Tables)

Provisions (Tables)	12 Months Ended
	Dec. 31, 2022
Provisions
Summary of movement in provisions	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unwinding of ​ ​ ​ ​ ​ ​ ​ discount and ​ ​ ​ ​ ​ ​ Additions/ ​ changes in ​ ​ In € thousand ​ 01/01/2022 ​ Reversals ​ discount rate ​ 12/31/2022 Asset retirement obligations 233 66 3 302 Post-employment benefits (note 25) 84 (9) — 75 Record retention obligations 56 22 (10) 68 Total non-current provisions 373 79 (7) 445 Year-end audit 1,067 (1,067) — — Legal Claims — 420 — 420 Severance payments 619 (505) — 114 Other 736 (540) — 196 Total current provisions 2,422 (1,692) — 730 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unwinding ​ ​ ​ ​ ​ ​ ​ of discount ​ ​ ​ ​ ​ ​ ​ ​ and changes ​ ​ ​ ​ ​ ​ Additions/ ​ in discount ​ ​ In € thousand ​ 01/01/2021 ​ Reversals ​ rate ​ 12/31/2021 Asset retirement obligations 175 54 4 233 Post-employment benefits (note 25) 193 (109) — 84 Record retention obligations 43 13 — 56 Total non-current provisions 411 (42) 4 373 Year-end audit — 1,067 — 1,067 Severance payments 80 539 — 619 Other — 736 — 736 Total current provisions 80 2,342 — 2,422 ​

Post-Employment Benefits (Table

Post-Employment Benefits (Tables)	12 Months Ended
	Dec. 31, 2022
Post-Employment Benefits
Schedule of present value of the defined benefit obligations and the fair value of the plan assets	​ ​ ​ ​ ​ ​ In € thousand 12/31/2022 12/31/2021 Present value of funded obligations 487 155 Fair value of plan assets (411) (71) Net defined benefit liability 76 84 ​
Schedule of reconciliation of the net defined benefit liability	​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Net defined liability at January 1 84 193 Defined benefit cost recognized in consolidated statement of operations 101 117 Defined benefit cost recognized in other comprehensive income (28) (162) Employer contributions (85) (74) Currency effects 4 10 Net defined liability at December 31 76 84 ​
Schedule of reconciliation of the amount recognized in the consolidated statement of financial position	​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Employee benefit obligations as of January 1 155 433 Actuarial adjustments (14) (233) thereof: experience adjustments 94 (202) thereof: demographic adjustments — (25) thereof: adjustments for financial assumptions (108) (6) Current service cost 95 112 Past service credit — (1) Interest expense 1 1 Currency effects 14 19 Employee contributions 85 74 Benefits recovered / (paid) 151 (250) Employee benefit obligations as of December 31 ​ 487 ​ 155 ​
Schedule of reconciliation of the plan assets	​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Fair value of plan assets as of January 1 71 240 Employer contributions 85 74 Employee contributions 85 74 Benefits recovered / (paid) 151 (250) Administration expenses (6) (5) Return on asset excl. interest income 14 (71) Interest income 1 0 Currency effects 10 9 Fair value of plan assets as of December 31 411 71 ​
Schedule of expense recognized in the consolidated statements of operations and other comprehensive income	​ ​ ​ ​ ​ ​ In € thousand 2022 2021 Actuarial losses (+) / gains (-) deriving from experience adjustments 94 (202) Actuarial gains (-) / losses (+) deriving from changes in demographical assumptions — (25) Actuarial gains (-) / losses (+) deriving from changes in financial assumptions (108) (6) Return on plan assets etc., interest (expense) / income (14) 71 Included in other comprehensive income (28) (162) Current service cost 95 112 Past service (credit) / cost — (1) Interest income (1) 0 Administrative expenses (effective) 6 5 Interest expense 1 1 Included in the consolidated statements of operations 101 117 Total expense / (income) included in the consolidated statements of operations and other comprehensive income 73 (45) ​
Schedule of principal actuarial assumptions	​ ​ ​ ​ ​ ​ ​ ​ 12/31/2022 12/31/2021 Future salary increases 3.00 % 1.00 % Inflation rate 1.60 % 0.60 % Future pension increases 0.00 % 0.00 % Discount rate 2.20 % 0.35 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 2021 2022 2021 Discount rate 0.25 % 0.25 % ​ (0.25) % (0.25) % Present value of the post-employment benefit obligations (in € thousand) 472 149 ​ 503 163 ​ Salary increase 0.25 % 0.25 % ​ (0.25) % (0.25) % Present value of the post-employment benefit obligations (in € thousand) 490 156 ​ 480 155 ​ Pension increase 0.25 % 0.25 % ​ (0.25) % (0.25) % Present value of the post-employment benefit obligations (in € thousand) 495 159 ​ n/a n/a ​ ​
Schedule of significant actuarial assumptions would have had the following impact on the present value of the post-employment benefit obligations as of the respective reporting dates	​ ​ ​ ​ ​ ​ ​ ​ (in € thousand) ​ December 31, 2022 Financial years 2023 2024-2027 2028-2032 Expected benefit payments 29 161 280 Total expected benefit payments 29 161 280 ​ ​ ​ ​ ​ ​ ​ ​ ​ (in € thousand) December 31, 2021 Financial years ​ 2022 ​ 2023-2026 ​ 2027-2031 Expected benefit payments 18 95 147 Total expected benefit payments 18 95 147

Trade and other Payables (Table

Trade and other Payables (Tables)	12 Months Ended
	Dec. 31, 2022
Trade and other Payables
Summary of trade and other payables	Trade and other payables are as follows: ​ ​ ​ ​ ​ In € thousand 12/31/2022 12/31/2021 Long term accruals 3,483 2,906 Non-current trade and other payables 3,483 2,906 Trade payables 19,195 14,936 Accruals for outstanding invoices 14,463 20,399 Current trade and other payables 33,658 35,335 Total trade and other payables 37,141 38,241 ​

Other Non-Financial Liabiliti_2

Other Non-Financial Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Other Non-Financial Liabilities
Summary of other non-financial liabilities	​ ​ ​ ​ ​ ​ In € thousand 12/31/2022 12/31/2021 Vacation accruals 2,474 2,488 Value added tax payables — 242 Payroll tax and social security 3,497 2,992 Miscellaneous other current non-financial liabilities 2,596 338 Total other non-financial liabilities 8,567 6,060 ​

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2022
Financial Instruments
Summary of financial instruments, analyzed by classes and categories	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 12/31/2022 In € thousand Category Carrying amount Fair value Financial assets, by class ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ AC 179,581 n/a Fixed term deposit ​ AC ​ 19,987 ​ n/a Non-current security deposits ​ AC 3,386 3,265 Security deposits ​ AC 2,594 n/a Total financial assets ​ ​ 205,548 ​ ​ Financial liabilities, by class ​ ​ ​ ​ ​ ​ Non-current trade and other payables ​ AC 3,483 3,239 Current trade and other payables ​ AC 33,658 n/a Non-current other liabilities ​ AC ​ 21 ​ 21 Current other financial liabilities ​ AC 4 ​ n/a Warrants ​ FVTPL 26,267 ​ 26,267 Total financial liabilities ​ ​ 63,433 ​ ​ ​ ​ ​ ​ ​ Thereof aggregated to categories according to IFRS 9 ​ Carrying ​ amount Financial assets measured at AC ​ 205,548 Financial assets measured at FVTPL — Financial liabilities measured at FVTPL 26,267 Financial liabilities measured at AC 37,166 ​ Financial instruments, analyzed by classes and categories ​ ​ ​ ​ ​ ​ ​ ​ ​ 12/31/2021 In € thousand Category Carrying amount Fair value Financial assets, by class Cash and cash equivalents AC 129,856 n/a Money market fund FVTPL 99,919 99,919 Fixed term deposit AC 119,664 n/a Non-current security deposits AC 3,779 3,787 Security deposits AC 42 n/a Total financial assets ​ 353,260 Financial liabilities, by class Non-current trade and other payables AC 2,906 2,868 Current trade and other payables AC 35,335 n/a Warrants FVTPL 21,405 21,405 Total financial liabilities ​ 59,646 ​ ​ ​ ​ ​ Carrying Thereof aggregated to categories according to IFRS 9 ​ amount Financial assets measured at AC 253,341 Financial assets measured at FVTPL 99,919 Financial liabilities measured at FVTPL 21,405 Financial liabilities measured at AC 38,241 ​
Summary of effect of reasonable changes of the most significant input parameters on the fair values of the embedded derivatives	​ ​ ​ ​ ​ ​ ​ ​ December 31, 2022 ​ ​ Effect on financial in € thousand ​ Shift in share price ​ Fair Value warrant ​ result Base — ​ (24,455) ​ — Up 10 % (28,316) (3,861) Down (10) % (21,023) 3,432 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Effect on financial in € thousand ​ Shift in volatility ​ Fair Value warrant ​ result Base — ​ (24,455) — Up 10 % (27,029) (2,574) Down (10) % (21,881) 2,575 ​
Summary of financial instruments, changes in fair Value of level 3 instruments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Convertible loan – ​ RDO and 2022 In € thousand Promissory Notes embedded derivative PIPE Warrants January 1, 2021 676 ​ 14,948 — Purchases / issuances 1,051 ​ 312 — Changes from fair value remeasurement 475 ​ (6,326) — Foreign exchange effects ​ 20 ​ — ​ — Conversion (2,222) ​ (8,934) — December 31, 2021 — ​ — — Initial recognition — ​ — 34,550 Changes from fair value remeasurement — ​ — (8,979) Foreign exchange effects — ​ — (1,116) December 31, 2022 — ​ — 24,455 ​
Summary of net gains and losses for each of the financial instrument measurement categories	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ Subsequent measurement ​ ​ ​ ​ Foreign ​ ​ ​ Impairment ​ ​ ​ ​ ​ ​ exchange ​ ​ ​ losses net of ​ Total per In € thousand Interest conversion Fair value reversal category Financial assets measured at amortized cost (412) 1,147 — 125 860 Financial liabilities measured at amortized cost (236) (560) — — (796) Financial assets and liabilities measured at fair value through profit or loss — (508) 29,667 — 29,159 Total (648) 79 29,667 125 29,223 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2021 ​ Subsequent measurement ​ ​ ​ ​ Foreign ​ ​ ​ Impairment ​ ​ ​ ​ ​ ​ exchange ​ ​ ​ losses net of ​ Total per In € thousand ​ Interest ​ conversion ​ Fair value ​ reversal ​ category Financial assets measured at amortized cost (364) 1,061 — (260) 437 Financial liabilities measured at amortized cost (3,483) (446) — — (3,929) Financial assets and liabilities measured at fair value through profit or loss — (1,018) (3,327) — (4,345) Total (3,847) (403) (3,327) (260) (7,837) ​
Summary of exposures to credit risk for all financial assets that are not measured at fair value through profit or loss	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 12/31/2022 ​ ​ Equivalent to ​ ​ ​ ​ ​ ​ ​ external Gross Impairment ​ ​ credit rating carrying loss ​ Credit- in € thousand [S&P] amount allowance impaired Grades 1–6: Low risk BBB- to AAA 205,683 (135) No Of which: ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ ​ ​ 179,640 ​ (59) ​ No Fixed-term deposits ​ ​ ​ 20,017 ​ (30) ​ No Security deposits ​ ​ ​ 6,026 ​ (46) ​ No ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 12/31/2021 ​ Equivalent to ​ ​ ​ ​ external Gross Impairment ​ ​ credit rating carrying loss ​ Credit- in € thousand [S&P] ​ amount ​ allowance ​ impaired Grades 1–6: Low risk BBB- to AAA 253,601 (260) No Of which: ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ ​ ​ 129,859 ​ (3) ​ No Fixed-term deposit ​ ​ ​ 119,920 ​ (256) ​ No Security deposits ​ ​ ​ 3,822 ​ (1) ​ No ​
Schedule of exposure to possible appreciation and depreciation in foreign currency	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ USD JPY GBP Total exposure At December 31, 2022 ​ (in € thousand) ​ (in € thousand) ​ (in € thousand) ​ (in € thousand) Cash and cash equivalents ​ 17,927 ​ — ​ — ​ 17,927 Current financial assets 2,158 — 3,793 5,951 Non-current financial assets 5,424 — 6,369 11,793 Non-current trade and other payables ​ (2,885) ​ (901) ​ — ​ (3,786) Current trade and other payables (7,097) — (138) (7,235) Current financial liabilities (8,358) — (10,107) (18,465) Warrants (26,267) — — (26,267) ​ (19,098) (901) (83) (20,082) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ USD GBP Total exposure At December 31, 2021 ​ (in € thousand) ​ (in € thousand) ​ (in € thousand) Cash and cash equivalents 18,174 8 18,182 Current trade and other payables (4,916) (402) (5,318) Warrants (21,405) — (21,405) ​ (8,147) (394) (8,541) ​
Summary of sensitivity of a change in foreign currency	The impact on the Group’s profit or loss before tax is due to changes in the carrying amount of monetary assets and liabilities as of December 31, 2022: ​ ​ ​ ​ ​ ​ ​ Effect of EUR appreciation on Effect of EUR depreciation on ​ ​ profit before tax ​ profit before tax Currency ​ (in € thousand) ​ (in € thousand) USD 1,736 (2,122) GBP 8 (9) JPY 82 (100) ​ The impact on the Group’s profit or loss before tax is due to changes in the carrying amount of monetary assets and liabilities as of December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ Effect of EUR appreciation on ​ Effect of EUR depreciation on profit ​ ​ profit before tax ​ before tax Currency (in € thousand) (in € thousand) USD 735 (898) GBP 15 (19) ​
Summary of details of the (undiscounted) cash outflows of financial liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 12/31/2022 ​ ​ ​ ​ ​ 2028 and in € thousand ​ 2023 ​ 2024 2025 to 2027 ​ thereafter Lease liabilities 2,970 2,457 6,463 — Trade and other payables 33,658 1,974 2,770 — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 12/31/2021 ​ ​ ​ ​ ​ ​ ​ ​ 2027 and in € thousand ​ 2022 ​ 2023 ​ 2024 to 2026 ​ thereafter Lease liabilities 2,356 2,705 8,001 2,187 Trade and other payables 35,335 29 3,498 — ​
Summary of reconciliation of changes in liabilities arising from financing activities	​ ​ ​ ​ ​ ​ ​ ​ In € thousand ​ Lease liabilities ​ Warrants Total Statement of Financial Position as of December 31, 2021 11,823 21,405 33,228 Principal elements of lease payments (2,720) — (2,720) Interest paid (443) — (443) Change in the cash flow from financing activities (3,163) — (3,163) Additions to lease liabilities due to new lease contracts 1,873 — 1,873 Additions to warrants — 34,550 34,550 Fair value changes — (30,196) (30,196) Effects of foreign exchange conversion — 508 508 Interest expenses 436 — 436 Capital contributions — — — Statement of Financial Position as of December 31, 2022 10,969 26,267 37,236 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Convertible ​ Lease ​ ​ In € thousand ​ loans ​ liabilities ​ Warrants ​ Total Statement of Financial Position as of December 31, 2020 99,235 ​ 11,118 — 110,353 Proceeds from convertible loans 1,850 ​ — — 1,850 Principal elements of lease payments — ​ (1,781) — (1,781) Interest paid — ​ (437) — (437) Change in the cash flow from financing activities 1,850 ​ (2,218) — (368) Additions to lease liabilities due to new lease contracts — ​ 2,486 ​ 2,486 Additions to warrants ​ — ​ ​ ​ 25,859 ​ 25,859 Fair value changes (6,326) ​ — (5,492) (11,818) Effects of foreign exchange conversion ​ ​ ​ 1,038 1,038 Interest expenses ​ 3,483 ​ 437 ​ ​ ​ 3,920 Capital contributions (98,242) ​ — ​ (98,242) Statement of Financial Position as of December 31, 2021 — ​ 11,823 21,405 33,228

Related Party Disclosures (Tabl

Related Party Disclosures (Tables)	12 Months Ended
	Dec. 31, 2022
Related Party Disclosures
Schedule of Share based ultimate controlling party	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Shares (in thousand units) Ownership Interest (%) Function ​ 12/31/2022 ​ 12/31/2021 ​ 12/31/2022 ​ 12/31/2021 Key management 28,302 25,743 7.2 % 9.1 % Other related parties 128,679 121,389 32.7 % 42.7 % Total 156,981 147,132 39.9 % 51.8 % ​
Schedule of annual remuneration and related compensation costs recognized as expense	​ ​ ​ ​ ​ ​ In € thousand ​ 2022 ​ 2021 1 Short-term employee benefits 4,657 3,607 Termination remuneration 52 619 Post-employment benefits 45 27 Share-based payment award remuneration 7,364 19,910 Success fees and JSOP (4,568) 9,872 Total 7,550 34,035 ​ 1 ​
Schedule of balances held by entities with significant influence over the company	​ ​ ​ ​ ​ ​ (in € thousand) 2022 2021 1 Research and development expenses 17 14 General and administration expenses — 96 Selling expenses 289 167 Finance income 7 — Finance expenses 6 — Purchase of property, plant and equipment 24 1 ​ 1 ​
Schedule of balances held by entities with significant influence over the company	​ ​ ​ ​ ​ ​ (in € thousand) ​ 2022 ​ 2021 1 Convertible loans Beginning of the year — 99,235 Proceeds from convertible loans — 1,007 Fair value changes of convertible loans — (6,337) Interest expenses (not paid) — 3,400 Subscribed capital — (7) Contribution to capital reserves — (97,298) End of the year — — ​ ​ ​ ​ ​ Azul Warrants ​ — ​ 13,030 Research and development expenses 1,323 347 ​ 1 ​

Corporate Information (Details)

Corporate Information (Details)		12 Months Ended
	Sep. 14, 2021	Dec. 31, 2022
Corporate Information
Share split	0.0004	0.0004
Percentage of shares acquired		31.40%
Business Combination Agreement
Corporate Information
Percentage of shares acquired	100%

Basis of Preparation - Going Co

Basis of Preparation - Going Concern (Details) € in Millions	12 Months Ended
	Dec. 31, 2022 EUR (€)
Basis Of Preparation
Cash flows from operations including accumulated losses	€ 970.2

Basis of Preparation - Group In

Basis of Preparation - Group Information (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Lilium N.V.
Basis of Preparation
Proportion of interest in subsidiary	100%	100%
Lilium GmbH
Basis of Preparation
Proportion of interest in subsidiary	100%	100%
Lilium Schweiz GmbH
Basis of Preparation
Proportion of interest in subsidiary	100%	100%
Lilium Aviation UK Ltd.
Basis of Preparation
Proportion of interest in subsidiary	100%	100%
Lilium Aviation Inc.
Basis of Preparation
Proportion of interest in subsidiary	100%	100%
Lilium eAircraft GmbH
Basis of Preparation
Proportion of interest in subsidiary	100%	100%
Stichting JSOP
Basis of Preparation
Proportion of interest in subsidiary	0%	0%
Lilium Aviation Spain SLU
Basis of Preparation
Proportion of interest in subsidiary	100%

Significant Accounting Polici_4

Significant Accounting Policies - Purchase of intangible assets (Details)	12 Months Ended
	Dec. 31, 2022
Minimum | Software
Significant Accounting Policies
Useful life of intangible assets	2 years
Minimum | Purchased concessions, rights and other intangible assets
Significant Accounting Policies
Useful life of intangible assets	10 years
Maximum | Software
Significant Accounting Policies
Useful life of intangible assets	15 years
Maximum | Purchased concessions, rights and other intangible assets
Significant Accounting Policies
Useful life of intangible assets	20 years

Significant Accounting Polici_5

Significant Accounting Policies - Estimated useful lives of property plant and equipment (Details)	12 Months Ended
	Dec. 31, 2022
Significant Accounting Policies
Useful life of property and equipment	5 years
Minimum | Rights to land and buildings including leasehold improvements
Significant Accounting Policies
Useful life of property and equipment	2 years
Minimum | Technical equipment and machinery
Significant Accounting Policies
Useful life of property and equipment	3 years
Minimum | Office and other equipment
Significant Accounting Policies
Useful life of property and equipment	3 years
Minimum | Vehicles [Member]
Significant Accounting Policies
Useful life of property and equipment	5 years
Maximum | Rights to land and buildings including leasehold improvements
Significant Accounting Policies
Useful life of property and equipment	9 years
Maximum | Technical equipment and machinery
Significant Accounting Policies
Useful life of property and equipment	25 years
Maximum | Office and other equipment
Significant Accounting Policies
Useful life of property and equipment	13 years
Maximum | Vehicles [Member]
Significant Accounting Policies
Useful life of property and equipment	11 years

Significant Accounting Polici_6

Significant Accounting Policies (Details) € in Thousands	12 Months Ended
	Dec. 31, 2022 EUR (€)
Significant Accounting Policies
Low value assets	€ 1
Minimum
Significant Accounting Policies
Lease term	2 years
Maximum
Significant Accounting Policies
Lease term	9 years

Significant Accounting Polici_7

Significant Accounting Policies - Share-based payments (Details) € / shares in Units, € in Thousands	1 Months Ended	12 Months Ended
	Sep. 30, 2021 item	Dec. 31, 2022 EUR (€) tranche item installment € / shares shares	Dec. 31, 2021 EUR (€)	Dec. 31, 2020 EUR (€) shares	Dec. 31, 2022 $ / shares	Oct. 23, 2022 shares	Oct. 22, 2021 shares	Dec. 31, 2019 EUR (€)
Significant Accounting Policies
Number of tranches | tranche		3
Share listing expense			€ 111,109
Number of shares issued during period | shares				23,261,694
Cash and cash equivalents		€ 179,581	129,856	€ 102,144				€ 59,571
Current liabilities		73,016	€ 75,764
Financial liabilities		€ 63,433
General population and executives - standard ESOP
Significant Accounting Policies
Vesting period (in years)		4 years
Contractual life		0 years
Lock-up period for options become exercisable		180 days
General population and executives - standard ESOP | Tranche one
Significant Accounting Policies
Vesting percentage		25%
General population - Restricted Stock Units ("RSU")
Significant Accounting Policies
Vesting period (in years)		1 year
Vesting percentage		100%
Price per share upon vesting | € / shares		€ 0.12
Executives - Restricted Stock Units ("RSU")
Significant Accounting Policies
Price per share upon vesting | € / shares		€ 0.12
Term of agreements		4 years
Executives - Performance-based stock options
Significant Accounting Policies
Contractual life		10 years
Period for exercise of shares upon vesting after cease from employment (in days)		90 days
Number of quarterly installments | installment		17
Executives - Time-based stock options
Significant Accounting Policies
Vesting percentage		31%
Contractual life		10 years
Period for exercise of shares upon vesting after cease from employment (in days)		90 days
Number of persons awarded | item		3
Executives - Success fees
Significant Accounting Policies
Number of awards settled | item	1
Executives - Presence bonus
Significant Accounting Policies
Number of persons awarded | item		1
Executives - Joint Stock Ownership plan (JSOP) and bonus
Significant Accounting Policies
Carry charge (in percent)		7.50%
Interest (in percent)		7.50%
Advisors - Strategic collaboration agreement
Significant Accounting Policies
Number of warrants to purchase shares | shares		8,000,000				6,200,000	1,800,000
Exercise price of warrant | € / shares		€ 0.12
Number of tranches | item		3
Share listing expense
Significant Accounting Policies
Number of tranches | tranche		3
Share listing expense | Total
Significant Accounting Policies
Net assets		€ 53,900
Cash and cash equivalents		83,300
Current liabilities		3,600
Financial liabilities		€ 25,800
Share listing expense | Total | Sponsor Lock-Up Shares
Significant Accounting Policies
Discount for lack of marketability (in percent)		5%
Share listing expense | Total | Sponsor Earnout Shares
Significant Accounting Policies
Discount for lack of marketability (in percent)		5%
Share listing expense | Qell share-holders
Significant Accounting Policies
Fair value of shares		€ 165,000
Net assets		53,900
Share listing expense		€ 111,100
Value per share traded | $ / shares					$ 9.41
Number of shares issued during period | shares		21,080,961
Share listing expense | Qell Sponsors | Sponsor Lock-Up Shares
Significant Accounting Policies
Number of shares issued during period | shares		4,595,133
Lock-up period		1 year
Share listing expense | Qell Sponsors | Sponsor Earnout Shares
Significant Accounting Policies
Number of shares issued during period | shares		3,063,422
Share listing expense | Qell Sponsors | Sponsor Earnout Shares | Tranche one
Significant Accounting Policies
Number of shares issued during period | shares		1,148,783
Share listing expense | Qell Sponsors | Sponsor Earnout Shares | Tranche two
Significant Accounting Policies
Number of shares issued during period | shares		1,148,783
Share listing expense | Qell Sponsors | Sponsor Earnout Shares | Tranche three
Significant Accounting Policies
Number of shares issued during period | shares		765,856
Share-based payment - Vendors
Significant Accounting Policies
Number of third parties | item		2

Significant Accounting Judgme_2

Significant Accounting Judgments, Estimates and Assumptions (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Significant Accounting Judgments, Estimates and Assumptions
Weighted average IBR	3.53%	3.75%
Period of ownership restriction for Private Warrants after the completion of the Business Combination	30 days

Significant Accounting Judgme_3

Significant Accounting Judgments, Estimates and Assumptions - Investment in associate - Purchase Price Allocation (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Significant Accounting Judgments, Estimates and Assumptions
Percentage of ownership interest in associate	27.70%	34.80%
Zenlabs Energy Inc
Significant Accounting Judgments, Estimates and Assumptions
Percentage of ownership interest in associate	27.70%
Hypothetical royalty rate	0.93%
Technology portfolio | Zenlabs Energy Inc
Significant Accounting Judgments, Estimates and Assumptions
Useful life of intangible assets	15 years
Brand asset | Zenlabs Energy Inc
Significant Accounting Judgments, Estimates and Assumptions
Useful life of intangible assets	15 years

Significant Accounting Judgme_4

Significant Accounting Judgments, Estimates and Assumptions - Share-based Payments (Details)	12 Months Ended
	Dec. 31, 2022
Significant Accounting Judgments, Estimates and Assumptions
Weighted average expected timing of fulfillment of performance condition	20 months
Percentage of weighted average probability	69%
Share listing expense, percentage for transfer restrictions imposed on Sponsor Lock-Up Shares and Sponsor Earnout Shares	5%

Revenue from Contracts with C_2

Revenue from Contracts with Customers and Cost of Sales (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue from Contracts with Customers and Cost of Sales
Revenue recognized	€ 47	€ 97

Research and Development Expe_3

Research and Development Expenses (Details) - Research and Development Expenses - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Research and Development Expenses
Salaries and social security	€ 77,455	€ 75,672	€ 66,536
Professional services	72,840	49,421	8,448
Materials	7,808	9,009	8,253
Depreciation/amortization/impairment	6,386	4,541	2,829
IT and communication expense	3,709	1,248	1,857
Other expenses by nature	7,420	4,667	2,422
Total	€ 175,618	€ 144,558	€ 90,345

Research and Development Expe_4

Research and Development Expenses - Additional Information (Details) - Research and Development Expenses - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Research and Development Expenses
Professional fees, consulting services	€ 54,734	€ 31,576	€ 3,732
Professional fees, contractors	€ 18,105	€ 17,845	€ 4,716

General and Administrative Ex_3

General and Administrative Expenses (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
General and Administrative Expenses
Share listing expense		€ 111,109
General and Administrative Expenses
General and Administrative Expenses
Share listing expense		111,109
Professional services	€ 28,851	70,380	€ 8,483
Salaries and social security	30,187	35,395	20,926
IT and communication expense	20,374	12,391	2,255
Depreciation/amortization	1,816	1,870	1,289
Insurances	6,457	1,698	73
HR related expenses (training, recruitment)	1,466	1,617	1,026
Other administrative expenses	4,736	4,633	1,354
Total	€ 93,887	€ 239,093	€ 35,406

General and Administrative Ex_4

General and Administrative Expenses - Additional Information (Details) - General and Administrative Expenses - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
General and Administrative Expenses
Amount of reduction in professional services expenses	€ 4,435	€ 5,438	€ 0
Professional services, consulting and legal fees	33,127
Professional services, issue of Azul warrants expenses	13,030
IT and communication expense incurred for cloud-based data analytics tool	€ 13,527	€ 6,590	€ 0

Selling Expenses (Details)

Selling Expenses (Details) - Selling Expenses - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Selling Expenses
Salaries, social security	€ 8,915	€ 11,971	€ 13,115
Professional services	1,690	1,983	1,196
Marketing	1,448	2,059	613
Travel	523	626	167
Depreciation/amortization	65	65	41
Other expenses by nature	288	485	140
Total	€ 12,929	€ 17,189	€ 15,272

Other Income (Details)

Other Income (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Other Income
Foreign currency gains	€ 3,842	€ 1,689	€ 19
Insurance recoveries	483	456	1,906
Grants received from the German government	1,038	51	307
Income from other grants			42
At-equity income from dilution	1,179
Other miscellaneous income	266	78	72
Total other income	€ 6,808	€ 2,274	€ 2,346

Other Income - Additional Infor

Other Income - Additional Information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Other Income
Foreign currency gains derived from favorable exchange rate movements	€ 3,842	€ 1,689	€ 19
Insurance recoveries, amount for damage to equipment sustained in transit	483
Insurance recoveries, amount for damage which occurred as a result of an accident during maintenance work		456	1,906
Gain on dilution in the investment	1,179
Other miscellaneous income related to health insurance reimbursements	€ 167	€ 0	€ 0

Other Expenses (Details)

Other Expenses (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Other Expenses
Foreign currency losses	€ 3,264	€ 1,054	€ 107
Miscellaneous other items	4	982	23
Total other expenses	€ 3,268	€ 2,036	€ 130

Financial Result (Details)

Financial Result (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Financial Result
Finance income	€ 30,322	€ 11,288	€ 80
thereof: fair value changes	29,922	11,280	58
thereof: impairment loss net of reversal	125	0	0
Finance expenses	(1,995)	(20,201)	(49,741)
thereof: fair value changes	763	15,645	15,222
thereof: interest portion of lease payments	(443)	(437)	(450)
thereof: impairment loss net of reversal		(260)
thereof: interest on convertible loans		(3,483)	(33,960)
Financial result	€ 28,327	€ (8,913)	€ (49,661)

Financial Result - Additional I

Financial Result - Additional Information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Financial Result
Changes in fair value of warrants included in finance income	€ 29,688	€ 4,454	€ 0
Fair value changes in the price of the warrants	30,196	5,492	0
Gain on foreign exchange conversion of RDO & 2022 PIPE Warrants	1,116	0	0
Offset by the loss on foreign exchange conversion of Reorganization Warrants	1,624	1,038	0
Gain on foreign currency contract	234	0	0
Impairment losses net of reversal	125	0	0
Fair value changes of money market funds included in finance expense	67	87	0
Fair value changes in the ELOC purchased put option	696	0	0
Fair value changes of foreign currency exchange contract included in finance expense		€ 15,532
Fair value changes from the embedded derivatives of the convertible loans			€ 15,222
Convertible loans outstanding	0
Investments in money market funds	€ 0

Income Taxes - Expense for Inco

Income Taxes - Expense for Income Tax Expense (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Taxes
Current income tax expense	€ (169)	€ (556)	€ (46)
Current income tax expense related to prior years	495	(143)
Current taxes	326	(699)	(46)
Deferred tax expense		(10)
Income tax benefits / (expense	€ 326	€ (709)	€ (46)

Income Taxes - Income Tax Expen

Income Taxes - Income Tax Expense (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Taxes
Corporation tax rate	15%
Solidarity surcharge on corporation tax rate	5.50%
Trade tax rate	11.73%
Total group tax rate	27.55%	27.55%	27.55%	27.55%

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of expected tax expense (Details) - EUR (€) € in Thousands	1 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Taxes
Profit (Loss) before income tax		€ (253,390)	€ (410,327)	€ (188,381)
Income tax rate		27.55%	27.55%	27.55%	27.55%
Expected income taxes on this		€ 69,809	€ 113,045	€ 51,899
Effects deriving from differences to the expected tax rate		9	40	54
Taxes for prior years		495	(143)
Other non-deductible expenses and taxes		(59)	(66)	(238)
Changes in the realization of deferred tax assets		(76,356)	(67,465)	(22,371)
Other		6,428	(46,120)	(29,390)
Income tax benefits / (expense)		€ 326	€ (709)	€ (46)
Effective tax rate in %		0.10%	(0.20%)	0%
Equity settled share-based payments		€ 27,380	€ 53,350	€ 71,990
Equity settled share-based payments		22,817
Reconciliation effect of share-based payments		6,286
Fair value adjustments of Reorganization Warrants and RDO & 2022 PIPE Warrants		29,689
Reconciliation effect of fair value adjustments of warrants		8,179	3,590
Transaction costs deducted from equity		7,402
Reconciliation effect of transaction costs deducted from equity		2,039
Non-cash share listing expense			111,109
Income tax reconciliation effect of non-cash share listing expense			30,610
Other share-based payments			40,321
Income tax reconciliation effect of other share-based payments			11,108
Conversion	€ 34,084	€ (562)	96,193	€ 102,207
Azul
Income Taxes
Fair value adjustments of Reorganization Warrants and RDO & 2022 PIPE Warrants			13,030
Conversion			6,351
Income tax reconciliation effect of embedded derivative of the convertible loans			1,750
Qell Acquisition Corp
Income Taxes
Fair value adjustments of Reorganization Warrants and RDO & 2022 PIPE Warrants			4,454
Reconciliation effect of fair value adjustments of warrants			€ 1,227

Income Taxes - Deferred tax rel

Income Taxes - Deferred tax related to Assets and Liabilities (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Taxes
Deferred tax assets, Total value	€ 3,111	€ 4,173
Deferred tax liabilities, Total value	3,121	4,183
Deferred tax assets, Netting	(3,111)	(4,173)
Deferred tax liabilities, Netting	(3,111)	(4,173)
Recognition of deferred tax liabilities in the statement of financial position	10	10
Non-current assets
Income Taxes
Deferred tax assets, Total value	2,378	3,010
Deferred tax liabilities, Total value	2,913	3,099
Intangible assets
Income Taxes
Deferred tax assets, Total value	2,341	2,995
Property, plant and equipment
Income Taxes
Deferred tax assets, Total value	37	15
Deferred tax liabilities, Total value	2,903	3,088
Financial assets
Income Taxes
Deferred tax liabilities, Total value	10	11
Current assets
Income Taxes
Deferred tax assets, Total value	149	14
Deferred tax liabilities, Total value		286
Inventories
Income Taxes
Deferred tax assets, Total value	123	11
Receivables and other assets
Income Taxes
Deferred tax assets, Total value	26	3
Deferred tax liabilities, Total value		286
Non-current liabilities
Income Taxes
Deferred tax assets, Total value	446	645
Deferred tax liabilities, Total value		167
Provisions
Income Taxes
Deferred tax assets, Total value	10	24
Deferred tax liabilities, Total value		3
Liabilities
Income Taxes
Deferred tax assets, Total value	436	621
Deferred tax liabilities, Total value		163
Current liabilities
Income Taxes
Deferred tax assets, Total value	138	222
Deferred tax liabilities, Total value	208	631
Provisions
Income Taxes
Deferred tax assets, Total value		91
Deferred tax liabilities, Total value	47
Liabilities
Income Taxes
Deferred tax assets, Total value	138	131
Deferred tax liabilities, Total value	€ 161	631
Loss carry forwards
Income Taxes
Deferred tax assets, Total value		€ 282

Income Taxes - Tax attributes (

Income Taxes - Tax attributes (gross) (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Income Taxes
Corporation tax loss carryforwards	€ 661,501	€ 388,980
Trade tax loss carryforwards	659,161	387,524
Interest carryforwards	15,348	€ 15,846
Tax loss carryforwards cannot be used	€ 56,891

Income Taxes - Deductible tempo

Income Taxes - Deductible temporary differences and tax loss and interest carryforwards (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Taxes
Unrecognized deferred tax assets, Beginning balance	€ 124,043	€ 56,578
Addition	77,682	70,891
Deductions	(137)	(3,426)
Unrecognized deferred tax assets, Ending balance	201,588	124,043
Temporary differences
Income Taxes
Unrecognized deferred tax assets, Beginning balance	13,850	17,276
Addition	1,541
Deductions		(3,426)
Unrecognized deferred tax assets, Ending balance	15,391	13,850
Tax losses
Income Taxes
Unrecognized deferred tax assets, Beginning balance	106,264	35,639
Addition	75,705	70,625
Unrecognized deferred tax assets, Ending balance	181,969	106,264
Interest carry forward
Income Taxes
Unrecognized deferred tax assets, Beginning balance	3,929	3,663
Addition	436	266
Deductions	(137)
Unrecognized deferred tax assets, Ending balance	€ 4,228	€ 3,929

Loss per Share (Details)

Loss per Share (Details) - EUR (€) € / shares in Units, € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Loss per Share
Anti-dilutive warrants excluded from the diluted EPS calculation	1,800,000
Comprehensive loss attributed to equity shareholders	€ (253,003)	€ (410,830)	€ (188,435)
Weighted average number of ordinary shares outstanding, Basic	316,474,576	214,858,203	193,722,062
Weighted average number of ordinary shares outstanding, Diluted	316,474,576	214,858,203	193,722,062
Basic EPS	€ (0.80)	€ (1.91)	€ (0.97)
Diluted EPS	€ (0.80)	€ (1.91)	€ (0.97)

Intangible Assets (Details)

Intangible Assets (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about intangible assets [line items]
Beginning balance	€ 1,394	€ 1,372
Ending balance	870	1,394
Software [Member]
Disclosure of detailed information about intangible assets [line items]
Beginning balance	1,304	1,276
Ending balance	750	1,304
Purchased concessions, rights and other intangible assets [Member]
Disclosure of detailed information about intangible assets [line items]
Beginning balance	90	96
Ending balance	120	90
Costs of acquisition or construction
Disclosure of detailed information about intangible assets [line items]
Beginning balance	4,106	2,509
Additions	200	1,586
Disposals		11
Ending balance	4,306	4,106
Costs of acquisition or construction | Software [Member]
Disclosure of detailed information about intangible assets [line items]
Beginning balance	3,998	2,401
Additions	163	1,586
Disposals		11
Ending balance	4,161	3,998
Costs of acquisition or construction | Purchased concessions, rights and other intangible assets [Member]
Disclosure of detailed information about intangible assets [line items]
Beginning balance	108	108
Additions	37
Ending balance	145	108
Accumulated amortization/write downs and depreciation
Disclosure of detailed information about intangible assets [line items]
Beginning balance	(2,712)	(1,137)
Amortization	(724)	(1,575)
Ending balance	(3,436)	(2,712)
Accumulated amortization/write downs and depreciation | Software [Member]
Disclosure of detailed information about intangible assets [line items]
Beginning balance	(2,694)	(1,125)
Amortization	(717)	(1,569)
Ending balance	(3,411)	(2,694)
Accumulated amortization/write downs and depreciation | Purchased concessions, rights and other intangible assets [Member]
Disclosure of detailed information about intangible assets [line items]
Beginning balance	(18)	(12)
Amortization	(7)	(6)
Ending balance	€ (25)	€ (18)

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of changes in property, plant and equipment
Property, plant and equipment at beginning of period	€ 30,610	€ 22,715
Property, plant and equipment at end of period	36,699	30,610
Impairment loss relating to assets that were obsolute and in process of being disposed of	52	0	€ 0
Costs of acquisition or construction
Reconciliation of changes in property, plant and equipment
Property, plant and equipment at beginning of period	41,661	28,863
Additions	13,174	12,826
Disposals	(201)	(1)
Transfer to intangible assets		(11)
Indexation impact	488	(26)
Foreign exchange	(6)	10
Property, plant and equipment at end of period	55,116	41,661
Accumulated amortization/write downs and depreciation
Reconciliation of changes in property, plant and equipment
Property, plant and equipment at beginning of period	(11,051)	(6,148)
Disposals	174
Foreign exchange	(3)	2
Depreciation	7,491	4,901
Impairment	(52)
Property, plant and equipment at end of period	(18,417)	(11,051)
Rights to land and buildings including leasehold improvements [Member]
Reconciliation of changes in property, plant and equipment
Property, plant and equipment at beginning of period	14,465	12,717
Property, plant and equipment at end of period	13,807	14,465
Rights to land and buildings including leasehold improvements [Member] | Costs of acquisition or construction
Reconciliation of changes in property, plant and equipment
Property, plant and equipment at beginning of period	19,903	15,774
Additions	2,366	3,444
Transfers	130	711
Indexation impact	488	(26)
Property, plant and equipment at end of period	22,887	19,903
Rights to land and buildings including leasehold improvements [Member] | Accumulated amortization/write downs and depreciation
Reconciliation of changes in property, plant and equipment
Property, plant and equipment at beginning of period	(5,438)	(3,057)
Depreciation	3,642	2,381
Property, plant and equipment at end of period	(9,080)	(5,438)
Vehicles [Member]
Reconciliation of changes in property, plant and equipment
Property, plant and equipment at beginning of period	84	120
Property, plant and equipment at end of period	87	84
Vehicles [Member] | Costs of acquisition or construction
Reconciliation of changes in property, plant and equipment
Property, plant and equipment at beginning of period	166	160
Additions	67	6
Disposals	(94)
Property, plant and equipment at end of period	139	166
Vehicles [Member] | Accumulated amortization/write downs and depreciation
Reconciliation of changes in property, plant and equipment
Property, plant and equipment at beginning of period	(82)	(40)
Disposals	94
Depreciation	64	42
Property, plant and equipment at end of period	(52)	(82)
Technical equipment and machinery [Member]
Reconciliation of changes in property, plant and equipment
Property, plant and equipment at beginning of period	9,069	5,555
Property, plant and equipment at end of period	15,643	9,069
Technical equipment and machinery [Member] | Costs of acquisition or construction
Reconciliation of changes in property, plant and equipment
Property, plant and equipment at beginning of period	10,738	6,195
Additions	6,328	2,532
Disposals	(12)
Transfers	2,466	2,009
Foreign exchange		2
Property, plant and equipment at end of period	19,520	10,738
Technical equipment and machinery [Member] | Accumulated amortization/write downs and depreciation
Reconciliation of changes in property, plant and equipment
Property, plant and equipment at beginning of period	(1,669)	(640)
Disposals	12	1
Depreciation	2,168	1,028
Impairment	(52)
Property, plant and equipment at end of period	(3,877)	(1,669)
Office and other equipment [Member]
Reconciliation of changes in property, plant and equipment
Property, plant and equipment at beginning of period	4,381	3,179
Property, plant and equipment at end of period	4,275	4,381
Office and other equipment [Member] | Costs of acquisition or construction
Reconciliation of changes in property, plant and equipment
Property, plant and equipment at beginning of period	8,243	5,590
Additions	1,519	2,644
Disposals	(95)	(1)
Transfers	22	2
Foreign exchange	(6)	8
Property, plant and equipment at end of period	9,683	8,243
Office and other equipment [Member] | Accumulated amortization/write downs and depreciation
Reconciliation of changes in property, plant and equipment
Property, plant and equipment at beginning of period	(3,862)	(2,411)
Disposals	68	1
Foreign exchange	(3)	2
Depreciation	1,617	1,450
Property, plant and equipment at end of period	(5,408)	(3,862)
Assets under construction
Reconciliation of changes in property, plant and equipment
Property, plant and equipment at beginning of period	2,611	1,144
Property, plant and equipment at end of period	2,887	2,611
Assets under construction | Costs of acquisition or construction
Reconciliation of changes in property, plant and equipment
Property, plant and equipment at beginning of period	2,611	1,144
Additions	2,894	4,200
Transfers	(2,618)	(2,722)
Transfer to intangible assets		(11)
Property, plant and equipment at end of period	2,887	2,611
Right-of-use assets
Reconciliation of changes in property, plant and equipment
Property, plant and equipment under security pledges	€ 10,499	€ 11,525

Property, Plant and Equipment -

Property, Plant and Equipment - Property, plant and equipment is distributed among geographical areas (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of detailed information about property, plant and equipment
Right-of-use assets	€ 10,499	€ 11,525	€ 10,941
Total	36,699	30,610	€ 22,715
Germany
Disclosure of detailed information about property, plant and equipment
Property, plant and equipment	26,063	18,933
Right-of-use assets	10,033	11,525
United Kingdom
Disclosure of detailed information about property, plant and equipment
Property, plant and equipment	97	100
United States
Disclosure of detailed information about property, plant and equipment
Property, plant and equipment	23	38
Switzerland
Disclosure of detailed information about property, plant and equipment
Property, plant and equipment	12	€ 14
Spain
Disclosure of detailed information about property, plant and equipment
Property, plant and equipment	5
Right-of-use assets	€ 466

Leases - Right-of-use assets (D

Leases - Right-of-use assets (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of quantitative information about right-of-use assets
Beginning balance	€ 11,525	€ 10,941
Additions to right-of-use assets	1,612	2,568
Transfer	(144)	(17)
Disposal of right-of-use assets	(4)
Depreciation	(2,977)	(1,941)	€ (1,631)
Indexation impact	488	(26)
Ending balance	10,499	11,525	10,941
Rights to land and buildings including leasehold improvements [Member]
Disclosure of quantitative information about right-of-use assets
Beginning balance	10,910	10,375
Additions to right-of-use assets	1,526	2,369
Depreciation	(2,889)	(1,808)
Indexation impact	488	(26)
Ending balance	10,034	10,910	10,375
Vehicles [Member]
Disclosure of quantitative information about right-of-use assets
Beginning balance	43	77
Additions to right-of-use assets	63
Disposal of right-of-use assets	(3)
Depreciation	(49)	(34)
Ending balance	54	43	77
Property, plant and equipment
Disclosure of quantitative information about right-of-use assets
Beginning balance	428	461
Additions to right-of-use assets	23	29
Transfer		(17)
Disposal of right-of-use assets	(1)
Depreciation	(39)	(45)
Ending balance	411	428	461
Office and other equipment [Member]
Disclosure of quantitative information about right-of-use assets
Beginning balance	144	28
Additions to right-of-use assets		170
Transfer	€ (144)
Depreciation		(54)
Ending balance		€ 144	€ 28

Leases - Lease liabilities (Det

Leases - Lease liabilities (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases
Beginning balance	€ 11,823	€ 11,118
Additions	1,385	2,512
Accrued interest	(7)
Interest	443	437	€ 450
Payments	(3,163)	(2,218)
Indexation impact	488	(26)
Ending balance	€ 10,969	€ 11,823	€ 11,118

Leases - Current and non-curren

Leases - Current and non-current portion of lease liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases
Current	€ 2,616	€ 1,962
Non-current	8,353	9,861
Total lease liabilities	€ 10,969	€ 11,823	€ 11,118

Leases - Related expense (Detai

Leases - Related expense (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases
Depreciation of right of-use-assets	€ 2,977	€ 1,941	€ 1,631
Interest expense on lease liabilities	443	437	450
Short-term lease expenses	6	488	108
Lease expenses for low-value assets	137	220	80
Total amount recognized in expense	€ 3,563	€ 3,086	€ 2,269

Leases - Composition of lease p

Leases - Composition of lease payments (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Leases
Fixed lease payments	€ 1,212	€ 204
Variable lease payments	1,951	2,014
Total amount of lease payments	€ 3,163	€ 2,218

Leases - Total cash outflow (De

Leases - Total cash outflow (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases
Principal paid	€ 2,720	€ 1,781	€ 1,439
Interest paid	443	437	450
Short term and low value leases	143	708	188
Total amount paid	€ 3,306	€ 2,926	€ 2,077

Investment in a Joint Venture_3

Investment in a Joint Venture / Associate (Details) € in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022 EUR (€) shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 EUR (€)	Sep. 27, 2021 EUR (€)	Sep. 27, 2021 USD ($)	Jul. 27, 2021 USD ($)	Jul. 16, 2021 EUR (€)	Jul. 15, 2021	Mar. 19, 2021 EUR (€)	Mar. 19, 2021 USD ($)	Mar. 10, 2021 EUR (€)	Mar. 10, 2021 USD ($)
Investment in a Joint Venture / Associate
Percentage of shares acquired	31.40%	31.40%
Percentage of outstanding capital diluted	27.70%
Shareholder voting rights	31.40%	31.40%
Gain on dilution | €	€ 1,179
Share capital
Investment in a Joint Venture / Associate
Share buyback common stock	273,227
Series B preferred stock
Investment in a Joint Venture / Associate
Number of shares issued	1,092,908	1,092,908
Zenlabs Energy Inc
Investment in a Joint Venture / Associate
Percentage of shares acquired								9.10%			25.70%	25.70%
Purchase price			€ 8,502	€ 7,400	$ 8,716	$ 8,716	€ 7,400				€ 8,502	$ 10,054
Conversion of outstanding promissory notes at a fair value included in consideration			€ 2,222						€ 2,222	$ 2,629
Promissory notes held included in conversion									€ 1,051	$ 1,250
Total fair value of identifiable net assets acquired	€ 8,344	$ 9,843
Goodwill	7,558	8,927
Identifiable net assets acquired	2,248	2,652
Fair value step-up brand and technology portfolio	8,688	10,250
Deferred taxation	€ 2,592	$ 3,059
Shareholder voting rights								9.10%			25.70%	25.70%

Investment in a Joint Venture_4

Investment in a Joint Venture / Associate - Valuation of investment in Zenlabs (Details) € in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 EUR (€)	Sep. 27, 2021 EUR (€)	Sep. 27, 2021 USD ($)	Jul. 27, 2021 USD ($)	Jul. 16, 2021 EUR (€)	Mar. 19, 2021 EUR (€)	Mar. 19, 2021 USD ($)	Mar. 10, 2021 EUR (€)	Mar. 10, 2021 USD ($)
Investment in a Joint Venture / Associate
Ending Balance	€ 13,410	€ 15,054
Beginning Balance	15,054
Zenlabs Energy Inc
Investment in a Joint Venture / Associate
Ending Balance	13,410	15,054
Initial recognition		8,502	€ 7,400	$ 8,716	$ 8,716	€ 7,400			€ 8,502	$ 10,054
Conversion of promissory notes (July 2021)		2,222					€ 2,222	$ 2,629
Capital increases (July and September 2021)		5,178
Gain on dilution	1,179
Share of loss in a joint venture/ associate	(2,823)	€ (848)
Beginning Balance	€ 15,054

Investment in a Joint Venture_5

Investment in a Joint Venture / Associate - Financial information for Zenlabs (Details) - EUR (€) € in Thousands		10 Months Ended	12 Months Ended
		Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2023	Dec. 31, 2019
Investment in a Joint Venture / Associate
Revenue				€ 47	€ 97
Net loss for the year			€ (253,064)	(411,036)	(188,427)
Current assets		€ 372,475	220,979	372,475
Non-current assets		58,950	67,852	58,950
Non-current liabilities		(13,150)	(12,312)	(13,150)
Current liabilities		(75,764)	(73,016)	(75,764)
Shareholders' equity		342,511	€ 203,503	€ 342,511	€ 57,722		€ (24,087)
Reconciliation to the Group's interest in at equity-accounted investee:
Group's effective interest in the joint venture / associate			27.70%	34.80%
Group's share in shareholders' equity		7,762	€ 7,780	€ 7,762
Goodwill		7,558	8,370	7,558
Currency translation difference		(266)	(2,740)	(266)
Investment in a joint venture / associate		15,054	13,410	15,054
Zenlabs Energy Inc
Investment in a Joint Venture / Associate
Revenue		806	1,927
Loss from continued operations		(3,482)	(7,777)
Net loss for the year		(2,907)	(7,369)
Current assets			13,487			€ 6,724
Non-current assets	[1]		25,438			24,255
Preferred stock reclassification			21,619			20,283
Non-current liabilities			(31,482)			(28,200)
Current liabilities			(933)			(756)
Shareholders' equity			€ 28,129			€ 22,306
Reconciliation to the Group's interest in at equity-accounted investee:
Group's effective interest in the joint venture / associate			27.70%
Investment in a joint venture / associate		€ 15,054	€ 13,410	€ 15,054
[1] As the purchase price allocation is performed at each acquisition date (as of March 10, July 16 and September 27, 2021), differences occur due to the different ownership rates used in purchase price allocation and equity accounting. These differences are adjusted in Ionblox’s summary consolidated financial statements.

Other Financial Assets - Other

Other Financial Assets - Other financial assets (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Other Financial Assets
Security deposits	€ 3,386	€ 3,779
Total non-current financial assets	3,386	3,779
Fixed term deposit	19,987	119,664
Money market funds		99,919
Security deposits	2,594	42
Total current other financial assets	22,581	219,625
Total other financial assets	€ 25,967	€ 223,404

Other Financial Assets - Fixed

Other Financial Assets - Fixed term deposit (Details) - EUR (€) € in Thousands	1 Months Ended	12 Months Ended
	Oct. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Nov. 30, 2021
Disclosure of financial assets [line items]
Payment of short-term deposits		€ 120,000	€ 220,006	€ 50,000
Total proceeds		99,853	0
Fixed term deposit
Disclosure of financial assets [line items]
Notional amount	€ 120,000	20,000
Amount of reduction in principal	336
Negative interest	80
Expected credit loss	257	30
Amount of increase in principal		17
Fixed-term deposit one
Disclosure of financial assets [line items]
Notional amount	€ 40,000
Term of promissory notes (in years)	6 months
Fixed-term deposit two
Disclosure of financial assets [line items]
Term of promissory notes (in years)	9 months
Fixed-term deposit three
Disclosure of financial assets [line items]
Term of promissory notes (in years)	12 months
Money Market Funds
Disclosure of financial assets [line items]
Notional amount					€ 100,006
Security deposits
Disclosure of financial assets [line items]
Amount pledged as collateral for customs		50	400
Amount pledged as collateral for furniture lease		182	253
Amount pledged as collateral for use of credit card facilities		427	196
Amount pledged as collateral for facility leases		2,941	2,942
Amount of deposits pledged as collateral for deposits to suppliers.		€ 2,530	€ 30

Non-Financial Assets (Details)

Non-Financial Assets (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Non-Financial Assets
Advance payments	€ 4,069	€ 8,113
Prepaid expenses	9,418
Total non-current non-financial assets	13,487	8,113
Value added tax claims	1,696	12,602
Prepaid expenses	16,241	9,924
Miscellaneous other current non-financial assets	711	468
Total current non-financial assets	18,648	22,994
Total non-financial assets	€ 32,135	€ 31,107

Non-Financial Assets - Prepaid

Non-Financial Assets - Prepaid expenses (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Non-Financial Assets
Prepayments for acquisition of fixed assets	€ 4,069	€ 8,113
Prepayments for multi-year supplier contracts	9,418	0
Insurance claim	374	372
Prepaid expenses	€ 16,241	€ 9,924

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash and Cash Equivalents
Petty cash		€ 2
Short-term deposits, classified as cash equivalents	€ 49,385
Cash at banks	130,196	129,854
Total cash and cash equivalents	€ 179,581	€ 129,856	€ 102,144	€ 59,571

Shareholders' Equity (Details)

Shareholders' Equity (Details) - shares		1 Months Ended	12 Months Ended
	Mar. 26, 2021	Mar. 31, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Sep. 14, 2021
Shareholders' Equity
Number of shares issued during period					23,261,694
Issued shares - convertible loans	20,533,259	19,156,185	274,272
Share buy-back - treasury shares					205,704
After reorganization
Shareholders' Equity
Number of shares outstanding, beginning balance			285,657,980	197,427,271	155,009,392
Outstanding as adjusted, beginning balance			284,403,289	197,221,567
Number of shares issued during period			91,524,935	45,000,000	23,261,694
Outstanding as adjusted, ending balance			393,283,886	284,403,289	197,221,567
Issued shares - convertible loans				20,533,259	19,156,185
Share buy-back - treasury shares					(205,704)
Issued shares for share-based payments exercised			10,857,264
Warrants exercised			10
Issued shares - ELOC			5,618,697
Conversion of Class B Shares			525,000
Repurchase of Class B Shares			50,000
Reorganization as of September 14, 2021				22,697,450
Treasury shares			(950,000)	(375,000)
Treasury shares (due to consolidation)				(879,691)
Number of shares outstanding, ending balance			394,233,886	285,657,980	197,427,271
Class A shares
Shareholders' Equity
Number of shares outstanding, beginning balance			261,244,915	173,014,206	130,596,327
Outstanding as adjusted, beginning balance			259,990,224	172,808,502
Number of shares issued during period			91,524,935	45,000,000	23,261,694
Outstanding as adjusted, ending balance			369,820,821	259,990,224	172,808,502
Issued shares - convertible loans				20,533,259	19,156,185
Share buy-back - treasury shares					(205,704)
Issued shares for share-based payments exercised			10,857,264
Warrants exercised			10
Issued shares - ELOC			5,618,697
Conversion of Class B Shares			525,000
Repurchase of Class B Shares			50,000
Reorganization as of September 14, 2021				22,697,450
Treasury shares				(375,000)
Treasury shares (due to consolidation)				(879,691)
Number of shares outstanding, ending balance			369,820,821	261,244,915	173,014,206
Exchange of shares			5,356,000
Class B shares
Shareholders' Equity
Number of shares outstanding, beginning balance			24,413,065	24,413,065	24,413,065
Outstanding as adjusted, beginning balance			24,413,065	24,413,065
Outstanding as adjusted, ending balance			23,463,065	24,413,065	24,413,065
Conversion of Class B Shares			(525,000)	0
Treasury shares			(425,000)
Number of shares outstanding, ending balance			23,888,065	24,413,065	24,413,065
Exchange of shares						24,413,065
Class C shares
Shareholders' Equity
Conversion of Class B Shares			525,000
Treasury shares			(525,000)
Number of shares outstanding, ending balance			525,000
Exchange of shares			0

Shareholders' Equity - Addition

Shareholders' Equity - Additional information (Details) € / shares in Units, € in Thousands			1 Months Ended	6 Months Ended	12 Months Ended
	Sep. 14, 2021 EUR (€) Vote € / shares shares	Mar. 26, 2021 EUR (€) shares	Mar. 31, 2020 EUR (€) shares	Dec. 31, 2022 EUR (€) € / shares shares	Dec. 31, 2022 EUR (€) € / shares shares	Dec. 31, 2021 EUR (€) shares	Dec. 31, 2020 EUR (€) shares	Dec. 31, 2019 EUR (€) shares
Shareholders' Equity
Share split	0.0004				0.0004
Number of shares transferred to Class B shares | shares	8,545
Nominal value per share | € / shares				€ 0.12	€ 0.12
Share capital				€ 53,104	€ 53,104	€ 40,138
Number of Class B shares converted to Class C share | shares	1
Number of Class B shares converted to Class A share | shares	1
Witten notice period (in days)	3 days
Consideration value for transfer of shares	€ 0
Number of shares issued during period | shares							23,261,694
Increase in share capital					€ 381,208		€ 96,810
Convertible loans, shares | shares		20,533,259	19,156,185		274,272
Conversion			€ 34,084		€ (562)	96,193	102,207
Transaction costs	€ 2,227				29,029		503
Amount of convertible loan		€ 85,900
Transfer of shares							€ 763
Share buyback, shares | shares							205,704
Share capital increased through reorganization					164,868	164,868
Proceeds From Reorganization						83,393
Share capital				203,503	€ 203,503	342,511	€ 57,722	€ (24,087)
Proceeds from the 2021 PIPE capital increase						€ 381,208
Shares issued due to execution of vested share based payments | shares					10,857,264	0
Subscribed capital					€ 1,303	€ 0
Other capital reserves				277,654	277,654	240,430
Share premium				€ 843,074	843,074	€ 779,141
Shares transferred | shares	8,545
Equity settled share-based payments					€ 22,817
Number of shares authorized for issue | shares				196,385,439	196,385,439	152,054,830
Success Fee
Shareholders' Equity
Convertible loans, shares | shares					293,230
After reorganization
Shareholders' Equity
Number of shares outstanding | shares				394,233,886	394,233,886	285,657,980	197,427,271	155,009,392
Number of shares issued during period | shares					91,524,935	45,000,000	23,261,694
Convertible loans, shares | shares						20,533,259	19,156,185
Share buyback, shares | shares							(205,704)
Shares converted | shares					525,000
Shares held under consolidation | shares						(879,691)
Class A shares
Shareholders' Equity
Exchange of shares | shares				5,356,000	5,356,000
Nominal value per share | € / shares	€ 0.12
Number of votes | Vote	12
Number of shares outstanding | shares				369,820,821	369,820,821	261,244,915	173,014,206	130,596,327
Number of shares issued during period | shares					91,524,935	45,000,000	23,261,694
Convertible loans, shares | shares						20,533,259	19,156,185
Share buyback, shares | shares							(205,704)
Proceeds from the 2021 PIPE capital increase				€ 12,498
Shares converted | shares					525,000
Shares held under consolidation | shares						(879,691)
Class B shares
Shareholders' Equity
Exchange of shares | shares	24,413,065
Nominal value per share | € / shares	€ 0.36
Number of votes | Vote	36
Number of shares outstanding | shares				23,888,065	23,888,065	24,413,065	24,413,065	24,413,065
Transfer of shares					€ 6
Shares converted | shares					(525,000)	0
Class C shares
Shareholders' Equity
Number of shares transferred to Class B shares | shares					525,000	0
Exchange of shares | shares				0	0
Nominal value per share | € / shares	€ 0.24
Number of votes | Vote	24
Number of shares outstanding | shares				525,000	525,000
Percentage of maximum profits on nominal value per share (in percent)	0.10%
Shares converted | shares					525,000
Shares transferred | shares					525,000	0
Subscribed capital
Shareholders' Equity
Increase in share capital					€ 5,400		€ 2,791
Conversion		2,464	2,299		1,303	€ 2,464	2,299
Share capital increased through reorganization					2,724	2,724
Share capital				€ 53,104	53,104	40,138	29,550	€ 24,460
Subscribed capital | Success Fee
Shareholders' Equity
Conversion					35
Subscribed capital | After reorganization
Shareholders' Equity
Conversion					33
Subscribed capital | Class B shares
Shareholders' Equity
Transfer of shares					6
Share premium
Shareholders' Equity
Increase in share capital					375,808		94,019
Conversion		127,813	65,824		207	127,813	65,824
Transfer of shares						(45)	738
Share capital increased through reorganization					51,116	51,116
Share capital				843,074	843,074	779,141	224,359	65,254
Share premium				207	207	0
Share premium | Success Fee
Shareholders' Equity
Conversion					1
Share premium | After reorganization
Shareholders' Equity
Conversion					2,023
Share premium | Class B shares
Shareholders' Equity
Conversion					126
Transfer of shares					108
Other capital reserves
Shareholders' Equity
Conversion		€ 34,084	€ 34,084		(2,072)	(34,084)	34,084
Share capital increased through reorganization					111,109	111,109
Share capital				277,654	277,654	240,430	110,055	€ 3,981
Other capital reserves				1,227	1,227	0
Equity settled share-based payments					845	0
Treasury shares
Shareholders' Equity
Transfer of shares						45	25
Share capital increased through reorganization						(81)
Share capital				€ (279)	(279)	€ (151)	€ (25)
Treasury shares | Success Fee
Shareholders' Equity
Conversion					81
Treasury shares | Class B shares
Shareholders' Equity
Conversion					(126)
Transfer of shares					€ (108)

Shareholders' Equity - Share Pu

Shareholders' Equity - Share Purchase Agreement ("ELOC") (Details) € in Thousands, $ in Millions			6 Months Ended	12 Months Ended
	Jun. 03, 2022 EUR (€) shares	Jun. 03, 2022 USD ($) shares	Dec. 31, 2022 EUR (€) shares	Dec. 31, 2022 EUR (€) shares	Dec. 31, 2021 EUR (€)
Shareholders' Equity
Fair value loss was recognized in financial expenses				€ 0	€ 696
Gross proceeds					€ 381,208
Class A shares
Shareholders' Equity
Commitment Shares paid as consideration	€ 696
Number of shares issued | shares			5,356,000	5,356,000
Gross proceeds			€ 12,498
Class A shares | Subscribed capital
Shareholders' Equity
Commitment Shares paid as consideration	31
Equity issuance cost			643
Class A shares | Share premium
Shareholders' Equity
Commitment Shares paid as consideration	€ 665
Equity issuance cost			€ 11,855
Class A shares | Agreement with Tumim Stone
Shareholders' Equity
Number of commitment shares | shares	262,697,000	262,697,000
Maximum amount committed to purchase subject to certain limitations | $		$ 75

Shareholders' Equity - Register

Shareholders' Equity - Registered Direct Offering ("RDO") (Details) - EUR (€) € in Thousands		1 Months Ended	12 Months Ended
	Nov. 18, 2022	Nov. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Shareholders' Equity
Shares issued					23,261,694
Class A shares
Shareholders' Equity
Shares issued			91,524,935	45,000,000	23,261,694
Class A shares | RDO Securities Purchase Agreement
Shareholders' Equity
Shares issued	22,499,997
Warrants to purchase class A shares	11,249,997
Aggregate gross proceeds	€ 28,217
Class A shares | RDO Warrants
Shareholders' Equity
Shares issued		69,024,938
Warrants to purchase class A shares		34,512,464
Aggregate gross proceeds		€ 85,754
Amount of liability to issue warrants		€ 26,009	€ 8,541

Shareholders' Equity - 2022 Pri

Shareholders' Equity - 2022 Private Placement ("2022 PIPE") (Details) € in Thousands	1 Months Ended	12 Months Ended
	Nov. 30, 2022 EUR (€) shares	Dec. 31, 2022 EUR (€) shares	Dec. 31, 2021 EUR (€) shares	Dec. 31, 2020 EUR (€) shares	Dec. 31, 2022 $ / shares	Nov. 30, 2022 $ / shares
Shareholders' Equity
Shares issued | shares				23,261,694
Price per share | $ / shares					$ 1.14
Share-based payment awards | €		€ 27,380	€ 53,350	€ 71,990
Class A shares
Shareholders' Equity
Shares issued | shares		91,524,935	45,000,000	23,261,694
Class A shares | 2022 PIPE Securities Purchase Agreement
Shareholders' Equity
Shares issued | shares	69,024,938
Warrants to purchase class A shares | shares	34,512,464
Price per share | $ / shares						$ 1.30
Aggregate cash proceeds | €	€ 85,754
Non-cash contribution | €	975
Share-based payment awards | €	€ 11,916
Warrants to purchase shares of common stock | shares	0.5
Amount of liability to issue warrants | €	€ 26,009	€ 8,541

Shareholders' Equity - Class B

Shareholders' Equity - Class B share transactions (Details) - EUR (€) € in Thousands	Aug. 31, 2022	Jul. 31, 2022
Class A shares
Shareholders' Equity
Consideration		€ 0
Shares that can be transferred		375,000
Shares transferred	375,000
Class B shares
Shareholders' Equity
Shares that can be returned		375,000
Shares returned	375,000

Shareholders' Equity - Treasury

Shareholders' Equity - Treasury Shares (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Shareholders' Equity
Beginning balance	1,254,691	205,704
Repurchase of Class B shares for Class A shares held in treasury	879,691
Repurchase of Class B shares for newly issued Class A shares	50,000
Conversion of Class B shares	525,000
Treasury shares sold by Stichting JSOP	(879,691)
Treasury shares of Lilium GmbH not exchanged into Lilium N.V. shares		(205,704)
Treasury shares acquired upon Reorganization		375,000
Treasury shares from consolidation of Stichting JSOP		879,691
Ending balance	950,000	1,254,691
Class A shares
Shareholders' Equity
Beginning balance	1,254,691	205,704
Repurchase of Class B shares for Class A shares held in treasury	(375,000)
Repurchase of Class B shares for newly issued Class A shares	50,000
Conversion of Class B shares	525,000
Treasury shares sold by Stichting JSOP	(879,691)
Treasury shares of Lilium GmbH not exchanged into Lilium N.V. shares		(205,704)
Treasury shares acquired upon Reorganization		375,000
Treasury shares from consolidation of Stichting JSOP		879,691
Ending balance		1,254,691
Class B shares
Shareholders' Equity
Repurchase of Class B shares for Class A shares held in treasury	375,000
Repurchase of Class B shares for newly issued Class A shares	50,000
Conversion of Class B shares	525,000
Ending balance	425,000
Class C shares
Shareholders' Equity
Conversion of Class B shares	525,000
Ending balance	525,000

Shareholders' Equity - Treasu_2

Shareholders' Equity - Treasury Shares - Additional Information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Shareholders' Equity
Shares repurchased against transfer of shares held in treasury	879,691
Consideration transferred	€ 983
Shares repurchased, issued and transferred	50,000
Increase in share premium	€ 877
Shares converted	525,000
Shares buyback	950,000	1,254,691	205,704
Share premium	€ 877
Class A shares
Shareholders' Equity
Shares repurchased against transfer of shares held in treasury	(375,000)
Shares repurchased, issued and transferred	50,000
Increase in treasury reserve for newly issued shares	€ 18
Increase in share premium	108
Increase in subscribed capital	€ 6
Shares converted	525,000
Shares buyback		1,254,691	205,704
Share premium	€ 108
Class B shares
Shareholders' Equity
Shares repurchased against transfer of shares held in treasury	375,000
Consideration transferred	€ 0
Increase in treasury share reserve due to difference in nominal capital	€ 90
Shares repurchased, issued and transferred	50,000
Shares converted	525,000
Shares buyback	425,000
Class C shares
Shareholders' Equity
Consideration transferred	€ 0
Increase in share premium	€ 126
Shares converted	525,000
Shares buyback	525,000
Increase in treasury share reserve due to conversion and buyback	126,000
Share premium	€ 126

Share-based Payments - Other pl

Share-based Payments - Other plans (Details) - EUR (€) € in Thousands		1 Months Ended	12 Months Ended
	Jun. 01, 2022	Nov. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Share-based Payments
Total expense	€ 1,553		€ 24,261	€ 48,349
General population and executives - standard ESOP
Share-based Payments
Total expense			7,942	29,286
General population - Restricted Stock Units ("RSU")
Share-based Payments
Total expense			4,977	77
Executives - ESOP modified
Share-based Payments
Total expense			1,101	2,135
Executives - Restricted Stock Units ("RSU")
Share-based Payments
Total expense			3,259	1,178
Executives - Performance-based stock options
Share-based Payments
Total expense			(375)	2,296
Executives - Time-based stock options
Share-based Payments
Total expense			2,200	3,505
Executives - Joint Stock Ownership plan (JSOP) and bonus
Share-based Payments
Total expense			(4,435)	€ 5,438
Share-based payment - Vendors
Share-based Payments
Total expense		€ 4,558	€ 9,726

Share-based Payments - expense

Share-based Payments - expense recognized for participant services (Details)										1 Months Ended		12 Months Ended
	Jun. 01, 2022 EUR (€) USD ($)	Mar. 31, 2022 € / shares	Dec. 31, 2021 EUR (€) USD ($) Options € / shares	Sep. 15, 2021 € / shares	Aug. 31, 2021 € / shares	Jul. 31, 2021 € / shares	Jun. 30, 2021 € / shares	Mar. 31, 2021 € / shares	Dec. 31, 2020 Options € / shares	Dec. 31, 2022 EUR (€) Options USD ($) € / shares shares	Nov. 30, 2022 EUR (€) item	Dec. 31, 2022 EUR (€) Options	Dec. 31, 2022 EUR (€) Options	Dec. 31, 2022 EUR (€) € / shares Options	Dec. 31, 2022 EUR (€) Options	Dec. 31, 2022 EUR (€) USD ($) Options	Dec. 31, 2022 EUR (€) Options shares	Dec. 31, 2022 EUR (€) Options	Dec. 31, 2022 EUR (€) Y Options	Dec. 31, 2021 EUR (€) USD ($) Options € / shares Y shares	Dec. 31, 2020 EUR (€) Options € / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense arising from equity-settled share-based payments | €													€ 7,942,000							€ 29,286,000
Expense recognized | €	€ 1,553,000												€ 24,261,000							€ 48,349,000
Weighted average remaining contractual life												9 years 6 months								9 years 10 months 24 days
Fair value option per share		€ 3.59	€ 6.12	€ 7.89	€ 7.71	€ 7.36	€ 7.05	€ 7.13	€ 6.05
Number of options exercisable			0							7,043,620		7,043,620	7,043,620	7,043,620	7,043,620	7,043,620	7,043,620	7,043,620	7,043,620	0
Options originally granted that were forfeited | $	4,341,000
Share-based payment awards | €													€ 27,380,000							€ 53,350,000	€ 71,990,000
Other capital reserves
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based payment awards | €													27,380,000							€ 53,350,000	€ 71,990,000
Equity-settled options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average remaining contractual life												10 years 4 months 13 days
Cash-settled options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average remaining contractual life												10 years 1 month 17 days
Key management
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding at January 1 | $																19,204,000
Exercised during the period | $																1,872,000				0
Forfeited during the year | $																(6,553,000)				0
Outstanding at December 31 | $			19,204,000							12,437,000						12,437,000				19,204,000
General population and executives - standard ESOP
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense recognized | €													7,942,000							€ 29,286,000
Options granted | Options																				0
Exercised during the period															979,661	2.52				3,300,960
Outstanding at December 31										€ 0				€ 0
Lock-up period for options become exercisable																				180 days
General population and executives - standard ESOP | Equity-settled options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding at January 1 | Options															19,573,307					13,962,159
Options granted																5,714				4,019,799
Exercised during the period | Options															10,318,085
Forfeited during the year | Options															(1,188,512)					(757,105)
Transferred from cash-settled | shares																	(22,856)			2,348,454
Outstanding at December 31 | Options			19,573,307						13,962,159	8,049,568					8,049,568					19,573,307	13,962,159
Outstanding at January 1														0						€ 0
Granted during the year														0						0
Exercised during the period														0
Forfeited during the year														€ 0						€ 0
Transferred from cash-settled														0						0
Outstanding at December 31			€ 0						€ 0	€ 0				€ 0						€ 0	€ 0
General population and executives - standard ESOP | Cash-settled options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding at January 1 | Options																				2,348,454
Exercised during the period | Options															17,142
Transferred from cash-settled | shares																	22,856			(2,348,454)
Outstanding at December 31 | Options									2,348,454	5,714					5,714						2,348,454
Exercised during the period														€ 0
Transferred from cash-settled														0						0
Outstanding at December 31										€ 0				€ 0
General population - Restricted Stock Units ("RSU")
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense arising from equity-settled share-based payments | €													4,977,000							€ 77,000
Expense recognized | €													€ 4,977,000							€ 77,000
Options granted													4,886,000							162,000
Outstanding at January 1														€ 0.12
Assigned during the year														0.12						0.12
Forfeited during the year														€ 0.12
Outstanding at December 31			€ 0.12							€ 0.12				€ 0.12						€ 0.12
Weighted average remaining contractual life												6 months 29 days								1 year 8 months 12 days
Number of options exercisable | Options			0							0		0	0	0	0	0	0	0	0	0
Executives - ESOP modified
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense arising from equity-settled share-based payments | €													€ 1,101,000							€ 2,135,000
Expense recognized | €													1,101,000							€ 2,135,000
Outstanding at January 1 | Options															1,888,477
Options granted | Options															531,449					0
Exercised during the period | Options															430,431					101,018
Forfeited during the year | Options															(1,160,457)
Outstanding at December 31 | Options			1,888,477							728,020					728,020					1,888,477
Outstanding at January 1														€ 7.90
Granted during the year																				€ 7.90
Forfeited during the year														8.50
Outstanding at December 31			€ 7.90							€ 6.94				6.94						€ 7.90
Weighted average remaining contractual life												11 years 4 months 24 days								12 years 4 months 24 days
Executives - Restricted Stock Units ("RSU")
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense arising from equity-settled share-based payments | €													3,259,000							€ 1,178,000
Expense recognized | €													3,259,000							€ 1,178,000
Weighted average remaining contractual life												1 year 6 months								2 years 8 months 12 days
Executives - Restricted Stock Units ("RSU") | Restricted Stock Units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding at January 1 | Options															1,050,913
Options granted | Options															1,699,411					1,050,913
Forfeited during the year | Options															(291,199)
Outstanding at December 31 | Options			1,050,913							2,324,725					2,324,725					1,050,913
Outstanding at January 1														€ 0.12
Granted during the year																				€ 0.12
Assigned during the year														0.12
Exercised during the period														€ 0.12
Forfeited during the year														0.12
Outstanding at December 31			€ 0.12							€ 0.12				0.12						€ 0.12
Executives - Performance-based stock options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense arising from equity-settled share-based payments | €													(375,000)							€ 2,296,000
Expense recognized | €													(375,000)							€ 2,296,000
Outstanding at January 1 | Options															7,036,501
Options granted | Options															1,272,059					7,036,501
Forfeited during the year | Options															(4,711,839)
Outstanding at December 31 | Options			7,036,501							3,596,721					3,596,721					7,036,501
Outstanding at January 1														8.15
Granted during the year														9.45						€ 8.15
Forfeited during the year														8.66
Outstanding at December 31			€ 8.15							€ 7.94				7.94						€ 8.15
Expected volatility (%)																				121.80%
Expected exercise term | Y																			3.4	4
Executives - Performance-based stock options | Minimum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility (%)																		108.86%
Risk free rate																		(0.69%)		0.69%
Expected exercise term | Y																			3.3
Executives - Performance-based stock options | Maximum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility (%)																		121.91%
Risk free rate																		2.01%		0.66%
Executives - Performance-based stock options | Options under Former Arrangement, for which Service Condition already Fulfilled [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted | Options															681,000
Executives - Performance-based stock options | Options must fulfill the service vesting condition until 2025
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted | Options															325,000
Executives - Performance-based stock options | Key management
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense recognized | €													121,000
Options granted | Options															1,006,000
Executives - Time-based stock options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense recognized | €													2,200,000							€ 3,505,000
Outstanding at January 1 | Options															2,951,000
Options granted | Options															2,199,488					2,951,000
Forfeited during the year | Options															(2,043,000)
Outstanding at December 31 | Options			2,951,000							3,107,488					3,107,488					2,951,000
Outstanding at January 1														7.25
Granted during the year														2.76						€ 7.25
Forfeited during the year														7.25
Outstanding at December 31			€ 7.25							€ 4.07				€ 4.07						€ 7.25
Expected volatility (%)																		121.90%
Weighted average remaining contractual life												9 years 6 months								9 years 10 months 24 days
Risk free rate																		(0.69%)
Expected dividend yield																		0%
Expected exercise term | Y																				4
Executives - Time-based stock options | Minimum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility (%)																		118.97%
Risk free rate																		0.69%
Expected exercise term | Y																			1.1
Executives - Time-based stock options | Maximum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility (%)																		124.10%
Risk free rate																		2.05%
Expected exercise term | Y																			1.8
Executives - Success fees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense arising from equity-settled share-based payments | €																				€ 1,844,000
Expense arising from cash-settled share-based payments | €													(134,000)							2,590,000
Expense recognized | €													(134,000)							4,434,000
Executives - Success fees | Equity-settled options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense recognized | €																				1,844,000
Executives - Success fees | Cash-settled options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense recognized | €													(134,000)							2,590,000
Executives - Joint Stock Ownership plan (JSOP) and bonus
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense recognized | €													(4,435,000)							5,438,000
Remaining liability amount | €																				1,676,000
Executives - Joint Stock Ownership plan (JSOP)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense recognized | €													(3,762,000)							3,762,000
Remaining liability amount | €													1,003,000							3,762,000
Executives - shadow bonus
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense recognized | €													(673,000)							€ 1,676,000
Weighted average remaining contractual life												0 years								4 years 8 months 12 days
Share-based payment - Vendors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense recognized | €											€ 4,558,000		9,726,000
Cash | €													4,500,000
Share-based payment awards | €													3,757,000							€ 0
Number of third parties | item											2
Prepayment of the goods and services to the vendors | €			€ 0							€ 19,502,000		€ 19,502,000	19,502,000	€ 19,502,000	€ 19,502,000	€ 19,502,000	€ 19,502,000	€ 19,502,000	€ 19,502,000	0
Release from prepayment recorded as share-based payment expense | €			€ 0							€ 1,114,000		€ 1,114,000	€ 1,114,000	€ 1,114,000	€ 1,114,000	€ 1,114,000	€ 1,114,000	€ 1,114,000	€ 1,114,000	€ 0
Share-based payment - Vendors | Class A shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issuance of units | shares										3,101,523

Share-based Payments - Movement

Share-based Payments - Movements during year - RSU (Detail)	12 Months Ended
	Dec. 31, 2022 Options € / shares	Dec. 31, 2021 Options
Disclosure of Weighted Average Exercise Prices Of Other Equity Instruments [Abstract]
Number of RSU exercisable	908	0
General population - Restricted Stock Units ("RSU") [Member]
Disclosure of Number Of Other Equity Instruments [Abstract]
Outstanding at January 1	4,275,098	162,800
Assigned during the year	4,886,077	162,800
Exercised during the year	(638,470)
Forfeited during the year	(135,309)
Outstanding at December 31	4,275,098	162,800
Disclosure of Weighted Average Exercise Prices Of Other Equity Instruments [Abstract]
Exercised during the year | € / shares	€ 0.12
Executives - ESOP modified
Disclosure of Weighted Average Exercise Prices Of Other Equity Instruments [Abstract]
Assigned during the year		1,888,477
Restricted Stock Units | Executives - Restricted Stock Units ("RSU") [Member]
Disclosure of Number Of Other Equity Instruments [Abstract]
Forfeited during the year	(134,400)

Share-based Payments - Measurem

Share-based Payments - Measurement of fair values (Details)											12 Months Ended
	Mar. 31, 2022 € / shares	Dec. 31, 2021 EUR (€) Options € / shares	Oct. 08, 2021 € / shares	Sep. 15, 2021 € / shares	Sep. 14, 2021 € / shares shares	Aug. 31, 2021 € / shares	Jul. 31, 2021 € / shares	Jun. 30, 2021 € / shares	Mar. 31, 2021 € / shares	Dec. 31, 2020 € / shares	Dec. 31, 2022 EUR (€) Options € / shares shares	Dec. 31, 2022 EUR (€) Options € / shares shares	Dec. 31, 2022 EUR (€) € / shares Options shares	Dec. 31, 2022 EUR (€) Options € / shares shares	Dec. 31, 2022 EUR (€) USD ($) Options € / shares shares	Dec. 31, 2022 EUR (€) Options € / shares shares	Dec. 31, 2022 EUR (€) Y Options € / shares shares	Dec. 31, 2021 EUR (€) Options € / shares	Dec. 31, 2021 EUR (€) Options € / shares	Dec. 31, 2021 EUR (€) € / shares Options	Dec. 31, 2021 EUR (€) Options € / shares	Dec. 31, 2021 EUR (€) Options € / shares	Dec. 31, 2021 EUR (€) Options Y € / shares	Dec. 31, 2022 $ / shares	Sep. 14, 2021 $ / shares
Share-based Payments
Exercise price													€ 9.45
Weighted average remaining contractual life											9 years 6 months							9 years 10 months 24 days
Number of options exercisable		0									7,043,620	7,043,620	7,043,620	7,043,620	7,043,620	7,043,620	7,043,620	0	0	0	0	0	0
Fair value option per share	€ 3.59	€ 6.12		€ 7.89		€ 7.71	€ 7.36	€ 7.05	€ 7.13	€ 6.05
Price per share | $ / shares																								$ 1.14
Minimum
Share-based Payments
Exercise price																				€ 7.11
Maximum
Share-based Payments
Exercise price																				€ 8.80
General population and executives - standard ESOP
Share-based Payments
Total fair value of options granted | €		€ 23,061,000									€ 17,483,000	€ 17,483,000	€ 17,483,000	€ 17,483,000	€ 17,483,000	€ 17,483,000	€ 17,483,000	€ 23,061,000	€ 23,061,000	€ 23,061,000	€ 23,061,000	€ 23,061,000	€ 23,061,000
Conversion rate			258,700%
Exercise price			€ 1
Weighted average exercise price for all option											€ 0	€ 0	€ 0	€ 0	€ 0	€ 0	€ 0
Exercised (in shares)															2.52	979,661						3,300,960
Number of options granted | Options																						0
Lock-up period for options become exercisable																		180 days
General population - Restricted Stock Units ("RSU")
Share-based Payments
Exercise price													0.12
Weighted average exercise price for all option		€ 0.12									€ 0.12	€ 0.12	€ 0.12	€ 0.12	€ 0.12	€ 0.12	€ 0.12	€ 0.12	€ 0.12	€ 0.12	€ 0.12	€ 0.12	€ 0.12
Weighted average remaining contractual life											6 months 29 days							1 year 8 months 12 days
Number of options granted														4,886,000							0	162,000
Number of options exercisable | Options		0									0	0	0	0	0	0	0	0	0	0	0	0	0
Weighted average fair value of options granted													1.92							5.97
Executives - ESOP modified
Share-based Payments
Total fair value of options granted | €		€ 11,229,000																€ 11,229,000	€ 11,229,000	€ 11,229,000	€ 11,229,000	€ 11,229,000	€ 11,229,000
Weighted average exercise price for all option		€ 7.90									€ 6.94	€ 6.94	€ 6.94	€ 6.94	€ 6.94	€ 6.94	€ 6.94	€ 7.90	€ 7.90	€ 7.90	€ 7.90	€ 7.90	€ 7.90
Weighted average remaining contractual life											11 years 4 months 24 days							12 years 4 months 24 days
Exercised (in shares) | Options																430,431						101,018
Number of options granted | Options																531,449						0
Executives - Restricted Stock Units ("RSU")
Share-based Payments
Weighted average remaining contractual life											1 year 6 months							2 years 8 months 12 days
Weighted average fair value of options granted | €														1.67							7.09
Executives - Performance-based stock options
Share-based Payments
Weighted average exercise price for all option		8.15									€ 7.94	€ 7.94	€ 7.94	€ 7.94	7.94	€ 7.94	€ 7.94	€ 8.15	€ 8.15	€ 8.15	€ 8.15	€ 8.15	€ 8.15
Number of options granted | Options																1,272,059						7,036,501
Weighted average fair value of options granted													1.14							5.68
Volatility rate (in percent)																			121.80%
Weighted average timing period (in years) | Y																	3.4						4
Executives - Performance-based stock options | Minimum
Share-based Payments
Volatility rate (in percent)												108.86%
Weighted average timing period (in years) | Y																	3.3
Executives - Performance-based stock options | Maximum
Share-based Payments
Volatility rate (in percent)												121.91%
Executives - Time-based stock options
Share-based Payments
Exercise price													€ 2.76							€ 7.25
Weighted average exercise price for all option		€ 7.25									€ 4.07	€ 4.07	€ 4.07	€ 4.07	€ 4.07	€ 4.07	€ 4.07	€ 7.25	€ 7.25	€ 7.25	€ 7.25	€ 7.25	€ 7.25
Weighted average remaining contractual life											9 years 6 months							9 years 10 months 24 days
Number of options granted | Options																2,199,488						2,951,000
Weighted average fair value of options granted													1.21							5.31
Volatility rate (in percent)												121.90%
Weighted average timing period (in years) | Y																							4
Executives - Time-based stock options | Minimum
Share-based Payments
Volatility rate (in percent)												118.97%
Weighted average timing period (in years) | Y																	1.1
Executives - Time-based stock options | Maximum
Share-based Payments
Volatility rate (in percent)												124.10%
Weighted average timing period (in years) | Y																	1.8
Executives - Success fees
Share-based Payments
Provision made for payments | €		€ 2,590,000									€ 0	€ 0	€ 0	€ 0	€ 0	€ 0	€ 0	€ 2,590,000	€ 2,590,000	€ 2,590,000	€ 2,590,000	€ 2,590,000	€ 2,590,000
success fees | €														€ 2,457,000
Percentage of success fee on proceeds from reorganization												0.50%
Number of shares converted | shares					293,230
Price per share | (per share)					€ 8.47																				$ 10
Advisors - Strategic collaboration agreement
Share-based Payments
Discount for lack of marketability												5%
Number of warrants to purchase shares | shares											1,800,000	1,800,000	1,800,000	1,800,000	1,800,000	1,800,000	1,800,000
Exercise price of warrant											€ 0.12	€ 0.12	€ 0.12	€ 0.12	€ 0.12	€ 0.12	€ 0.12
Expiration period (in years)											5 years
Transfer restriction period (in months)											12 months
Professional fees | €														€ 13,030,000

Warrants, Convertible Loans a_2

Warrants, Convertible Loans and Other Financial Liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Ifrs Class of Warrant or Right [Line Items]
Other non-current financial liabilities	€ 21
Other current financial liabilities	4
Warrants	26,267	€ 21,405
Reorganization Warrants
Ifrs Class of Warrant or Right [Line Items]
Warrants	1,811	€ 21,405
Warrant Agreement Dated November 18,2022 With Each Of Registered Direct Offering Private Investment In Public Equity Investors [Member]
Ifrs Class of Warrant or Right [Line Items]
Warrants	€ 24,456

Warrants and Other Financial _2

Warrants and Other Financial Liabilities - Reorganization Warrants (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Reorganization Warrants
Ifrs Class of Warrant or Right [Line Items]
Warrants exercisable term	30 days
Warrants expiration term	5 years
Public Warrants
Ifrs Class of Warrant or Right [Line Items]
Warrants exercised		0
Public Warrants | Reorganization Warrants
Ifrs Class of Warrant or Right [Line Items]
Number of warrants assigned from Qell to Liliium upon Reorganization	12,649,946
Warrants exercised	10
Warrants outstanding	12,649,936	12,649,946
Private Warrants | Reorganization Warrants
Ifrs Class of Warrant or Right [Line Items]
Number of warrants assigned from Qell to Liliium upon Reorganization	7,060,000
Warrants outstanding	7,060,000	7,060,000

Warrants and Other Financial _3

Warrants and Other Financial Liabilities - RDO Warrants & 2022 PIPE Warrants (Details)	12 Months Ended
	Dec. 31, 2022 D € / shares $ / shares shares	Dec. 31, 2022 $ / shares shares	Dec. 31, 2021 shares	Sep. 14, 2021 € / shares
Ifrs Class of Warrant or Right [Line Items]
Share price		$ 1.14
Nominal value | € / shares	€ 0.12
Class A Shares
Ifrs Class of Warrant or Right [Line Items]
Nominal value | € / shares				€ 0.12
Warrant Agreement Dated November 18,2022 With Each Of Registered Direct Offering Private Investment In Public Equity Investors [Member]
Ifrs Class of Warrant or Right [Line Items]
Exercisable period	4 years
Exercise price of warrant		1.30
Minimum trading days required for prior written notice to registered holders of warrants | D	20
Warrant Agreement Dated November 18,2022 With Each Of Registered Direct Offering Private Investment In Public Equity Investors [Member] | Class A Shares
Ifrs Class of Warrant or Right [Line Items]
Maximum share price subject to exceptions		1.30
Redemption price per share		$ 0.01
Minimum market price required for at least 20 trading days during 30 consecutive trading day period	€ 2.60
PIPE Warrants
Ifrs Class of Warrant or Right [Line Items]
Warrants outstanding | shares	34,512,464	34,512,464	0
PIPE Warrants | Class A Shares
Ifrs Class of Warrant or Right [Line Items]
Number of warrant to purchase shares | shares	0.50	0.50
Share price		$ 1.30
Nominal value | € / shares	€ 0.12
RDO Warrants
Ifrs Class of Warrant or Right [Line Items]
Warrants outstanding | shares	11,249,997	11,249,997	0
RDO Warrants | Class A Shares
Ifrs Class of Warrant or Right [Line Items]
Number of warrant to purchase shares | shares	0.5	0.5
Share price | € / shares	€ 1.30
Nominal value		$ 0.12

Provisions (Details)

Provisions (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Asset retirement obligations
Provisions
Beginning balance	€ 233	€ 175
Additions/ Reversals	66	54
Unwinding of discount and changes in discount rate	3	4
Ending balance	302	233
Post-employment benefits
Provisions
Beginning balance	84	193
Additions/ Reversals	(9)	(109)
Ending balance	75	84
Record retention obligations
Provisions
Beginning balance	56	43
Additions/ Reversals	22	13
Unwinding of discount and changes in discount rate	(10)
Ending balance	68	56
Total non-current provisions
Provisions
Beginning balance	373	411
Additions/ Reversals	79	(42)
Unwinding of discount and changes in discount rate	(7)	4
Ending balance	445	373
Year-end audit
Provisions
Beginning balance	1,067
Additions/ Reversals	(1,067)	1,067
Ending balance		1,067
Legal Claims
Provisions
Additions/ Reversals	420
Ending balance	420
Severance payments
Provisions
Beginning balance	619	80
Additions/ Reversals	(505)	539
Ending balance	114	619
Other
Provisions
Beginning balance	736
Additions/ Reversals	(540)	736
Ending balance	196	736
Total current provisions
Provisions
Beginning balance	2,422	80
Additions/ Reversals	(1,692)	2,342
Ending balance	€ 730	€ 2,422

Post-Employment Benefits (Detai

Post-Employment Benefits (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Post-Employment Benefits
Expense for defined contribution plans	€ 635	€ 465
Contributions	€ 1	€ 28

Post-Employment Benefits - Pres

Post-Employment Benefits - Present value of the defined benefit obligations and the fair value of the plan assets (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Present value of the defined benefit obligations and the fair value of the plan assets
Present value of funded obligations	€ 487	€ 155
Fair value of plan assets	(411)	(71)
Net defined benefit liability	€ 76	€ 84

Post-Employment Benefits - Reco

Post-Employment Benefits - Reconciliation of the net defined benefit liability (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Post-Employment Benefits
Net defined liability at January 1	€ 84	€ 193
Defined benefit cost recognized in consolidated statement of operations	101	117
Defined benefit cost recognized in other comprehensive income	(28)	(162)
Employer contributions	(85)	(74)
Currency effects	4	10
Net defined liability at December 31	€ 76	€ 84

Post-Employment Benefits - Re_2

Post-Employment Benefits - Reconciliation of the amount recognized in the consolidated statement of financial position (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Post-Employment Benefits
Net defined liability at January 1	€ 84	€ 193
thereof: experience adjustments	94	(202)
thereof: adjustments for financial assumptions	(108)	(6)
Current service cost	95	112
Past service credit		(1)
Currency effects	4	10
Net defined liability at December 31	76	84
Employee benefit obligations
Post-Employment Benefits
Net defined liability at January 1	155	433
Actuarial adjustments	(14)	(233)
thereof: experience adjustments	94	(202)
thereof: demographic adjustments		(25)
thereof: adjustments for financial assumptions	(108)	(6)
Current service cost	95	112
Past service credit		(1)
Interest expense	1	1
Currency effects	14	19
Employee contributions	85	74
Benefits recovered / (paid)	151	(250)
Net defined liability at December 31	€ 487	€ 155

Post-Employment Benefits - Re_3

Post-Employment Benefits - Reconciliation of the plan assets (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Post-Employment Benefits
Net defined liability at January 1	€ 84	€ 193
Employer contributions	85	74
Administration expenses	6	5
Return on asset excl. interest income	(14)	71
Currency effects	4	10
Net defined liability at December 31	76	84
Fair value of plan assets
Post-Employment Benefits
Net defined liability at January 1	71	240
Employer contributions	85	74
Employee contributions	85	74
Benefits recovered / (paid)	151	(250)
Administration expenses	(6)	(5)
Return on asset excl. interest income	14	(71)
Interest income	1	0
Currency effects	10	9
Net defined liability at December 31	€ 411	€ 71

Post-Employment Benefits - Expe

Post-Employment Benefits - Expense recognized in the consolidated statements of operations and other comprehensive income (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Post-Employment Benefits
Actuarial losses (+) / gains (-) deriving from experience adjustments	€ 94	€ (202)
Actuarial gains (-) / losses (+) deriving from changes in demographical assumptions		(25)
Actuarial gains (-) / losses (+) deriving from changes in financial assumptions	(108)	(6)
Return on plan assets etc., interest (expense) / income	(14)	71
Included in other comprehensive income	(28)	(162)
Current service cost	95	112
Past service (credit) / cost		(1)
Interest income	(1)	0
Administrative expenses (effective)	6	5
Interest expense	1	1
Included in the consolidated statements of operations	101	117
Total expense / (income) included in the consolidated statements of operations and other comprehensive income	73	(45)
Expected payment contributions	€ 84	€ 56

Post-Employment Benefits - Prin

Post-Employment Benefits - Principal actuarial assumptions (Details)	Dec. 31, 2022	Dec. 31, 2021
Post-Employment Benefits
Future salary increases	3%	1%
Inflation rate	1.60%	0.60%
Future pension increases	0%	0%
Discount rate	2.20%	0.35%

Post-Employment Benefits - Sens

Post-Employment Benefits - Sensitivity Analysis (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Post-Employment Benefits
Present value of the post-employment benefit obligations	€ 487	€ 155
Average duration of the obligations	15 years	18 years
Discount rate
Post-Employment Benefits
Increase in assumption (in percent)	0.25%	0.25%
Decrease in assumption (in percent)	(0.25%)	(0.25%)
Present value of the post-employment benefit obligations	€ 503	€ 163
Present value of the post-employment benefit obligations decrease	€ 472	€ 149
Salary increase
Post-Employment Benefits
Increase in assumption (in percent)	0.25%	0.25%
Decrease in assumption (in percent)	(0.25%)	(0.25%)
Present value of the post-employment benefit obligations	€ 490	€ 156
Present value of the post-employment benefit obligations decrease	€ 480	€ 155
Pension increase
Post-Employment Benefits
Increase in assumption (in percent)	0.25%	0.25%
Decrease in assumption (in percent)	(0.25%)	(0.25%)
Present value of the post-employment benefit obligations	€ 495	€ 159

Post-Employment Benefits - Ex_2

Post-Employment Benefits - Expected Benefit Payments (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Post-Employment Benefits
Expected benefit payments	€ 84	€ 56
Total expected benefit payments	84	56
Not later than one year
Post-Employment Benefits
Expected benefit payments	29	18
Total expected benefit payments	29	18
Later than one year and not later than five years
Post-Employment Benefits
Expected benefit payments	161	95
Total expected benefit payments	161	95
Later than five years and not later than ten years [member]
Post-Employment Benefits
Expected benefit payments	280	147
Total expected benefit payments	€ 280	€ 147

Trade and other Payables (Detai

Trade and other Payables (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Trade and other Payables
Long term accruals	€ 3,483	€ 2,906
Non-current trade and other payables	3,483	2,906
Trade payables	19,195	14,936
Accruals for outstanding invoices	14,463	20,399
Current trade and other payables	33,658	35,335
Total trade and other payables	€ 37,141	€ 38,241

Other Non-Financial Liabiliti_3

Other Non-Financial Liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Other Non-Financial Liabilities
Vacation accruals	€ 2,474	€ 2,488
Value added tax payables		242
Payroll tax and social security	3,497	2,992
Miscellaneous other current non-financial liabilities	2,596	338
Total other non-financial liabilities	€ 8,567	€ 6,060

Financial Instruments - Financi

Financial Instruments - Financial assets, by class (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Financial instruments
Carrying amount	€ 205,548	€ 353,260
AC
Financial instruments
Carrying amount	205,548	253,341
AC | Cash and cash equivalents
Financial instruments
Carrying amount	179,581	129,856
AC | Fixed term deposit
Financial instruments
Carrying amount	19,987	119,664
AC | Non-current security deposits
Financial instruments
Carrying amount	3,386	3,779
Fair value	3,265	3,787
AC | Security deposits
Financial instruments
Carrying amount	€ 2,594	42
FVTPL
Financial instruments
Carrying amount		99,919
FVTPL | Money Market Funds
Financial instruments
Carrying amount		99,919
Fair value		€ 99,919

Financial Instruments - Finan_2

Financial Instruments - Financial liabilities, by class (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Financial Instruments
Carrying amount	€ 63,433
Fair value		€ 59,646
Financial liabilities measured at amortized cost
Financial Instruments
Carrying amount	37,166	38,241
Financial liabilities measured at amortized cost | Non-current trade and other payables
Financial Instruments
Carrying amount	3,483	2,906
Fair value	3,239	2,868
Financial liabilities measured at amortized cost | Current trade and other payables
Financial Instruments
Carrying amount	33,658	35,335
Financial liabilities measured at amortized cost | Non-current other liabilities
Financial Instruments
Carrying amount	21
Fair value	21
Financial liabilities measured at amortized cost | Current other financial liabilities
Financial Instruments
Carrying amount	4
FVTPL
Financial Instruments
Carrying amount	26,267	21,405
FVTPL | Warrants
Financial Instruments
Carrying amount	26,267	21,405
Fair value	€ 26,267	€ 21,405

Financial Instruments - Thereof

Financial Instruments - Thereof aggregated to categories according to IFRS 9 (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Financial Instruments
Carrying amount, financial assets	€ 205,548	€ 353,260
Carrying amount, financial liabilities	63,433
Financial assets measured at amortized cost
Financial Instruments
Carrying amount, financial assets	205,548	253,341
FVTPL.
Financial Instruments
Carrying amount, financial assets		99,919
FVTPL
Financial Instruments
Carrying amount, financial liabilities	26,267	21,405
Financial liabilities measured at amortized cost
Financial Instruments
Carrying amount, financial liabilities	€ 37,166	€ 38,241

Financial Instruments - Effect

Financial Instruments - Effect of reasonable changes of the most significant input parameters on the fair values of the embedded derivatives (Details) € in Thousands	12 Months Ended
	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 EUR (€)	Dec. 31, 2022 Y $ / shares
Financial Instruments
Share price | $ / shares			$ 1.14
Fair Value Warrant, Base	€ (24,455)	€ (24,455)
Fair Value Warrant, up	(28,316)	(27,029)
Fair Value Warrant, down	(21,023)	(21,881)
Effect on financial result, up	(3,861)	(2,574)
Effect on financial result, down	€ 3,432	€ 2,575
Historical and implied volatilities
Financial Instruments
Percentage, Base			70
Remaining contractual term
Financial Instruments
Warrant remaining contractual term | Y			4
Share Price
Financial Instruments
Percentage, up			10%
Percentage, down			(10.00%)
Volatility
Financial Instruments
Percentage, up		10%
Percentage, down		(10.00%)
Dividend rate
Financial Instruments
Percentage, Base			0

Financial Instruments - Finan_3

Financial Instruments - Financial instruments, changes in Fair Value of level 3 instruments (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Financial assets
Beginning balance, Financial assets	€ 431,425
Ending balance, Financial assets	288,831	€ 431,425
Level 3 | Convertible loans - embedded derivative
Financial liabilities
Beginning balance, Financial liabilities		14,948
Purchases / issuances		312
Changes from fair value remeasurement		(6,326)
Conversion		(8,934)
Level 3 | RDO and 2022 PIPE Warrants
Financial liabilities
Initial recognition	34,550
Changes from fair value remeasurement	(8,979)
Foreign exchange effects	(1,116)
Ending balance, Financial liabilities	24,455
Level 3 | Promissory notes
Financial liabilities
Beginning balance, Financial liabilities		676
Purchases / issuances		1,051
Changes from fair value remeasurement		475
Foreign exchange effects		20
Conversion		€ (2,222)
Ending balance, Financial liabilities	€ 0

Financial Instruments - Net gai

Financial Instruments - Net gains and losses for each of the financial instrument measurement categories (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Financial Instruments
Interest	€ (648)	€ (3,847)
Foreign exchange conversion	79	(403)
Fair value	29,667	(3,327)
Impairment losses net of reversal	125	(260)
Total per category	29,223	(7,837)
Interest income for financial assets not measured at FVTPL	145	5
Interest expense on financial assets	557	369
Interest expense for financial liabilities not measured at FVTPL	236	3,483
Financial assets measured at amortized cost
Financial Instruments
Interest	(412)	(364)
Foreign exchange conversion	1,147	1,061
Impairment losses net of reversal	125	(260)
Total per category	860	437
Financial liabilities measured at amortized cost
Financial Instruments
Interest	(236)	(3,483)
Foreign exchange conversion	(560)	(446)
Total per category	(796)	(3,929)
Financial assets and liabilities measured at fair value through profit or loss
Financial Instruments
Foreign exchange conversion	(508)	(1,018)
Fair value	29,667	(3,327)
Total per category	€ 29,159	€ (4,345)

Financial Instruments - Finan_4

Financial Instruments - Financial Instrument Risk Management Objectives and Policies (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Oct. 31, 2021
Financial Instruments
Carrying amount	€ 205,548	€ 353,260
Percentage of cash and cash equivalents and fixed term deposits are held with a single financial institution	52%	83%
Impairment loss		€ 260
Fixed term deposit
Financial Instruments
Credit impaired	€ 20,000		€ 120,000
Credit Risk | BBB- to AAA
Financial Instruments
Impairment loss	135	260
Carrying amount	205,683	253,601
Credit impaired	0	0
Impairment loss	135	260
Credit Risk | Cash and cash equivalents
Financial Instruments
Impairment loss	59	3
Carrying amount	179,640	129,859
Credit impaired	0	0
Credit Risk | Fixed term deposit
Financial Instruments
Impairment loss	30	256
Carrying amount	20,017	119,920
Credit impaired	0	0
Impairment loss	131	260
Reversal of impairment loss allowance	256	0
Credit Risk | Security deposits
Financial Instruments
Impairment loss	46	1
Carrying amount	6,026	3,822
Credit impaired	0	0
Liquidity Risk | Year one
Financial Instruments
Lease liabilities	2,970	2,356
Trade and other payables	33,658	35,335
Liquidity Risk | Year two
Financial Instruments
Lease liabilities	2,457	2,705
Trade and other payables	1,974	29
Liquidity Risk | Year 3-5
Financial Instruments
Lease liabilities	6,463	8,001
Trade and other payables	€ 2,770	3,498
Liquidity Risk | Later than five years [member]
Financial Instruments
Lease liabilities		€ 2,187

Financial Instruments - Foreign

Financial Instruments - Foreign Currency Risk (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Financial Instruments
Total exposure	€ (20,082)	€ (8,541)
Cash and cash equivalents
Financial Instruments
Total exposure	17,927	18,182
Current financial assets
Financial Instruments
Total exposure	5,951
Non-current financial assets
Financial Instruments
Total exposure	11,793
Non-current trade and other payables
Financial Instruments
Total exposure	(3,786)
Current trade and other payables
Financial Instruments
Total exposure	(7,235)	(5,318)
Current financial liabilities
Financial Instruments
Total exposure	(18,465)
Warrants
Financial Instruments
Total exposure	(26,267)	(21,405)
USD
Financial Instruments
Total exposure	(19,098)	(8,147)
USD | Cash and cash equivalents
Financial Instruments
Total exposure	17,927	18,174
USD | Current financial assets
Financial Instruments
Total exposure	2,158
USD | Non-current financial assets
Financial Instruments
Total exposure	5,424
USD | Non-current trade and other payables
Financial Instruments
Total exposure	(2,885)
USD | Current trade and other payables
Financial Instruments
Total exposure	(7,097)	(4,916)
USD | Current financial liabilities
Financial Instruments
Total exposure	(8,358)
USD | Warrants
Financial Instruments
Total exposure	(26,267)	(21,405)
JPY
Financial Instruments
Total exposure	(901)
JPY | Non-current trade and other payables
Financial Instruments
Total exposure	(901)
GBP
Financial Instruments
Total exposure	(83)	(394)
GBP | Cash and cash equivalents
Financial Instruments
Total exposure		8
GBP | Current financial assets
Financial Instruments
Total exposure	3,793
GBP | Non-current financial assets
Financial Instruments
Total exposure	6,369
GBP | Current trade and other payables
Financial Instruments
Total exposure	(138)	€ (402)
GBP | Current financial liabilities
Financial Instruments
Total exposure	€ (10,107)

Financial Instruments - carryin

Financial Instruments - carrying amount of monetary assets and liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
USD
Financial Instruments
Effect of EUR depreciation on profit before tax		$ (898)
GBP
Financial Instruments
Effect of EUR depreciation on profit before tax		(19)
Currency Risk | USD
Financial Instruments
Effect of EUR appreciation on profit before tax	$ 1,736	735
Effect of EUR depreciation on profit before tax	(2,122)
Currency Risk | GBP
Financial Instruments
Effect of EUR appreciation on profit before tax	8	$ 15
Effect of EUR depreciation on profit before tax	(9)
Currency Risk | JPY
Financial Instruments
Effect of EUR appreciation on profit before tax	82
Effect of EUR depreciation on profit before tax	$ (100)

Financial Instruments - Interes

Financial Instruments - Interest Rate Risk (Details) - EUR (€) € in Thousands	Dec. 31, 2022	Dec. 31, 2021
Financial Instruments
Cash at banks	€ 130,196	€ 129,854
Interest Rate Risk
Financial Instruments
Increase (decrease) in cash at banks due to reasonably possible increase in risk assumption	411	130
Increase (decrease) in cash at banks due to reasonably possible decrease in risk assumption	411	130
Cash at banks	€ 82,128	€ 130,000
Percentage hypothetical reasonable increase or decrease in basis points	0.50%	0.10%

Financial Instruments - Other P

Financial Instruments - Other Price Risk (Details) - Other Price Risk € in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022 EUR (€) shares	Dec. 31, 2021 EUR (€) shares	Dec. 31, 2021 USD ($) shares
Warrants
Financial Instruments
Percentage of reasonably possible increase (decrease) in risk component	10%
Increase (decrease) in profit and loss due to reasonably possible increase (decrease) in designated risk component	€ 181	€ 2,140
Warrants outstanding | shares	65,472,000	19,710	19,710
Promissory notes
Financial Instruments
Notional amount		€ 1,051	$ 1,250
Money Market Funds
Financial Instruments
Notional amount		€ 99,919
Percentage of reasonably possible increase (decrease) in risk component		10%
Increase (decrease) in profit and loss due to reasonably possible increase (decrease) in designated risk component		€ 9,992

Financial Instruments - Reconci

Financial Instruments - Reconciliation of changes in liabilities arising from financing activities (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Financial Instruments
Beginning balance	€ 33,228	€ 110,353
Proceeds from convertible loans		1,850
Principal elements of lease payment	(2,720)	(1,781)
Interest paid	(443)	(437)
Change in the cash flow from financing activities	(3,163)	(368)
Additions to lease liabilities due to new lease contracts	1,873	2,486
Additions to warrants	34,550	25,859
Fair value changes	(30,196)	(11,818)
Effects of foreign exchange conversion	508	1,038
Interest expenses	436	3,920
Capital contributions		(98,242)
Ending balance	37,236	33,228
Convertible loans
Financial Instruments
Beginning balance		99,235
Proceeds from convertible loans		1,850
Change in the cash flow from financing activities		1,850
Fair value changes		(6,326)
Interest expenses		3,483
Capital contributions		(98,242)
Lease liabilities
Financial Instruments
Beginning balance	11,823	11,118
Principal elements of lease payment	(2,720)	(1,781)
Interest paid	(443)	(437)
Change in the cash flow from financing activities	(3,163)	(2,218)
Additions to lease liabilities due to new lease contracts	1,873	2,486
Interest expenses	436	437
Ending balance	10,969	11,823
Warrants
Financial Instruments
Beginning balance	21,405
Additions to warrants	34,550	25,859
Fair value changes	(30,196)	(5,492)
Effects of foreign exchange conversion	508	1,038
Ending balance	€ 26,267	€ 21,405

Commitments and Contingencies -

Commitments and Contingencies - Lease contracts (Details) € in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022 EUR (€) tranche	Nov. 30, 2022 EUR (€)	Nov. 30, 2022 USD ($)	Dec. 31, 2021 EUR (€)
Commitments and contingencies
Number of tranches upon achieving certain performance and market conditions | tranche	3
Cap of future fundraising		€ 9,300	$ 9,900
Property, plant and equipment
Commitments and contingencies
Commitments to acquire assets	€ 5,016			€ 12,003
Intangible assets
Commitments and contingencies
Commitments to acquire assets	4,344			2,731
Within one year
Commitments and contingencies
Future lease payments for non-cancellable lease contracts not yet commenced	400			0
Future payments for operating contracts	73,779			2,175
Later than one year and not later than five years
Commitments and contingencies
Future lease payments for non-cancellable lease contracts not yet commenced	1,601			1,601
Future payments for operating contracts	100,177			37,517
Thereafter
Commitments and contingencies
Future lease payments for non-cancellable lease contracts not yet commenced	0			400
Future payments for operating contracts	€ 18,558			€ 7,063

Related Party Disclosures (Deta

Related Party Disclosures (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Related Party Disclosures
Number of shares held	156,981	147,132
Ownership Interest (as a percent)	39.90%	51.80%
Key management
Related Party Disclosures
Number of shares held	28,302	25,743
Ownership Interest (as a percent)	7.20%	9.10%
Other related parties
Related Party Disclosures
Number of shares held	128,679	121,389
Ownership Interest (as a percent)	32.70%	42.70%

Related Party Disclosures - PIP

Related Party Disclosures - PIPE participation (Details) € in Thousands, $ in Thousands	1 Months Ended		12 Months Ended
	Nov. 30, 2022 EUR (€) shares	Nov. 30, 2022 USD ($)	Dec. 31, 2022 EUR (€) USD ($) shares	Dec. 31, 2021 EUR (€) USD ($)	Dec. 31, 2020 EUR (€)	Nov. 30, 2022 USD ($) shares
Related Party Disclosures
Cash remuneration			€ 320	€ 72
Other income			6,808	2,274	€ 2,346
Future fund rasing cap				0
Cash payment				0
General and administrative expense	€ 4,558		93,887	239,093	35,406
Non current prepaid expenses			4,069	8,113
Other capital			53,104	40,138
Current trade payables			19,195	14,936
Non-cancelable commitment			7,702	7,946
Ifrs General And Administrative Expense [Member]
Related Party Disclosures
Other expenses by nature			€ 4,736	4,633	€ 1,354
Joint Stock Ownership Plan
Related Party Disclosures
Exchange of shares | shares			879,691
Percentage of key management controlled			100%
Issuance of shares | shares			879,691
Other income			€ 3,762
Other expenses by nature				3,762
Liabilities from share-based payment transactions			0	3,762
Bonus recognized			1,003	1,676
Future fund rasing cap	9,300	$ 9,900	2,457
Cash payment	€ 9,300	9,900	2,457
Cloud subscription
Related Party Disclosures
Exchange of shares | shares	3,101,523					3,101,523
Issuance of shares | shares	3,101,523					3,101,523
Cash settled for services | $		$ 4,500
Payment of cash on agreements	€ 9,376					$ 10,000
General and administrative expense	4,558
Other capital			8,315	0
Trade payables related parties			€ 1,226	€ 45
Key management
Related Party Disclosures
Contribution of related party	€ 15,461
Exchange of shares | shares	12,192,306					12,192,306
Acquiring ownership percentage	3.10%	3.10%
Grants (in shares) | $			3,557	14,964
Exercised (in shares) | $			1,872	0
Forfeited (in shares) | $			6,553	0
Options outstanding | $			12,437	19,204
Issuance of shares | shares	12,192,306					12,192,306
General and administrative expense				€ 96
Non current prepaid expenses			€ 1	0
Current trade payables			€ 20	10
Shares in exchange returned | shares			950,000
Non current trade payables			€ 149	150
Key management | Warrant reserve
Related Party Disclosures
Exchange of shares | shares	6,096,151					6,096,151
Issuance of shares | shares	6,096,151					6,096,151
Key management | Joint Stock Ownership Plan
Related Party Disclosures
Other income			€ 673
Other expenses by nature				€ 1,676

Related Party Disclosures - Ann

Related Party Disclosures - Annual remuneration and related compensation costs recognized as expense (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Related Party Disclosures
Short-term employee benefits	€ 4,657	€ 3,607
Termination remuneration	52	619
Post-employment benefits	45	27
Share-based payment award remuneration	7,364	19,910
Success fees and JSOP	(4,568)	9,872
Total	€ 7,550	€ 34,035

Related party Disclosures - Con

Related party Disclosures - Convertible Loan (Details) - EUR (€) € in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Significant shareholder or party having significant influence
Related Party Disclosures
Original amount of loan converted	€ 1,000		€ 85,900
Shares issued upon conversion of loan	148,564	0	20,533,259
License & Development agreement | Ionblox
Related Party Disclosures
Research and Development expenditure		€ 1,323	€ 347
Remaining commitments on the contract		€ 1,226	€ 45

Related Party Disclosures - Oth

Related Party Disclosures - Other transactions with key management personnel (Details) - EUR (€) € in Thousands	1 Months Ended	12 Months Ended
	Nov. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Related Party Disclosures
Research and development expenses		€ 175,618	€ 144,558	€ 90,345
General and administrative expense	€ 4,558	93,887	239,093	35,406
Selling expense		12,929	17,189	15,272
Finance income		30,322	11,288	80
Finance expenses		1,995	20,201	49,741
Purchase of property, plant and equipment		8,942	17,099	€ 7,657
Key management
Related Party Disclosures
Research and development expenses		17	14
General and administrative expense			96
Selling expense		289	167
Finance income		7
Finance expenses		6
Purchase of property, plant and equipment		€ 24	€ 1

Related Party Disclosures - Tra

Related Party Disclosures - Transactions with related parties (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Related Party Disclosures
Research and development expenses	€ 175,618	€ 144,558	€ 90,345
Convertible loans
Related Party Disclosures
Beginning of the year		99,235
Proceeds from convertible loans		1,007
Fair value changes of convertible loans		(6,337)
Interest expenses (not paid)		3,400
Subscribed capital		(7)
Contribution to capital reserves		(97,298)
End of the year			€ 99,235
Azul Warrants		13,030
Research and development expenses	€ 1,323	€ 347

Related Party Disclosures - T_2

Related Party Disclosures - Transactions with shareholders (Details) - Cloud subscription - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Related Party Disclosures
Prepayments	€ 0	€ 2,927
Remaining commitments on the contract	26,894	34,015
General and Administrative Expenses
Related Party Disclosures
Gain on dilution	€ 13,527	6,590
Shareholders
Related Party Disclosures
Purchase obligation		42,433
Term for Installment Payments		€ 50,000

Events after the Reporting Pe_2

Events after the Reporting Period (Details) - EUR (€) € in Thousands		1 Months Ended
	Jan. 23, 2023	Feb. 28, 2023	Feb. 23, 2023	Jan. 31, 2023	Dec. 31, 2022	Oct. 23, 2022	Oct. 22, 2021
Advisors - Strategic collaboration agreement
Events after the Reporting Period
Number of warrants to purchase shares					8,000,000	6,200,000	1,800,000
Major Ordinary Share Transactions
Events after the Reporting Period
Shares held in treasury	375,000
Decrease in treasury shares in value	€ 135
Transfer of shares		350,000	350,000
Increase in treasury shares transaction		€ 84
Major Ordinary Share Transactions | Class A Shares
Events after the Reporting Period
Transfer of shares		350,000
Major Ordinary Share Transactions | Advisors - Strategic collaboration agreement
Events after the Reporting Period
Number of warrants to purchase shares				6,200,000